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Terminology and Glossary 
This study uses the term ‘variant’ to describe any sequence change that differs from the reference 
genome. This includes heterozygous (unless specifically stated that the variant is homozygous) single 
nucleotide variants, insertions and deletions. Unless otherwise specified, combined counts of variants 
across genes or terms represent the sum of the allele counts of identified variants, where a heterozygous 
alternative variant is equal to one, and a homozygous alternative variant is equal to two.  
The term ‘protein-affecting variants’ will be used to describe loss of function, inframe indels and 
predicted deleterious and probably damaging missenses (as flagged by SIFT and PolyPhen respectively; 
variants with a missing prediction by either SIFT or PolyPhen but otherwise meet the above criteria 
were also included). 
Term Definition 
AC Allele count 
ACC Adrenocortical carcinoma 
AD Allelic depth 
ADP Adenosine diphosphate 
AF Allele frequency 
ALT Alternative allele to reference 
ATP Adenosine triphosphate 
BAM Binary alignment mapping 
BC Breast cancer 
BCC Basal cell carcinoma 
BCL Base call file format 
BQSR Base quality score recalibration 
BWA Burrows-Wheeler Aligner 
cAMP Cyclic adenosine monophosphate 
CAST Cohort allelic sums test 
CBC Contralateral breast cancer 
CDS Coding sequence 
cGMP cyclic guanosine monophosphate 
CMC Combined multivariate and collapsing 
CNV Copy number variant  
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COSMIC Catalogue of somatic mutations in cancer 
CSD3 Cambridge service for data driven discovery 
CT Computed tomography  
DGC Diffuse gastric cancer 
dNTP Deoxynucleotide triphosphate 
DP Depth 
dTE Desmoplastic trichoepithelioma  
ER Estrogen receptor 
EVE Exon variability estimate 
ExAC Exome aggregation consortium 
FDR False discovery rate 
FFPE Formalin-fixed paraffin embedded  
FPKM Fragments Per Kilobase of transcript per Million mapped read 
GAF Gene ontology annotation file  
GATK Genome analysis toolkit 
gnomAD Genome aggregation database 
GO Gene ontology 
GQ Genotype quality 
GT Genotype 
GWA Genome wide association 
HDGC Hereditary diffuse gastric cancer 
HMM Hidden Markov model 
HNPCC Hereditary nonpolyposis colorectal cancer 
HPA Human protein atlas 
HPC High performance computing 
HR Hormone receptor 
IHC Immunohistochemistry 
IHCAP Investigating Hereditary Cancer Predisposition 
KEGG Kyoto encyclopedia of genes and genomes  
LoH Loss of heterozygosity 
MAC Microcystic adnexal carcinoma 
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MALTA  MYH9 associated elastin aggregation 
MINAS multi-locus inherited neoplasia alleles syndrome  
MRI Magnetic resonance imaging 
MRPD MYH9-related platelet disorder 
MSI Microsatellite instability 
MT Mitochondrial 
NBS Nijmegen breakage syndrome 
NFE Non-Finnish European 
NGS Next generation sequencing 
NMM Non-muscle myosin 
NMMIIA Non-muscle myosin II A 
NPV No pathogenic variant 
PAV Protein-affecting variant 
PCA Principle component analysis 
PCR Polymerase chain reaction 
PHTS PTEN Hamartoma Tumour Syndrome  
PKA Protein kinase A 
PL Phred-scaled likelihood 
REF Reference allele 
RPKM Reads Per Kilobase of transcript per Million mapped reads 
SCC Squamous cell carcinoma 
SEER Surveillance, Epidemiology and End Results  
SIFT Sorting intolerant from tolerant 
SKAT Sequence kernel association test 
SLURM Simple Linux Utility for Resource Management 
SNP Single nucleotide polymorphism 
SRCC Signet ring cell carcinoma 
TCGA The cancer genome atlas 
TS Truth sensitivity 
UBC Unilateral breast cancer 
UV Ultraviolet 
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VAF Variant allele frequency 
VCF Variant call file 
VEP Variant effect predictor 
VQSR Variant quality score recalibration 
WECARE Women’s Environmental Cancer and Radiation Epidemiology  
WES Whole exome sequencing 
WGS Whole genome sequencing 
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Abstract 
The development of whole exome sequencing has transformed the study of disease predisposition. The 
sequencing of both large disease sets and smaller rare disease families enables the identification of 
new predisposition variants and potentially provide clinical insight into disease management. There is 
no standard protocol for analysing exome sequencing data. Outside of extremely large sequencing 
studies including thousands of individuals, statistical approaches are often underpowered to detect rare 
disease associated variants. Aggregation of variants into functionally related regions, including genes, 
gene clusters, and pathways, allows for the detection of biological processes that, when interrupted, 
may impact disease risk. In silico functional studies can also be utilised to further understand how 
variants disrupt biological processes and identify genotype-phenotype relationships.  
This study describes the exploration of sequencing datasets from cancers and benign tumour diseases 
including: i) hereditary diffuse gastric cancer, ii) sweat duct proliferation tumours, iii) adrenocortical 
carcinoma, and iv) breast cancer. Each set underwent germline whole exome sequencing followed by 
additional tumour or targeted sequencing to identify associated predisposition genes. Variants within 
a cluster of risk genes that are involved in double strand break repair were identified as associated with 
hereditary diffuse gastric cancer risk via gene ontology enrichment analysis. This cluster included 
PALB2 within which, using externally collated data, loss of function variants were identified as 
significantly associated with hereditary diffuse gastric cancer risk. Germline protein-affecting variants 
in the myosin gene MYH9 were identified in all individuals with a rare sweat duct proliferative 
syndrome, suggesting a role for MYH9 in skin development, regulation and tumorigenesis. These 
MYH9 variants were analysed in silico to identify a genotype-phenotype relationship between the 
clinical presentation and variants in the ATP binding pocket of the protein. Sequencing data from 
adrenocortical carcinoma cases was used to elucidate the role of Lynch syndrome genes in disease 
pathogenesis. Within the breast cancer set, candidate genes were selected to undergo targeted 
sequencing in a larger set of cases to further explore their role in breast cancer risk.  
Risk associated genes identified within this study may ultimately aid in diagnosis and management of 
disease. This thesis has also generated multiple novel tools and sequencing analysis techniques that 
may be of use for further studies by aiding in the prioritisation of candidate variants. The described 
techniques will provide support to researchers working on rare, statistically underpowered datasets and 
to provide standard analysis pipelines for a range of dataset sizes and types, including familial data 
and unrelated individuals. 
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1 Introduction 
1.1 Rare cancer predisposition 
Cancer is primarily a genetic disease, arising as a result of an accumulation of genetic and epigenetic 
abnormalities allowing uninterrupted cell proliferation. Changes that develop within the cells of the 
affected tissue (somatic variants) are the main drivers behind aberrant cellular proliferation and tumour 
development. The likelihood of these variants arising can be increased by hereditary defects (germline 
variants) in key systems such as DNA repair (Stratton, Campbell and Futreal, 2009). Being able to 
understand the hereditary pathogenic variants that predispose to this oncogenic process can provide 
means to identify high risk patients, and therefore apply preventative or surveillance strategies. In some 
cases, it can also provide insight into effective treatment options. For example, PARP inhibitors such 
as olaparib have been effectively shown to treat women with pathogenic BRCA1 variants who carry 
defects in the homologous recombination pathway (Tutt et al., 2010). 
Pedigrees describing the pattern of disease in a family can be used to discern how likely that disease is 
to be caused by hereditary defects, and how those defects have been inherited. The vast majority of 
familial cancers are inherited in an autosomal dominant manner, meaning that the variant resides on 
one of the 22 pairs of non-sex chromosomes and that only one copy of the affected gene is required to 
carry the causal variant (which is therefore heterozygous) for the phenotype to be present. This is in 
contrast to an autosomal recessive model where the inheritance of two copies of the causal variant 
(homozygous) is required to produce a phenotype. However these mendelian inheritance patterns 
overlook issues of penetrance and effect size. Penetrance describes the extent to which a variant causes 
a particular phenotype, where a penetrant variant produces the associated phenotype in all carriers 
whereas a low-penetrance variant may only cause the associated phenotype in a small proportion of 
carriers. 
Within breast cancer genetics, many predisposition genes have been identified with varying levels of 
penetrance. The most well described breast cancer risk genes are BRCA1 and BRCA2. Although these 
genes are highly penetrant, the occurrence of pathogenic variants is relatively rare and so they are only 
predicted to account for around 30% of hereditary breast cancer cases (Lalloo and Evans, 2012; Siegel, 
Naishadham and Jemal, 2013). The Li-Fraumeni syndrome gene TP53 is also highly penetrant, with 
pathogenic mutations conferring an increase in risk of 18 to 60 fold, although again these variants are 
extremely rare and are thought to account for less than 0.1% of all breast cancer cases (Lalloo and 
Evans, 2012). In contrast, pathogenic variants in moderate penetrance breast cancer susceptibility genes, 
including ATM, CHEK2, and PALB2, carry an increase in relative risk of around two to four fold (Lalloo 
and Evans, 2012). Low penetrance variants have been described by genome wide association studies 
for breast cancer predisposition (Easton et al., 2007; Turnbull, Ahmed and Morrison, 2010; Michailidou 
et al., 2017). Although the low relative risks associated with these variants are more complicated to 
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interpret clinically, they may be used to generate polygenic risk scores such as those generated to assess 
prostate cancer risk (Szulkin et al., 2015; Michailidou et al., 2017). 
Cancer risk studies in twins suggests that the proportion of disease risk that is due to heritable factors 
is greatly dependent on the type of cancer, with inherited genetic factors contributing to 57% of prostate 
cancers but only 15% of colon cancers (Mucci et al., 2016). Inherited cancers and causal genes are often 
discovered through segregation and linkage analysis of large pedigrees. One of the first cases of 
hereditary cancer was identified as far back as 1895 by Dr Aldred Warthin who described one family 
of 50 individuals of which 18 were affected with cancers of the stomach, uterine, and liver (Warthin, 
1913). Since then, the development of genetic analysis has made it possible to identify key 
predisposition genes, such as the identification of the BRCA1 gene in breast and ovarian cancer families 
(Miki et al., 1994) and the discovery of pathogenic variants in E-cadherin gene CDH1 in a large set of 
kindred from New Zealand (Aotearoa) affected with diffuse gastric cancer (Guilford et al., 1998). 
The identification of highly penetrant variants in cancer genes has greatly impacted disease 
management strategies. The latest cumulative risk estimates for breast cancer development by 80 years 
of age for BRCA1 and BRCA2 pathogenic variant carriers are 72% and 69% for each gene respectively 
(Kuchenbaecker et al., 2017). For carriers, management options range from regular magnetic resonance 
imaging (MRI) surveillance to bilateral risk-reducing mastectomy. For individuals with high lifetime 
risk estimates, bilateral risk-reducing mastectomy has been shown to substantially improve survival in 
comparison to surveillance alone (Heemskerk-Gerritsen et al., 2013). As pathogenic variants in BRCA1 
and BRCA2 also confer a risk to ovarian cancer, a bilateral risk-reducing oophorectomy is also a 
preventative option for carriers. When performed alongside a risk-reducing mastectomy, a bilateral 
oophorectomy has been shown to confer no additional risk of postoperative morbidity and so could be 
a viable option for high risk individuals (Elmi et al., 2018). 
Families carrying pathogenic CDH1 variants have a cumulative risk of diffuse gastric cancer (DGC) 
development of 70% for men and 56% for women (van der Post et al., 2015). Current guidelines 
recommend that pathogenic CDH1 variant carriers undergo risk reducing gastrectomy at the earliest 
possible point (van der Post et al., 2015). However such an invasive procedure carries a relatively high 
morbidity rate, with perioperative mortality ranging from 3-6% and risk of fatal complications between 
8-15% (Lewis et al., 2001; Norton et al., 2007). Female carriers of pathogenic CDH1 variants are also 
at risk of developing lobular breast cancer, with a cumulative risk by the age of 80 years of 39% 
(Pharoah, Guilford and Caldas, 2001). These individuals are recommended to undergo regular breast 
cancer surveillance (Pharoah, Guilford and Caldas, 2001). The well-studied risks associated with CDH1 
variants means that carriers can make informed decisions about risk reducing strategies. However, it is 
predicted that around 60% of hereditary diffuse gastric cancer (HDGC) families are negative for 
pathogenic CDH1 variants and so their own personal risk estimates are more difficult to predict. 
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As well as the problem surrounding cancer families with no known pathogenic variants in the primary 
disease-causing gene, it is now becoming apparent that pathogenic variants in cancer genes originally 
considered to be associated with one cancer phenotype have an association with multiple phenotypes. 
Lynch syndrome (Lynch et al., 1966) causes a predisposition to colorectal cancer via germline 
pathogenic variants in mismatch repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM). Originally 
named hereditary non-polyposis colorectal cancer (HNPCC) to describe the primary associated 
phenotype, this syndrome was later renamed Lynch to account for the other cancer phenotypes that 
were also attributed to pathogenic variants in these genes. Lynch syndrome is currently also associated 
with an increased risk of uterine, stomach, breast, ovarian, and pancreatic cancer (Engel et al., 2012). 
The story of novel associations between cancer phenotypes and pathogenic variants in known cancer 
genes is being increasingly described in the literature. A recent study of germline variants in 10,389 
adult cancers using The Cancer Genome Atlas (TCGA) cohort described an association between loss 
of function variants within homologous recombination gene PALB2 and stomach adenocarcinomas 
(Huang et al., 2018). A similar observation has previously been described by Sahasrabudhe et al, linking 
pathogenic germline variants in homologous recombination genes PALB2, BRCA1, and RAD51C with 
HDGC and sporadic gastric cancer (Sahasrabudhe et al., 2017). Additionally, the TCGA cohort study 
found loss of function germline variants in SDHA in melanoma, despite these being predominantly 
associated with predisposition to paragangliomas and pheochromocytomas (Burnichon et al., 2010). 
This adds complications to the story of cancer predisposition. Particularly in familial cases showing 
generations of unusual genotype-phenotype associations, it appears as though other currently unknown 
genetic factors influence the presenting phenotype. 
The concept of cancer genes causing variable phenotypes has been previously explored by Whitworth 
et al (Whitworth, Skytte, Sunde, Derek H. Lim, et al., 2016). The study designated the term Multilocus 
Inherited Neoplasia Alleles Syndrome (MINAS) to define cases with multiple pathogenic variants in 
cancer associated genes, and suggests that these may produce extreme or unexpected phenotypes 
(Whitworth, Skytte, Sunde, Derek H. Lim, et al., 2016). An example of this is the extreme phenotype 
of macrocephaly, multifocal papillary thyroid cancer, paraganglioma of the left common carotid artery, 
and paraganglioma of the right carotid body (all diagnosed within a three year time period) in an 
individual with germline variants in PTEN and SDHC (Zbuk et al., 2007). The study also demonstrated 
a number of cases where the phenotype is not associated with pathogenic variants in either of the 
identified genes, such as pathogenic variants in BRCA1 and PALB2 in an individual diagnosed with 
uterine myomas and a meningioma prior to a diagnosis of breast invasive ductal carcinoma which is 
more typical of the identified genotype (Pern et al., 2012). 
Within most cancer phenotypes, there remains some degree of missing heritability. Within breast 
cancer, around 50% of familial risk remains unexplained (Skol, Sasaki and Onel, 2016). Genome wide 
17 | P a g e  
 
association (GWA) studies have played a great part in uncovering breast cancer associated variants, 
with over 80 loci being identified which explain around 18% of heritability (Michailidou et al., 2015, 
2017; Skol, Sasaki and Onel, 2016). According to the ‘common disease, common variant’ hypothesis 
(Pritchard and Cox, 2002), heritability of rarer cancers such as gastric cancer, and in particular the 
diffuse subtype, are less likely to be explained by GWA studies which typically look for variants that 
have an allele frequency of above 1% in the tested population. One GWA study identified a particular 
association between gastric cancer and loss of function variants in DNA repair gene ATM, however this 
study used a homogenous Icelandic population and so was possibly subject to a founder effect, making 
the identification of rare variants possible in this case (Helgason et al., 2015). 
The rarity of certain cancers also greatly limits the ability for large sequencing studies to be performed 
due to limited participant numbers. In these cases, utilising familial data and populations that are 
enriched for genetic disease predisposition can allow for the identification of rare disease associated 
variants in small, statistically underpowered datasets. Recruiting and sequencing affected and 
unaffected individuals from families allows researchers to select variants that co-segregate with 
phenotype using a high to moderate penetrance, autosomal dominant inheritance model. This technique 
has been successfully utilised to further explore the role of pathogenic variants in PALB2, BRCA1, and 
RAD51C in diffuse gastric cancer families (Sahasrabudhe et al., 2017).  
Homogenous populations and those enriched for disease have also been key to identify rare disease 
predisposing variants. Disease predisposing founder variants are often discovered in previously 
geographically isolated regions (e.g. Quebec and Newfoundland), countries (e.g. Finland and Iceland), 
and ethnic groups (e.g. Ashkenazi Jewish populations) where a limited population size leads to low 
levels of genetic variation (Ponti et al., 2015). Around 55 founder variants have been discovered in 
Lynch syndrome, proving clinically useful for panel testing of colorectal cancer families (Ponti et al., 
2015). In particular, sequencing studies within the Finnish population identified two pathogenic variants 
in MLH1 which are responsible for around 50% of Finnish Lynch syndrome cases (Nyström-Lahti et 
al., 1995; Moisio et al., 1996; Ponti et al., 2015). 
The basic concept of selecting study participants who are more likely to be affected by genetic 
predisposition factors can be achieved in several different ways. On one hand, one can select study 
participants who are not nor have ever been exposed to environmental risk factors; for example, 
studying lung cancer risk in individuals who have never smoked (Lan et al., 2012). However this 
removes the ability to study the combinatory effect of genetic and environmental risk factors as was 
done in a GWA study of smokers and non-smokers with lung cancer by McKay et al (McKay et al., 
2017). The selection of young onset cases also enriches the case population for genetic factors, as 
demonstrated by Wasserman et al who showed that young onset adrenocortical carcinoma (ACC) cases 
are more likely to carry germline, pathogenic TP53 variants (Wasserman et al., 2015). Some studies 
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have utilised the identification of multiple primary tumours as an indication of increased risk of 
germline cancer predisposing factors (Cybulski, Nazarali and Narod, 2014). One study that used this 
model is the Women’s Environment, Cancer and Radiation Epidemiology (WECARE) GWA study of 
individuals with contralateral in comparison to unilateral breast cancer, identifying single nucleotide 
polymorphisms (SNPs) that modify contralateral breast cancer risk (Teraoka et al., 2011). 
These techniques for study design provide researchers with the ability to study rare disease-causing 
variants in smaller populations which are often limited in the study of rare diseases. In an age of data 
sharing, researchers are fortunate to also have access to external resources such as the TCGA cohort. 
Similarly, sequencing studies are encouraged to make data publicly available, providing the opportunity 
to collect and collate sequencing data from a variety of different resources. With some rare cancers such 
as ACC and diffuse gastric cancer, public datasets are still limited in size. It is therefore important that 
studies such as those described in this thesis provide new sequencing data to the scientific community 
to increase understanding of predisposition to rare cancers and diseases. 
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1.2 The process of oncogenesis 
The hallmarks of cancer describe a set of capabilities acquired by a healthy cell as it undergoes 
oncogenic transformation. In 2000, Hanahan and Weinberg described six capabilities of cancer cells, 
including sustaining proliferative signalling, evading growth suppressors, activating invasion and 
metastasis, enabling replicative immortality, inducing angiogenesis, and resisting cell death (Hanahan 
and Weinberg, 2000). These capabilities arise in part through variants in key regulatory genes. It is 
estimated that a human cell acquires around 70,000 genomic lesions per day, of which around 75% are 
single-stranded DNA breaks (Lindahl and Barnes, 2000; Tubbs and Nussenzweig, 2017). In healthy 
cells the DNA undergoes extensive surveillance and repair of damage, preventing a large-scale 
accumulation of DNA damage. Additionally, a complex checkpoint system forces damaged cells into 
either senescence or apoptosis (Jackson and Bartek, 2009). Often cancer cells evade these two genomic 
maintenance systems, creating a feedback loop of further damage and pathway evasion. 
The process of key pathway evasion can begin at birth for carriers of cancer predisposing variants. 
Many typical cancer genes, including BRCA1, BRCA2, TP53, and PALB2 function in the DNA repair 
pathway; it has been shown that a large proportion of breast cancer patients with germline pathogenic 
BRCA1 or BRCA2 variants lose the second copy of the gene in the tumour (Staff et al., 2000; Osorio et 
al., 2002; Simon and Zhang, 2008). This DNA repair deficiency can produce a “mutator phenotype”, 
creating genomic instability that facilitates further somatic variants (Loeb, 2001; Chae et al., 2016).  
This mutator phenotype can also be caused by somatic driver mutations in DNA polymerase ε and δ, 
producing an ultra-hypermutated cancer which has been described in the context of mismatch repair 
deficient childhood brain tumours (Shlien et al., 2015). Additionally, germline variants in the 
proofreading domains of these two polymerases have been shown to predispose to colorectal cancer, 
with 16% of colorectal tumours being hypermutated in the TCGA database (Muzny et al., 2012; Loeb, 
2016). An array of different variants can be produced in this manner, the majority of which are dubbed 
‘passenger’ lesions, which do not contribute to a malignant or invasive phenotype (Pon and Marra, 
2015). However some pathogenic variants result in the activation of oncogenes, or inactivation of 
tumour suppressor genes, giving cells a particular selective advantage in the tumour microenvironment 
(Stratton, Campbell and Futreal, 2009; Pon and Marra, 2015).  
The idea of cancer as an evolutionary process was described by Peter Nowell in 1976 (Nowell, 1976), 
suggesting that somatic variants are selected for in a tumour microenvironment in a mechanism 
mirroring Darwinian natural selection. The tumour micro-environment provides selective pressures, 
within which cells compete for space and resources. The majority of cells don’t succeed, as 
demonstrated by the tumour doubling time which has been shown to be markedly slower than the 
cellular doubling time, which suggests that the majority of cancer cells are unable to survive to mitosis 
(Klein, 2009). 
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Those cells which do survive have often gained the ability of ‘sustained proliferative signalling’, the 
first of Hanahan and Weinberg’s hallmarks of cancer (Hanahan and Weinberg, 2011). An example of 
this can be seen in melanomas, of which a study showed 42% of tumours carried somatic pathogenic 
BRAF variants which caused constitutive signalling of the mitogen activated protein-kinase (MAPK) 
pathway (Hocker and Tsao, 2007; Davies and Samuels, 2010). In additional studies, 73% of melanoma 
samples have been shown to carry pathogenic variants in 13 different genes which activate the MAPK 
and PI3K signalling pathways (Shain et al., 2015). The MAPK pathway is a key regulator of 
proliferation and differentiation in melanocytes and is hyperactivated by UV damage induced receptor 
tyrosine kinase stimulation or by pathogenic variants, allowing for uncontrolled melanocyte 
proliferation (Wellbrock, 2014). 
In addition to sustaining proliferation, cancer cells must be able to evade growth suppressors. One of 
the most well studied tumour suppressor genes is TP53, which has been shown to be one of the most 
highly mutated genes in tumours, being mutated in 26.9% of all cancers from the catalogue of somatic 
mutations in cancer (COSMIC) database (Chae et al., 2016). Inactivation of tumour suppressors is often 
caused by loss of function variants, however the majority of TP53 somatic variants (73.4%) are 
missenses which can cause a gain or loss of protein function (Olivier, Hollstein and Hainaut, 2010). 
The proportion of missense variants in TP53 that are predicted to create a non-functioning protein, as 
measured by the transactivation activity of the protein generated by single nucleotide variants, changes 
by cancer type. Transactivation activity was measured in mutated proteins in comparison to the wild-
type protein and variants were categorised as ‘supertrans’, ‘functional’, ‘partially functional’ or ‘non-
functional’ (Petitjean et al., 2007). In colorectal cancer, 84.9% of somatic pathogenic TP53 variants 
were predicted to create a non-functioning protein, this is in comparison to 66.7% of skin squamous 
cell carcinomas (SCC) tested (Petitjean et al., 2007). The tumour suppressor p53 acts in a pathway 
receiving intracellular signals such as genome damage, nucleotide pool levels, and growth-promotor 
signals and can halt the cell-cycle progression accordingly (Olivier, Hollstein and Hainaut, 2010; 
Hanahan and Weinberg, 2011). 
The apoptotic machinery receive both extrinsic signals involving tumour necrosis factors on the cell 
surface, and intrinsic signals regulated by the BCL2 protein pathway (Adams and Cory, 2007). These 
signals go on to activate a caspase pathway which executes cell apoptosis. One of the sensors involved 
in detecting DNA damage uses the p53 tumour suppressor pathway. In response to DNA damage and 
chromosomal abnormalities, p53 removes cells from the cell cycle and signals for cell death. Therefore, 
variants in TP53 as previously described can help cells evade apoptosis. In addition to loss of p53, 
BCL2 has been described as influencing tumorigenesis. Somatic pathogenic variants in the promoter 
region have been associated with increased gene expression and apoptosis evasion in breast cancer cells 
(bhushann Meka et al., 2016). Additionally expression of BCL2 has been linked to chemotherapy and 
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radiotherapy response, making it an interesting prognostic factor for breast cancer patients (bhushann 
Meka et al., 2016). 
Another related tumour mechanism is inducing replicative immortality. Healthy cells are limited in their 
potential to replicate by eroding telomeric regions at the end of chromosomes. In immortalised cells, a 
specialised DNA polymerase, Telomerase, adds telomeric repeat sequences to chromosomal ends 
preventing erosion and causing a resistance to senescence. Somatic pathogenic variants in the promoter 
of telomerase reverse transcriptase gene (TERT), leading to a promotion of expression, have been 
described in many cancer types, and have been shown to be linked to outcomes and prognosis in bladder 
cancer (Li et al., 2015). 
Angiogenesis is the process of vasculature development that provides tumours with nutrients and 
oxygen and removes metabolic waste (Hanahan and Weinberg, 2011). In adults, angiogenesis is only 
switched on temporarily in the event of wound healing or female reproductive cycling. However, this 
process is often switched on during tumour progression due to overexpression of regulators such as 
vascular endothelial growth factor-A (VEGF-A). Somatic amplification of this gene has been seen in a 
number of tumour types, in particular in hepatocellular, pancreatic and intestinal adenocarcinomas, and 
large cell carcinomas of the lung (Andreozzi et al., 2014).  
The development of an invasive or metastatic tumour phenotype is associated with late stage and 
aggressive disease. To facilitate this, cancer cells often change shape and detach from other cells and 
from the extracellular matrix. One key protein involved in the adhesion to the extracellular matrix is E-
cadherin, encoded by the gene CDH1. Reduced expression of this gene somatically and its adhesion 
partner beta catenin (CTNNB1) has been linked to poor prognosis in oesophageal cancer (Ishiguro et 
al., 2016), in addition to reduced expression in gastric and breast cancer (Asiaf et al., 2014; Hansford 
et al., 2015). 
The expression of genes in proliferation, angiogenesis and invasion-related pathways has been shown 
to be a key process in oncogenesis. However, a number of these pathways are also affected by germline 
cancer predisposing variants. The initiation of genomic instability by many cancer risk genes has 
previously been discussed. However other cancer predisposition genes have been described that target 
different cancer hallmarks. Von Hippel-Lindau disease is caused by pathogenic variants in the VHL 
gene and is associated with various tumours including clear-cell renal cell carcinoma and 
phaeochromocytomas (Gossage, Eisen and Maher, 2015). Loss of the second wild type allele of VHL 
has been associated with overexpression of growth factor VEGF inducing angiogenesis in a HIF-α 
dependent manner (Gnarra et al., 1996; Gossage, Eisen and Maher, 2015). Germline pathogenic variants 
in extracellular matrix genes CDH1 and CTNNA1 are associated with an increased risk of gastric cancer 
(Pharoah, Guilford and Caldas, 2001; Slavin et al., 2017). However, the majority of cancer cells rely 
on the occurrence of genome instability as an early event to provide genotypic variability allowing for 
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the selection of further favourable variants. This can occur through classic DNA repair deficiency 
variants, exposure to UV-damage, or in the case of pancreatic cancer, through the simultaneous 
development of genome rearrangements, possibly facilitated through replication or transcriptional stress 
(Notta et al., 2016; Tubbs and Nussenzweig, 2017). 
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1.3 Whole exome sequencing 
The human genome consists of around 3 x 109 bases, of which only 1% code for proteins. According to 
data from the 1000 genomes project, the average human differs from the reference (GRCh37) at 4.1 to 
5.0 million sites (Auton et al., 2015). The vast majority of these variants are within the 99% of the 
genome which is not protein coding. Of the small number of exonic (protein coding) variants, around 
11,000 contain synonymous variants which cause no change in amino acid (Auton et al., 2015). An 
estimated 10,000 to 12,000 variants alter or truncate the protein sequence (Auton et al., 2015). The 
majority of germline variants found naturally among populations are not disease causing. However it 
has been estimated that 85% of disease causing variants are within protein coding or regulatory regions 
(Rabbani, Tekin and Mahdieh, 2014). For this reason, when looking for disease causing variants, a 
whole exome sequencing (WES) strategy is often employed to only identify those variants in protein 
coding regions. 
The first sequencing technologies focused on simple RNA species such as tRNA and single-stranded 
RNA bacteriophages. In 1965, two separate teams led by Robert Holley and Fred Sanger developed 
related techniques to sequence RNA fragments (Holley et al., 1965; Sanger, Brownlee and Barrell, 
1965). The technique developed by Sanger used two-dimensional fractionation and radiolabelling to 
detect partial-digestion fragments (Sanger, Brownlee and Barrell, 1965). This 2-D fractionation 
technique was used by Walter Fiers in 1972 to produce the first protein coding gene sequence, followed 
by the complete genome sequence of bacteriophage MS2 (Jou et al., 1972; Fiers et al., 1976). After a 
number of rapid developments in the field of nucleotide sequencing, in 1977 Sanger developed the 
‘chain-termination’ technique, using deoxyribonucleotides (dNTPs) to produce sequences of increasing 
length and label the final nucleotide for detection and therefore infer the targeted DNA sequence 
(Sanger, Nicklen and Coulson, 1977). This technique became known as Sanger sequencing and formed 
the basis for first-generation sequencing machines. 
Second-generation sequencing techniques took a different approach, measuring luminescence produced 
by pyrophosphate conversion to ATP, and subsequently to luciferase, as nucleotides are washed 
sequentially over template DNA (Nyrén and Lundin, 1985). This pyrosequencing technique was 
licensed by biotechnology company 454 Life Sciences where it developed into commercially successful 
next-generation sequencing (NGS) technology (Heather and Chain, 2016). Technological developments 
including the generation of flowcells to bind DNA strands allowed for the creation of paired-end 
sequencing, usually of short reads, providing greater accuracy when mapping to reference sequences. 
Further advances in technology gradually led to the development of longer read sequencing techniques, 
and importantly, lower costs at a greater read depth, making the technology viable in a research and 
clinical environment. 
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A WES strategy has since been applied in many different research contexts, providing high depth, 
protein-coding data that is cheap enough to make large scale projects financially viable. In addition to 
its lower costs when compared to whole genome sequencing (WGS), aligned and merged WES data are 
more compact. An average aligned whole exome BAM file (at 60x coverage) will take around 4GB of 
disk space, in comparison to a whole genome file (at 60x coverage) which can take around 150GB. This 
vastly different file size means that one has to factor in the costs of greater data storage for WGS 
projects, in addition to greater computational power for alignment. These factors have made WES more 
practical in a clinical and diagnostics setting, where potential candidate genes may not be covered by a 
targeted panel, or for heterogenous diseases such cardiac diseases and intellectual disabilities (Y. Sun 
et al., 2015).  
The advent of GWA studies has proved invaluable in identifying common SNPs that contribute to 
complex traits such as autoimmune diseases and cancer and allows for the interrogation of lesser studied 
regulatory regions (Michailidou et al., 2015; Ji et al., 2016). This approach utilises the principle of 
linkage disequilibrium (LD; the non-random association between alleles positioned at different 
locations) to map disease causing variants to marker alleles which are genotyped on an array. Using 
this principle, one can impute genotypes and test for associations for over 10 million common SNPs in 
non-African populations by genotyping only 500,000 (Belmont et al., 2005). Some have pointed out 
that GWA studies have not lived up to the high expectations that they will explain large proportions of 
complex trait heritability. An example of this is the studies of human height, which has an estimated 
heritability of around 80%, of which three research consortia have reported 54 phenotype associated 
variants (Visscher, 2008). However the variants identified in this study of ~63,000 people explain only 
5% of phenotypic variance (Visscher, 2008; Manolio et al., 2009). Despite many different GWA studies 
covering hundreds of thousands of individuals, a degree of missing heritability still exists. This has led 
some to suggest that the common disease-common variant hypothesis has been found not to apply to 
the majority of complex human diseases (Visscher, 2008; Manolio et al., 2009; Visscher et al., 2012). 
As sequencing costs continue to drop, it is now feasible to perform genome wide studies on WGS data. 
A number of studies make use of lower coverage WGS to detect rare variants or structural variants, then 
impute these into pre-existing GWA study data (Gudbjartsson et al., 2015; Luo et al., 2017). This opens 
new avenues for exploring rare variants in large cohorts and may provide a balance between rare variant 
detection and the affordability of genotyping. 
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1.4 Development of sequencing analysis techniques 
There is no single approach to analysing WES data, although best practice guides do exist to guide 
researchers through the basics of alignment, processing, variant calling, hard filtering, and variant 
annotation. The Genome Analysis Toolkit (GATK) provides a number of tools for use in quality control, 
data manipulation, and variant discovery (Auwera et al., 2014). Although the basic sequencing analysis 
processes largely remain the same between pipelines, which tools are used to undertake these processes 
can vary greatly depending on ease of installation, personal and institutional preference, and 
concordance with previous work. 
In addition to differences in sequencing pipeline composition, researchers can apply different technical 
filters to their sets with the aim of improving overall variant quality. Next generation sequencing 
technologies are associated with greater error rates in comparison to the more traditional capillary based 
methods (Koboldt et al., 2010). To account for this, often filters are applied in addition to the 
recommended GATK Variant Quality Score Recalibration (VQSR) filtering step. The GATK VQSR 
filtering creates an adaptive error model based on variant quality by depth, mapping quality, variant 
position within reads, and strand bias of validated variants from the HapMap project, then uses this 
model to calculate the probability that variants are real (Carson et al., 2014). GATK recommends a 
VQSR threshold of 99% sensitivity for true variants, however low quality genotypes and unvalidated 
variants have been shown to pass these filters (O’Rawe et al., 2013). 
Genotyping errors can cause problems for association testing, particularly when they differentially 
affect cases and controls, and have been shown to negatively impact both common variant and 
aggregated rare variant association tests (Mayer-Jochimsen, Fast and Tintle, 2013). Although non-
differential errors which occur equally in cases and controls do not affect type I error rate, they have 
been shown to significantly decrease statistical power, particularly in rare variant association tests 
(Powers, Gopalakrishnan and Tintle, 2011). Importantly, it is noted by GATK that VQSR does not 
account for low quality genotypes which are a major source of sequencing error, and so recommends 
additional downstream genotype and dataset specific filters (McKenna et al., 2010). One study that 
tested the use of additional filters recommended genotype filtering on read depth (DP) and genotype 
quality (GQ) metrics generated by the GATK variant caller (Carson et al., 2014). This study also 
suggested that after genotype filtering, implementing a call rate filter provided the greatest data quality 
improvement, as calculated by testing the transition/transversion (Ti/Tv) ratio before and after filters 
(Carson et al., 2014). 
Once detected and filtered, the discovery of associations between rare variants and disease can also 
provide difficulties. As previously discussed, gathering rare disease cases in great enough numbers for 
the detection of rare, disease associated variants is not always feasible. As such, association tests can 
be statistically underpowered and provide inaccurate estimates of rare variant effect (Hoffmann, Marini 
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and Witte, 2010). One technique to increase statistical power for small sample sizes is to aggregate rare 
variants into functional groups. This can be done by summing variant counts in cases and controls. A 
comparable technique was performed by Morgenthaler et al to identify variant carrying genes that 
confer a risk to disease and was defined as a cohort allelic sums test (CAST) (Morgenthaler and Thilly, 
2007). However this test does not weight variants and therefore assumes that all tested variants carry 
the same direction of effect (Morgenthaler and Thilly, 2007). 
A similar variant aggregation approach can be taken that includes variant weighting, with the primary 
aim of upweighting variants that are most likely to be disease causing. The Madsen and Browning 
approach weights alleles by the inverse of the estimated standard deviation of the total number of variant 
alleles in unaffected samples (Madsen and Browning, 2009; Hoffmann, Marini and Witte, 2010). 
Variants can be gathered into functional regions such as genes, that region is then tested for an 
association. In comparison, the Combined Multivariate and Collapsing (CMC) method aggregates rare 
variants into functional regions but analyses more common variants on an individual basis (Li and Leal, 
2008). This analysis provides the benefit of rare variant aggregation without reducing the power for 
detecting individual common variant associations. 
Outside the realms of variant association tests, there are many tools available for variant prioritisation 
and candidate selection. These tools may be less necessary for familial studies where segregation 
analysis can provide a basis for highlighting candidate variants. However, where datasets consist of 
affected, unrelated individuals, these tools can provide the basis to only study variants that are most 
likely to cause disease predisposition. In smaller datasets, filtering variants based on the frequency of 
that variant within the case set is less informative. In these sets one might utilise external control cohorts 
such as the 1000 genomes project data to exclude common variants (Auton et al., 2015). 
The third phase of the 1000 genomes project describes the genomes of 2,504 individuals from 26 
populations (Auton et al., 2015). The study utilises low-coverage WGS, high coverage WES, and 
microarray genotyping to describe over 88 million SNPs, short insertions and deletions, and structural 
variants (Auton et al., 2015). Study participants are divided into five ethnic ‘super populations’ which 
can be used to ascertain specific population based allelic frequencies. Similar control sequencing 
cohorts such as the Exome Aggregation Consortium (ExAC) data also provide population specific allele 
frequencies (Lek et al., 2016). The ExAC dataset includes WES data of 60,706 individuals gathered 
from large sequencing consortiums, some of which are disease affected such as the Myocardial 
Infarction Genetics Consortium and TCGA (Lek et al., 2016). The latest version of ExAC, renamed 
Genome Aggregation Database (gnomAD) to reflect the inclusion of WGS data, is larger than its 
predecessor, containing 123,136 exomes and 15,496 genomes. However, unlike ExAC, a version of 
gnomAD has not been released which excludes TCGA data and so is it is currently not a valid control 
set for cancer association studies. 
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Other control sets that could be applicable include the 1958 Birth Cohort project and subsequent 
ICR1000 project which provides users with access to germline WES data from 1000 white British 
individuals born in one week in 1958 (Ruark et al., 2015). Although not publicly available, this set 
provides individual exome sequences from an ethnically controlled population and so could be a useful 
control set to researchers studying disease association in British individuals (Ruark et al., 2015).  
In addition to the exclusion of variants that commonly appear in healthy individuals, variant 
consequences can be predicted and used to select those that are most likely to be protein-affecting. The 
variant effect predictor (VEP) tool by GATK assigns a variant consequence based on sequence 
information in the predicted canonical transcript or in all transcripts (Auwera et al., 2014). The VEP 
tool also applies other well-used variant prediction algorithms to predict whether variants might affect 
protein structure or lie within key binding regions and therefore have a deleterious effect on protein 
function. This is less relevant for variants that are predicted to cause loss of protein function due to an 
early stop codon or shift in reading frame. However, predictions are important (and in some cases only 
applied) to variants that cause a one amino acid substitution, allowing users to prioritise variants by 
effect. 
Methodologies for variant prediction tools can be divided into four approach styles: sequence 
conservation, protein structure, combined structural and sequence approach, and meta-predictors that 
integrate results of other prediction tools (Tang and Thomas, 2016). By studying sequence homology, 
tools such as the ‘Sorting Tolerant from Intolerant’ (SIFT) algorithm predict the effect of all possible 
substitutions at given amino acid positions (Kumar, Henikoff and Ng, 2009). This is based upon the 
assumption that key amino acids in a protein are conserved throughout evolution. The same principle 
is used by the MutationAssessor functional impact score to estimate variant pathogenicity (Reva, 
Antipin and Sander, 2011). In contrast, machine learning algorithms such as AUTO-MUTE use 
databases of known protein structures to calculate how amino acid changes affect protein structure 
stability (Masso and Vaisman, 2010). 
PolyPhen-2 is a widely used variant prediction tool that combines information about sequence 
conservation with knowledge of structural protein-affecting factors (Adzhubei, Jordan and Sunyaev, 
2015). The tool feeds information from sequence, phylogenetic, and structural factors into a classifier 
trained on known pathogenic and non-pathogenic variants to predict the probability that the queried 
variant is damaging (Adzhubei, Jordan and Sunyaev, 2015). SIFT and PolyPhen-2 are some of the most 
well used prediction techniques and multiple scores have been developed integrating the two 
approaches. CAROL is one such scoring system, using a linear weighted Z-score to combine SIFT and 
PolyPhen-2 (Lopes et al., 2012). 
Which tools a researcher implements and how they select cut-offs for variant filtering should be decided 
on a per dataset basis. For example, stringent variant rarity filters using control sets will be more 
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appropriate for the study of extremely rare disease predisposition, or where complete penetrance is 
expected. Many studies have been conducted comparing sequencing pipelines (Pabinger et al., 2014), 
variant filtering strategies (Carson et al., 2014), and available prioritisation tools (Tang and Thomas, 
2016) to help researchers choose the most appropriate methods for their data. 
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1.5 Aims 
The purpose of the work presented in this thesis is to answer questions about the missing heritability in 
cancer syndromes by studying the whole exome sequencing data from young onset cases, familial cases, 
and multiple primary tumour cases using novel variant analysis techniques. The aims are as follows: 
1. To identify novel associations between genes with protein-affecting germline variants and a 
predisposition to hereditary diffuse gastric cancer in families without pathogenic CDH1 
variants. 
2. To identify if genetic factors cause the development of sweat duct proliferations and an irregular 
distribution of elastin fibres in the skin. 
3. To identify predisposing genetic factors associated with adrenocortical carcinoma development 
with a particular focus on the oncocytic subtype. 
4. To study predisposition genes in unilateral and contralateral breast cancer cases from two 
research cohorts. 
5. To create novel data analysis approaches to identify genetic factors associated with rare disease 
predisposition and development. 
Although this thesis deals more generally with cancer predisposition and the issues surrounding whole 
exome sequencing analysis for rare diseases, it will also describe each studied phenotype in more detail 
within chapters. Accordingly, information about known predisposing factors, pathology, and cohort 
specific methods can be found within each chapter, while this introduction and the methods chapter 
have been aimed towards describing overarching concepts, themes, and analysis methods. 
  
*Germline WES pipeline was created by bioinformatician Alexey Larionov, and updated and maintained by 
Alexey and me 
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2 Materials and Methods 
The number and variety of different sequencing datasets explored within this study required a range of 
different analysis techniques. After sequencing, many of the sets required the same germline WES VCF 
generation pipeline, generated in-house*. However somatic and RNA sequencing pipelines were 
generated specifically for some studies presented in this thesis. Additionally, tools were developed to 
create more efficient or thorough analysis workflows as required, and where possible were made 
available for other studies. This included tools that provide unique information for variant filtering and 
candidate selection. During the process of tool creation, temporary solutions were often created prior to 
the generation of the final tool version. These will not be discussed in this section, which focuses on 
complete pipelines and tools that were developed for use in this study. All tools and pipelines discussed 
here are freely available on GitHub (https://github.com/elliefewings). 
2.1 Germline whole exome sequencing VCF generation pipeline* 
The eight-step germline WES VCF generation pipeline was run on the High Performance Computing 
(HPC) Cambridge Service for Data Driven Discovery (CSD3) platform. The computing clusters 
required the use of Simple Linux Utility for Resource Management (SLURM) systems to submit and 
queue jobs. Therefore, each stage of the pipeline required a multistep job submission process of data 
copying, job performance, and summarising prior to copying data back to the long-term storage blades. 
 Alignment and quality control 
The raw basecall (BCL) files generated by Illumina sequencing instruments were converted to FASTQ 
files using the Illumina bcl2fastq tool. During this processing step, completed by the sequencing facility, 
demultiplexing of multi-sample sequencing lanes and trimming of adapters was performed. This study 
generated paired-end sequencing data and so prior to alignment a sample file (giving the sample name, 
first FASTQ, second FASTQ and md5 checksums file) was generated. Prepared data for each lane of 
sequencing were passed to the alignment script in a job description file, specifying data locations on 
storage blades and tool versions amongst other parameters required for the script. 
FastQC reports were generated for raw FASTQ files. The Burrows-Wheeler Aligner (BWA)-MEM (Li 
and Durbin, 2010) algorithm (v.0.7.12) was used for efficient long read alignment to hg19. Samtools 
(Li et al., 2009) (v1.2) fixmate fills in mate coordinates of sorted BAM files prior to cleaning with 
Picard (http://broadinstitute.github.io/picard) (v1.133) CleanSam and the addition of read groups with 
the AddOrReplaceReadGroups option. Summary metrics were created with the generated files using 
Flagstat by Samtools and Qualimap (Okonechnikov, Conesa and García-Alcalde, 2015) (v2.1.1). 
These alignment steps were performed per lane of sequencing prior to merging.
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 Lane Merging 
Often samples are run across several lanes of sequencing for increased read depth and quality. However, 
if a single lane of sequencing is given to this stage of the pipeline, merging is skipped. If multiple lanes 
of sequencing data were available, Samtools was used to merge the BAMs per sample across each lane 
of sequencing. Picard MarkDuplicates was used to mark PCR duplicates which were later removed 
using Samtools view. The deduplicated BAM files were indexed and md5 sums regenerated prior to 
further quality control, including Picard’s CollectInsertsSizeMetrics and 
CollectAlignmentSummaryMetrics, and other metrics generated by Qualimap and Samstat (Lassmann, 
Hayashizaki and Daub, 2011) (v.1.5.1). 
 BAM pre-processing and gVCF generation 
Once BAMs from each library had been merged across lanes, they underwent local realignment around 
insertions and deletions with GATK (McKenna et al., 2010) (v3.6.0) IndelRealigner tool. All GATK 
tools allow the user to set padding around target intervals; a padding of 10 base pairs around exons was 
introduced at this stage. BAM files were checked for any additional PCR duplicates that had been 
created by realignment, these were again marked and removed. Files underwent base quality score 
recalibration (BQSR) with GATK using a generated BQSR table to detect sequencing errors by 
estimating base call quality scores. The processed BAMs underwent variant calling using GATK’s 
HaplotypeCaller in gVCF mode to generate a gVCF file per sample. 
 Combining gVCFs 
At this stage, sample gVCFs were combined into datasets for joint variant calling. These datasets are 
often of one phenotype, so analysis was completed generating one gVCF per phenotypic group. For 
each dataset, gVCFs were copied from their libraries into a common location and ran through GATK’s 
CombineGVCFs. At this stage, our standard intervals padding of 10bp around exons were removed as 
this generates non-specific errors further downstream. One multi-sample gVCF with index and md5 
was generated for further analysis. 
 Joint variant calling 
Variant calling was performed on the combined gVCF. According to GATK best practices (Auwera et 
al., 2014; Poplin et al., 2017), this approach uses shared information across samples to provide greater 
sensitivity across areas of lower coverage. It also provides genotypes in all samples if one sample is 
called with a variant, allowing the data user to distinguish between reference sites and missing data. 
GATK’s GenotypeGVCFs was used to perform joint variant calling (using parameters: 
maxAltAlleles=6, stand_call_conf=30, stand_emit_conf=30) prior to filtering to remove variants not 
detected in any genotype. GATK’s SelectVariants and VariantAnnotator were used to flag multiallelic 
variants. To improve data quality, GATK’s VariantRecalibrator trains a variant quality score 
recalibration (VQSR) SNPmodel which was applied with ApplyRecalibration, using a SNP truth 
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sensitivity (TS) of between 97-99.5 depending on the set. For the HDGC set, this value was raised to 
99.5 as it was noticed that previously validated variants were being filtered out using the standard 97 
TS. A comparable indel model was trained and applied using the same tools, with a lower TS threshold 
of 95-97, again the higher end of this threshold was selected for the HDGC set. A histogram report was 
generated using a custom R markdown script and a summary of statistics on the output VCF was 
generated using BCFtools (Li, 2011) (v.1.2). 
 Hard filtering 
Filters were selected based on VCF summary statistics generated after joint variant calling. Variants 
with a total depth across samples of less than 10 x the number of samples in the set (equivalent to an 
average depth of 10 per sample for each variant) were flagged. A QUAL filter was selected 
corresponding to a transition/transversion (Ti/Tv) ratio of 2, and those with score lower than this were 
flagged. These flagged variants were then removed using the GATK SelectVariants --excludeFiltered 
option.  
 Annotation 
Filtered VCFs underwent splitting of flagged multiallelic variants using the GATK 
LeftAlignAndTrimVariants tool with the --splitMultiallelics flag. This ensured that multiallelic variants 
are treated as separate variants, and therefore are placed in separate rows in the VCF. Without this step, 
multiallelic variants can cause errors downstream as they often have several values, one for each 
alternative allele, in VCF fields. At this stage, variants were labelled with a unique ID. This ensured 
that the user could track variant information across different annotation files created further 
downstream. The GATK VariantAnnotator was used to add allele frequencies from the super-
populations in the phase 3 1000 genomes control data (Auton et al., 2015), and from the ExAC non-
TCGA control data (Lek et al., 2016). Variant Effect Predictor (VEP) (McLaren et al., 2016) (v82) was 
used to annotate predicted variant consequences including gene names and SIFT (Kumar, Henikoff and 
Ng, 2009) and PolyPhen (Adzhubei, Jordan and Sunyaev, 2015) scores. The pick option was enabled 
to select the most likely canonical transcript for annotation. 
 Export 
GATK VariantsToTable was used to export variants and genotype information into usable text formats 
for input into R and other downstream analysis. Each table was labelled with a code to describe the 
contents and unique variant IDs applied to each for indexing. A VEP table (VV) including predicted 
variant consequences was then exported. Separately, a table of previously applied 1000 genomes allele 
frequencies (kgen) and ExAC allele frequencies (exac) were exported for downstream use. Separate 
files were also generated for genotypes (GT), genotype qualities (GQ), sequencing depth (DP), allelic 
depths (AD), and phred-scaled likelihoods (PL scores). 
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These files were input into R scripts to check table dimensions (each file should contain information 
for the same number of variants and genotypes). In addition to the file containing standard alphabetic 
genotypes, these were converted to numeric codes and three additional tables are output based on the 
assumption of additive variant effect (homozygous reference =0, heterozygous=1, homozygous 
alternative= 2), dominant variant effect (homozygous reference =0, heterozygous=1, homozygous 
alternative= 1), and recessive variant effect (homozygous reference =0, heterozygous=0, homozygous 
alternative= 1). 
The tables described above, including an md5 file, were output into text format for input into 
downstream genotype and variant filtering specific to each dataset. 
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2.2 Somatic whole exome sequencing VCF generation pipeline 
A tumour specific pipeline was required using a somatic variant caller. Tumour data were called 
alongside data from a normal sample to call somatic variants that appear exclusively in the tumour 
sample. The pipeline uses similar processes to the germline pipeline, however omits certain 
incompatible stages such as gVCF generation. As the somatic variant caller used only calls one 
tumour/normal sample at a time, generation of gVCFs and joint variant calling is currently unsupported 
by variant calling tool MuTect2.  
Additionally, somatic variant calling over just one sample takes a large amount of time, even when 
multithreaded. Each sample takes in excess of the maximum of 36 hours allowed for each requested 
node on the high-performance computers. Initially the variant calling step was run on an in-house server, 
with some whole exome tumour/normal pairs taking around 10 days for variant calling. To speed up 
this process, manual parallelization was completed by performing somatic variant calling in genomic 
chunks across different computing nodes on the high-performance computers. Generated VCFs for each 
genomic chunk were then combined into one sample VCF, which is combined into a multi-sample VCF 
if requested. 
 Alignment and quality control to lane merging 
The first two scripts of the somatic pipeline used the same processes as the germline pipeline. The first 
included alignment of FASTQ files with BWA-MEM to hg19, filling in mate coordinates, and adding 
read groups before the generation of summary metrics as before. Lane merging was also comparable, 
using Samtools to merge and Picard to mark PCR duplicates before removal (see Germline whole 
exome sequencing VCF generation pipeline*: Alignment and quality control and Lane Merging) 
 BAM pre-processing 
BAMs underwent the same pre-processing as in the germline WES pipeline, including local 
realignment, removal of introduced PCR duplicates, and base quality score recalibration. However 
variant calling was not performed at this stage. Processed BAM files for tumour and normal samples 
were output for further analysis. 
 Somatic variant calling 
Apart from the absence of gVCF creation, the above stages of the somatic variant calling pipeline were 
comparable to the germline WES pipeline. At this point, BAM files from samples to undergo variant 
calling were collected into one location. This stage required a file containing the sample name, the name 
of the processed tumour BAM file, and normal BAM file for each sample. To multi-thread this analysis, 
the job submission script reads this file and requests 20 new computing nodes for each sample, running 
variant calling between the tumour and normal files over different intervals.  
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The Nextera Rapid Capture Exome (Illumina) intervals file was split into 20 chunks. Chunks 1 to 19 
cover chromosomes 1 to 19, whereas chunk 20 incorporates chromosomes 20, 21, 22, X, Y, and 
mitochondrial DNA (MT). Collectively these last chromosomes are still comprised of fewer intervals 
than chromosome 1 alone, and so variant calling within chromosome 1 is likely to be the rate limiting 
factor within this analysis. During job submission, the node was allocated a chunk number and a 
corresponding intervals file to run variant calling across. 
GATK MuTect2 (Cibulskis et al., 2013) was used for variant calling because of its high sensitivity, 
particularly at lower variant allele frequencies (VAFs) (Cai et al., 2016). For each sample and each 
chunk, MuTect2 was called using maxAltAlleles of 6, stand_call_conf of 30 and tumor_lod of 4. The 
tumour lod score was lowered from the default of 6.3 which was found to generate very few variant 
calls, possibly due to a low sequencing depth in the supplied tumour samples. 
Once variant calling was complete, the script checked the number of completed chunk VCFs. If all 
chunks are complete, GATK CatVariants tool (org.broadinstitute.gatk.tools.CatVariants) was used to 
concatenate the completed raw VCFs. MuTect2 outputs genotypes with columns ‘Tumor’ and ‘Normal’ 
for each sample. These were renamed to include the sample name prior to creating a multi-sample VCF. 
Additionally, the QSS score (sum of base quality scores for each allele) was removed as it consisted of 
two values (one for each allele) which causes errors during VCF merging. 
If multiple samples had been input into variant calling, the script checks if each requested sample has a 
complete, concatenated VCF file. If all samples are completed, these are then merged with BCFtools 
merge option, creating one VCF for the input set.  
 Hard filtering 
The GATK SelectVariants tool was used to trim variants not detected in any genotype, although by the 
nature of the somatic variant calling pipeline, these sites should not exist. The VariantAnnotator tool 
flags multiallelic variants for splitting further downstream. Summary stats were generated using 
BCFtools both before and after removal of variants that did not pass technical filters using GATK 
SelectVariants. 
 Annotation 
The annotation step again shares similarities to the germline pipeline. Multiallelic variants were split 
using GATK’s LeftAlignAndTrimVariants tool with the --splitMultiallelics flag. Unique variant IDs 
were assigned, and variants were annotated with 1000 genomes and ExAC population allele 
frequencies. Variant Effect Predictor (VEP) (v82) was used to annotate predicted variant consequences 
using the pick option to select the most likely canonical transcript. 
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 Export 
VCF files called by MuTect2 have fewer technical fields, and so previously exported GQ and PL scores 
were unavailable to the somatic pipeline. A VEP table (VV) including predicted variant consequences 
was exported alongside the applied 1000 genomes allele frequencies (kgen) and ExAC allele 
frequencies (exac). Additional files were generated for genotypes (GT) (including numeric codes for 
predicted additive, dominant and recessive inheritance patterns), allelic depths (AD), and tumour and 
normal LOD scores for each sample (LOD). All generated tables were checked for correct dimensions 
with an R markdown script. 
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2.3 RNA sequencing and differential expression analysis pipeline 
The RNA sequencing pipeline was generated to analyse raw FASTQs downloaded from the TCGA 
database (Zheng et al., 2016). Paired-end FASTQ files often need renaming to include the sample name 
before being entered into analysis. 
Each script takes the following three parameters: -d allows the user to set the name of the dataset, -i 
specifies the location of data to be input, -o sets the output location of the results. This pipeline was ran 
on the local medical genetics server, and so due to limits in computational resources, samples were 
analysed successively. 
 Alignment 
Prior to alignment, this script created a working directory within the analysis folder and copied over the 
specified source FASTQs. Within this directory, a samples file was created, listing each sample name, 
and the names of the first and second FASTQs. For each sample within the list, FASTQC (v0.11.6) was 
run on both FASTQs and alignment was performed with TopHat (Kim et al., 2013) (v2.1.1) which uses 
Bowtie2 (Langmead and Salzberg, 2012) (v2.3.1) to align to hg19. The no-coverage-search option was 
implemented to speed up alignment which omitted coverage searching, a feature that is recommended 
for splice junction mapping particularly in short single end read sequencing. The script generated a 
directory for each sample, containing the FASTQC report for each FASTQ and an ‘accepted_hits’ BAM 
file as well as summary files. 
 Processing 
The aligned BAM files required processing before they undergo differential expression analysis. A new 
samples file was created containing a list of all folders (and therefore samples) within the alignment 
directory. The SAMtools (v1.6) sort option sorts the aligned BAM file and rmdup was used to remove 
PCR duplicates. A FASTQC report was generated for the new processed BAM file and Samtools 
flagstat is run on the pre-processed and processed BAM file. 
 Differential expression analysis 
An additional, optional parameter was accepted for this script, allowing the user to check differential 
expression between all combinations of input samples, or to input a case control file (with the -c option) 
and test for differential expression between two groups of samples. Prior to this, Cufflinks (Trapnell et 
al., 2013) (v2.2.1) was used to quantify RNA expression over genes using a GRCh37.p13 build GTF 
file downloaded from ensembl (release-75) (ftp://ftp.ensembl.org/pub/release-75/gtf/homo_sapiens/). 
For each sample, fragments per kilobase of transcript per million mapped reads (FPKM) were counted 
over the genes described in the GTF file. 
If a case control file is not supplied, the script ran differential expression across all samples using 
cuffdiff by Cufflinks across genes in the above mentioned GTF file. If a case control file is specified, 
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the samples were split into comma separated lists of cases and controls and supplied to cuffdiff as 
different replicates of the same sample. This technique allowed expression to be summarised and 
compared between the two groups across genes, coding sequences (CDS) and isoforms. The output 
gene expression txt file was then used to select significantly differentially expressed genes. 
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2.4 Control data browsers 
When exploring candidate variants and genes in germline WES data, it is useful to know variant allele 
frequencies and how variable that gene is in a healthy population. Many control datasets such as ExAC 
offer a web browser to explore genes and variants, giving allele frequencies in different ethnic 
populations. However, the ExAC control dataset includes germline data from TCGA. A version of the 
ExAC VCF that excludes TCGA data is available to download and explore, however this requires a 
certain degree of computational knowledge. The online web browser of ExAC does not offer the option 
of searching for non-TCGA data only, and so for cancer-focused researchers, genetic counsellors and 
clinicians who are not comfortable working with a VCF this is a great hindrance. 
One of the tools developed as part of this thesis was an R shiny (https://shiny.rstudio.com/) hosted web 
app for interactively searching and exploring ExAC non-TCGA, 1000 genomes and the 1958 birth 
cohort control sets (Auton et al., 2015; Ruark et al., 2015; Lek et al., 2016). The shiny apps underwent 
several stages of correction and optimisation. The methods below describe the ExAC non-TCGA app 
script development and deployment, which was then applied to each of the three mentioned datasets. 
The apps are available at the following link: https://medgenbrowser.wordpress.com/. 
 Initial data filtering 
A memory limit of 1GB was given to any shiny app deployed on the RStudio server. Loading large 
amounts of raw data from control datasets will force the app to surpass this limit and the app will crash, 
generating a memory error. For this reason, and for ease of viewing, raw datasets were initially filtered 
to cut out unnecessary data fields and select only protein-affecting variants. 
A raw VEP annotated ExAC (release 1) non-TCGA VCF file was downloaded. GATK (v3.8.0) tools 
SelectVariants and VariantAnnotator and BCFtools (v1.3.1) were used to mask, flag and split 
multiallelic variants. Info field annotations labelling heterozygous counts were removed and VEP (v91) 
was used to reannotate the VCF using the ‘pick’ algorithm to select the transcript that is most likely to 
be functional. GATK VariantsToTable was used to select specific fields including variant location, ID, 
population allele counts, and VEP annotated consequence which was also split into separate fields.  
The annotated and separated table was saved to a txt file for further filtering in RStudio. Protein-
affecting variants were selected, including loss of function variants, inframe indels, and predicted 
deleterious and damaging missense variants (by SIFT and PolyPhen respectively). No allele frequency 
filters were applied to the set. A local version of the app, ran using a Windows batch file, was also 
available including all ExAC variants without consequence filtering, however this was too large to run 
on the shiny servers. 
To further cut down the file size, columns were removed, including population allele frequencies which 
can easily be calculated by the user from allele counts and numbers, and variant quality metrics. The 
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app allowed users to apply their own variant filters, during which the complete files are copied within 
the instance memory prior to these filters being applied. Therefore, to prevent memory related crashes, 
the complete data input into app needs to be less than half of the 1GB limit, allowing it to be duplicated 
during processing. The generated dataframe was saved in packaged Rdata format which expanded to 
410.9MB, carrying 1,275,972 variants.  
 RStudio Shiny App 
With the aid of Shiny by RStudio app development guides (RStudio Inc, 2013), the described app was 
developed using RStudio (v0.99.903) and the Shiny library (v1.0.5). The app development process 
comprises of two parts, 1) the development of the user interface, 2) the defining of the server logic 
required to generate the desired output. 
The user interface of the app utilised the fluidPage tool to assign outputs to certain sectors of the 
webpage. Using this tool, a title and description of the meaning of variant consequence filters is defined. 
Two input sections are specified, the first allows the user to input a string as a gene name and select 
whether that should completely or partially match the genes in the table, the second allows the user to 
select variant consequence (either loss of function only, or all protein-affecting variants (default)) and 
allele frequencies (< 0.05, < 0.01, or all (default)) to be included from dropdown menus. A download 
button was also created, which downloads the output file from the applied filters. The user interface 
also specifies a dataTable (DT library v0.4) output to display the filtered results. 
The server section of the script takes the input filter values and uses a combination of reactive and 
eventReactive functions to filter the dataset. Reactives are implemented by the selection of an option 
from the dropdown menu, causing the dataset to be re-filtered every time a new option is chosen. 
EventReactives were used to filter on gene name when the user presses the ‘search’ button, this prevents 
the app from searching until the user finishes typing a gene of interest. Additionally, an option was 
supplied to allow the user to match the gene name exactly, changing the filtering type from a grepl 
function (base R), which matches partial strings, to the filter function in Dplyr (v0.7.4), which only 
selects complete matches. 
In addition to variant filtering, when a gene is searched, summary metrics are created to describe 
occurrences of variants in that gene. A table was produced showing the total number of loss of function 
alleles and deleterious and damaging (by Sift and PolyPhen) missense alleles in each of the major ExAC 
populations (African, East Asian, European (Finnish), European (Non-Finnish), Latino, South Asian, 
and other) and a total across the set. This table is unaffected by consequence filters as it described both 
loss of functions and missenses. The counts however are affected by allele frequency filters and the 
filter selected is described at the top of the table. 
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The ggplot2 library (v2.2.1) was used to create a bar plot, summarising the allele frequencies of different 
consequence variants in the searched gene. The generated plot shows the numbers of loss of function 
and deleterious and damaging (by Sift and PolyPhen) missense alleles with an allele frequency below 
0.01 and greater than or equal to 0.01 within that gene. This allowed the user to discern whether that 
gene contains many common or rare variants of that specific consequence category. 
The apps for the ExAC and 1000 genomes are available to access via one web link, hosted by WordPress 
(https://medgenbrowser.wordpress.com/) which contains information about the apps and how to use 
them. As the 1958 cohort is not publicly accessible, this app is only available to run locally using either 
Windows batch script or a Mac command script depending on the users operating system. A full version 
of the ExAC non-TCGA data are also available in this format and can be requested using the contact 
form on the website. 
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2.5 Multigrep R package 
The multigrep R package was originally developed as a function and placed into a package as it was 
frequently used in analysis. The premise of the function was to allow users to search for a vector of 
incomplete strings in a set. It was particularly used in this study to filter variants on consequence. As 
some variants are labelled with multiple consequence flags, one often has to filter by searching for any 
variant that contains the consequence of interest, and therefore is an incomplete match. This can be 
achieved with the grepl function, which takes one string and searches for incomplete matches across an 
object. However, grepl does not accept more than one string, and so this must be called multiple times 
when trying to search for several incomplete strings, for example when looking to find missense variants 
or stop gained variants. When searching for multiple complete matches, value matching can be achieved 
with the %in% operator (base R), which accepts a vector of values to match. The multigrep package 
aimed to combine both concepts and allow the user to search for a vector of strings for an incomplete 
match.  
The multigrep function uses grepl inside a sapply (base R) across the vector of strings to match and 
returns a logical for each string in the object that was explored.  
vect <- c(“a”, “b”, “c”) 
x <- c(“apple”, “kiwi”, “melon”, “pear”) 
multigrep(vect, x) 
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2.6 Exon Variability Estimate (EVE) score 
During analysis of rare variants across the different cohorts described in this work, several genes were 
consistently prioritised due to their carrying a number of different rare variants in a case set. Some of 
these genes, for example TTN, are large in size and so are likely to carry a large number of variants by 
chance. However, other genes were prioritised after more complex analysis, for example selecting genes 
that contain different rare variants across multiple affected families. Often this type of analysis removes 
genes such as TTN but prioritises others that contain rare variants that are unique to one family, despite 
variability in this gene being common. This is usually the case if a gene is functionally variable, 
examples of which include olfactory receptor genes or HLA genes whose variability is key to providing 
unique tastes or immune functions to individuals. These genes are often flagged as candidates in familial 
studies, where the gene contains multiple different rare variants in affected families. These genes can 
be removed using published lists of highly variable genes, such as those identified by the FLAGs study 
(Shyr et al., 2014). However this study did not account for gene size when labelling those that are highly 
variable and so flagged genes like TTN, but not those that are smaller such as olfactory receptors (Shyr 
et al., 2014). 
 Creating the EVE score 
A VEP annotated VCF file from Phase 3 of the 1000 genomes project was used to generate a tool in R 
script which labels variants as within variable or invariable regions in a healthy population. 
Synonymous and non-synonymous variants from within this VCF file were organised into exons as 
determined by refGene coordinates (downloaded from UCSC table browser in 2016 with the following 
settings; clade: Mammal, genome:Human, assembly: Feb. 2009 (GRCh37/hg19), group: Genes and 
Gene Predictions, track: RefSeq Genes, table:refGene, output:GTF) and labelled with an exon number 
and the length of that exon in base pairs. Allele counts for each variant were determined from allelic 
frequencies for each subpopulation within the 1000 genomes project (AFR, AMR, EAS, SAS and EUR) 
as well as overall allelic frequencies. A variability score was generated by the number of alternative 
alleles per base pair in each exon, using a combined allele count of variants and the length of each exon. 
Labels were applied to each exon to show whether that score was in the lower quartile, mid-low quartile, 
mid-high quartile or upper quartile of all exons. A file was created of such scores and their 
corresponding exon positions that can be applied to any CSV format VCF within another R script. 
To test the results of this scoring system, combined variability scores were generated for each gene by 
calculating the average variability scores across exons in a gene. Genes were sorted to determine the 
most variable within the 1000 genomes population and a word cloud was generated with the Tagxedo 
online tool (http://www.tagxedo.com/) to create results that were comparable to similar studies 
identifying variable genes (Shyr et al., 2014) (figure 2.1). 
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2.7 Sanger sequencing 
Filtering of genomic data based on quality aims to reduce the number of false positives discovered, 
however inevitably there is always a risk of being too stringent and losing a large number of true 
positives. Filtering optimisation aims to find a balance between these, however validation of variants 
via Sanger sequencing is still required to confirm identified variants. 
 Primer design 
To amplify candidate variants, flanking primers are designed. The Genome Compiler 
(http://www.genomecompiler.com/) software was used to provide a user-friendly, interactive design 
environment. Ensembl was used to select a large portion of the sequence surrounding the variant of 
interest, which was then copied into Genome compiler. Using the software’s integrated IDT 
OligoAnalyzer (v3.1), forward and reverse primer sequences were selected that are between 17-30bp 
in length, and preferably at least 100bp up or downstream of the candidate variant. The total product 
size was less than 800bp. 
Primers are designed with a melting temperature of around 60°C and with less than 2°C between 
primers. If possible, primers are designed with a 3’ end that has multiple guanines or cytosines to 
improve binding. IDT OligoAnalyzer was used to predict secondary structures and homodimers that 
might occur. If a primer is predicted to homodimerize at greater than 4 bases, the primer was edited or 
redesigned to avoid this region. 
Once the primer sequences were completed, they were checked using UCSC in silico PCR tool 
(https://genome.ucsc.edu/cgi-bin/hgPcr) to ensure that primers were specific to the region of interest. If 
multiple products were predicted the primers were redesigned.  
 Polymerase Chain Reaction (PCR) and gel electrophoresis 
A PCR master mix was made using AmpliTaq Gold DNA polymerase with buffer I kit (Applied 
Biosystems). For each reaction, 2.5µl of 10x Reaction buffer (with MgCl2), 0.5µl of dNTPs (10mM) 
(Invitrogen), and 0.125µl of AmpliTaq Gold DNA polymerase was made into a master mix and 
aliquoted out with 100ng of DNA, 0.5µl of the forward and 0.5µl of the reverse primer (10µM). The 
reaction was made up to 25µl with H2O. 
PCR reaction plates or tubes were placed on a BioRad Tetrad 2 (MJ Research DNA Engine Tetrad PTC-
225) and ran for the following cycles; initial denaturing at 95°C for 10 minutes, 30 cycles of (denature 
at 95°C for 15 seconds, anneal at 60°C for 30 seconds, extend at 72°C for 1 minute), then the final 
extension at 72°C for 5 minutes before holding the plate at 4°C until the next stage of the protocol. 
The reaction mix was analysed by gel electrophoresis to test for the correct sized PCR products. A 1% 
agarose gel is made up with BioLine agarose and TAE (Tris/Acetic acid/EDTA) with a 1:20000 dilution 
of ThermoFisher Scientific SYBR® Safe for UV visualisation of PCR products using a Bio-Rad Gel 
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Doc™ XR+ System and Quantity One® 1-D analysis software (version 4.6.9). A ThermoFisher 
Scientific GeneRuler 100 bp DNA Ladder (cat. SM024) was used as a reference. 
 BigDye and Sanger Sequencing 
Excess primers and dNTPs were cleaned from PCR products using 1µl of ExoSap (made from 
Exonuclease I (New England Biolabs) and shrimp alkaline phosphatase (GE Healthcare) at a 1:2 ratio) 
and incubated at 37°C for 60 minutes. The ExoSap was then deactivated at 80°C for 15 minutes. 
Bidirectional Sanger sequencing was run using 2µl of purified PCR product, 0.75µl of BigDye (v3.1), 
2µl 5x BigDye sequencing buffer, 1µl of either forward or reverse primer (10µM), and 4.25µl of H2O. 
The semi-skirted reaction plates were placed on a BioRad Tetrad 2 (MJ Research DNA Engine Tetrad 
PTC-225) and for 25 cycles of; denaturing at 96°C for 10 seconds, annealing at 50°C for 5 seconds and 
extend at 60°C for 3 minutes and 30 seconds. 
The BigDye reactions were cleaned with 40µl of 75% isopropanol and incubated at room temperature 
for 30 minutes. The sealed plate was centrifuged at 2092RCF for 45 minutes. The open plate was then 
inverted on to absorbent paper to remove the supernatant and placed inverted into a centrifuge at 33RCF 
for 30 seconds. The open plate was air dried for 10 minutes in a dark box or drawer. 
Each reaction pellet was resuspended in 10µl of Hi-Di™ Formamide (Applied Biosystems) and 10μl 
of H2O prior to analysis on an ABI sequence analyser (Applied Biosystems). 
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3 Investigating predisposition to CDH1-negative hereditary diffuse 
gastric cancer 
3.1 Introductory statement 
This work is adapted from the following publication:  
Fewings, E., Larionov, A., Redman, J., Goldgraben, M.A., Scarth, J., Richardson, S., Brewer, C., 
Davidson, R., Ellis, I., Evans, D.G., et al. (2018). Germline pathogenic variants in PALB2 and other 
cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a 
whole-exome sequencing study. Lancet Gastroenterol. Hepatol. 3, 489–498. 
Library preparation and sequencing of the germline DNA samples described in this chapter was 
performed by James Redman, the Cancer Research UK Cambridge Institute Genomics Core, and the 
Department of Medical Genetics Stratified Medicine Core Laboratory. Sequencing data were 
downloaded and processed by me using an in-house WES pipeline generated by Alexey Larionov. All 
data analysis was designed and performed by me. Variant validation by Sanger sequencing was 
performed by me. 
3.2 Abstract 
The development of hereditary diffuse gastric cancer (HDGC) syndrome is associated with germline 
pathogenic variants in the E-cadherin gene CDH1. The risk assessment and management of HDGC 
families that do not carry a CDH1 variant is restricted. It is therefore difficult for such families to make 
informed choices about surveillance and risk reducing surgery. This study aimed to identify new 
candidate genes for HDGC predisposition in families with no detected pathogenic CDH1 variants 
(CDH1-NPV). Whole exome sequencing was performed on DNA extracted from blood obtained as part 
of the Familial Gastric Cancer Study. Analysis was performed across 39 individuals (28 affected and 
11 unaffected) from 22 CDH1-NPV families that fulfil the international criteria for HDGC. Genes with 
loss-of-function variants were prioritised using gene interaction analysis to identify clusters of genes 
that could be involved in HDGC predisposition. Germline variants were identified in known cancer 
predisposition genes or lesser studied DNA repair genes in six HDGC families. A frameshift deletion 
within PALB2 was found in a family with a history of gastric and breast cancer. Two MSH2 variants 
were identified, one frameshift insertion and one previously described start loss, in unrelated affected 
individuals. One family was identified with a unique combination of variants in DNA repair genes ATR 
and NBN. A missense variant and a splice acceptor variant were seen in two unrelated families in DNA 
repair gene RECQL5. This study expands the role of known cancer predisposition genes PALB2 and 
MSH2 in the HDGC syndrome. It also puts forward new candidates in relation to HDGC risk within 
CDH1-NPV families. 
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3.3 Introduction 
 Hereditary Diffuse Gastric Cancer 
Gastric cancer is the fourth most common cancer globally and the best characterised autosomal 
dominant inherited gastric cancer is the diffuse type, the hallmark of which is the presence of multiple 
foci of signet-ring cells (Guilford et al., 2007). The term hereditary diffuse gastric cancer (HDGC) is 
applied to families with a history of diffuse gastric cancer (DGC) that meet one of the following 
criteria:(Caldas et al., 1999; van der Post et al., 2015) 
a) At least two cases of GC in first or second-degree relatives regardless of age of onset, with one 
confirmed case of DGC.  
b) One case of DGC diagnosed before the age of 40.  
c) Any family history of DGC and lobular BC diagnosed before the age of 50. 
 Genetic predisposition to HDGC 
Germline pathogenic variants in the E-cadherin gene (CDH1) explain 25-30% of HDGC cases with 
over 100 pathogenic germline variants currently described within this gene (Hansford et al., 2015). E-
cadherin is a transmembrane protein that interacts with the actin cytoskeleton via α-catenin, β-catenin 
and γ-catenin to maintain cell adhesion and differentiation (Sereno et al., 2011). The cumulative lifetime 
risk of gastric cancer in CDH1 pathogenic variant carriers ranges from 40-60% in males and 63-83% in 
females (Hansford et al., 2015). Female carriers are also at risk of developing lobular breast cancer, 
with breast cancer surveillance also recommended to CDH1 pathogenic variant carrying families. 
Families with a strong history of DGC or lobular breast cancer, usually in combination with early onset 
cases, are recommended for CDH1 testing. Families that meet such testing criteria are often defined as 
HDGC disorder families regardless of whether a known pathogenic CDH1 variant is identified. For 
HDGC families with known pathogenic CDH1 variants, there are guidelines for risk assessment, disease 
management and surveillance. Risk reducing therapy such as prophylactic gastrectomy is often offered 
to pathogenic variant carriers, and completely eliminates risk of gastric cancer (van der Post et al., 
2015), however the effect that surgery has on the patients quality of life should be considered and only 
offered where a true risk of DGC development has been ascertained. Because of this, prophylactic 
gastrectomies are rarely recommended to families without CDH1 pathogenic variants.  
Families that meet CDH1 testing criteria but are negative for pathogenic CDH1 variants or decide not 
to undergo or to delay surgery are offered regular screening by endoscopy (Fitzgerald et al., 2010; Mi 
et al., 2017). Individuals are tested for the presence of microscopic signet ring cells, which are treated 
as a precursor lesion to DGC. Individuals in which these precursor legions are identified are referred 
for a gastrectomy, however the nature of such lesions means that it is possible that foci remain 
undetected by endoscopy and random biopsy (van der Post et al., 2015). For CDH1-no pathogenic 
variant (NPV) families, risk assessment is uncertain and therefore the efficacy of risk reducing strategies 
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is harder to assess. These families are therefore reliant on endoscopies to decide their treatment options, 
putting them at higher risk of developing undetected DGC.  
Other familial cancer syndromes that have been linked to gastric cancer predisposition include Lynch 
syndrome, which is categorised by pathogenic variants in DNA mismatch repair genes, Peutz-Jeghers 
syndrome caused by pathogenic variants in STK11, and Li-Fraumeni syndrome which is associated with 
germline pathogenic TP53 variants (Masciari et al., 2011; Sereno et al., 2011; van Lier et al., 2011; van 
der Post et al., 2015). DGC does not appear to be overrepresented in these syndromes, although this has 
not been comprehensively studied. 
Lynch syndrome is commonly associated with an increased risk of colorectal cancer and is therefore 
often known as hereditary nonpolyposis colorectal cancer (HNPCC). Mismatch repair genes associated 
with this syndrome are MLH1, MSH2, MSH6, PMS2, and EPCAM. Pathogenic variants in this pathway 
lead to an instability of microsatellite repeat regions which is often detected in tumours by microsatellite 
instability (MSI) testing. As well as conferring a risk of colorectal cancer, Lynch syndrome variant 
carriers are also at risk of developing gastric cancer, with MLH1 and MSH2 pathogenic variants carrying 
a 4.8% and 9% risk respectively (Oliveira et al., 2015). 
Additionally, predicted pathogenic variants in the DNA double strand break repair genes ATM, BRCA2, 
and PALB2 have been identified in HDGC families (Hansford et al., 2015; Sahasrabudhe et al., 2017). 
However, given the rarity of the findings, the associated DGC risk is hard to quantify, and therefore 
these variants are not used in routine clinical testing to aid identification of HDGC families. 
 Environmental and lifestyle risk factors 
Of the known environmental risk factors to gastric cancer, infection with Helicobacter pylori (H.pylori) 
is the most well studied and carries around a six-fold increase in gastric cancer risk (Vogelaar et al., 
2017). Within developed countries, gastric cancer incidence associated with H.pylori infection has been 
cut by improving sanitation and food refrigeration (Lee and Derakhshan, 2013). However estimated 
infection rates from the World Gastroenterology Organization database (Hunt et al., 2011) remain high 
in Africa and South America, in particular in Brazil where it is predicted that 82% of the population 
carry an H.pylori infection and gastric cancer incidence is estimated to be higher than average at 10.9 
(world age-standardized rates per 100,000) (Lee and Derakhshan, 2013).  
Smoking and alcohol consumption have also been associated with an increased risk of many different 
cancer types. Studies across Europe suggest that 17.6% of gastric cancers were associated with tobacco 
smoking (González et al., 2003). No difference exists between smoking and gastric cancer risk in 
Caucasian and Asian populations (LaTorre et al., 2009). There is currently no definitive evidence to 
suggest that heavy alcohol consumption alone increases gastric cancer risk, as it is suggested that 
smoking and dietary habits are confounding factors in these analyses (Tramacere et al., 2012). 
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Dietary factors including red and processed meat and fat consumption increase risk of developing 
gastric cancer. This is particularly the case for H.pylori infected individuals in the top quartile of meat 
consumption who have an absolute risk of gastric cancer development of 0.3% in ten years. Fatty acids 
including oleic acid, α-linolenic acid and di-homo-γ-linolenic acid were suggested by the EPIC-
EURGAST study to also be associated with an increased risk of gastric cancer (Chajès, Jenab and 
Romieu, 2011). 
 Surveillance and survival 
Endoscopic screening is the primary technique used to identify individuals that are at a risk of HDGC 
but with no identified pathogenic CDH1 variant. Frequency of endoscopies depends on the predicted 
risk of the individual however annual screening is currently recommended to HDGC families to identify 
early signs of malignancies and prompt referral for a risk reducing gastrectomy (van der Post et al., 
2015). The procedure, using white-light examination with random and targeted biopsies of the mucosa, 
aims to detect microscopic signet ring cell carcinoma (SRCC) foci. Targeted biopsies look for pale areas 
of the mucosa and have been shown to have a 41.7% sensitivity for SRCC detection (Mi et al., 2017). 
In comparison, random biopsies have a higher sensitivity for SRCC at around 75% (Mi et al., 2017).  
For patients with a known pathogenic CDH1 variant, who decide to delay gastrectomy, regular 
endoscopies have been shown to identify SRCC in 61.1% of cases, with the majority of these (63.6%) 
being detected on the first endoscopy (Mi et al., 2017). It has however been noted that upon 
gastrectomy, 100% of samples have multiple SRCC foci, including those that appeared normal after 
high-magnification endoscopy, and multiple gastric biopsies (Chun et al., 2001; Norton et al., 2007). 
Additionally, due to the penetrance of CDH1 pathogenic variants in HDGC, it is likely that SRCC will 
have developed prior to endoscopy. This suggests that although endoscopies are currently the primary 
method to assess the risk of invasive HDGC for an individual, regular endoscopies are still not 
recommended over a risk reducing gastrectomy for CDH1 pathogenic variant carriers. 
 Features of diffuse gastric cancer  
The development of SRCC is a known precursor to HDGC and is observed in endoscopies to ascertain 
an individual’s risk of developing invasive disease. SRCC, named as such because the large amount of 
mucin in these cells pushes the nucleus to the periphery, causing the cells to resemble signet rings, can 
be defined as in situ or pagetoid depending on whether they are identified in the basal membrane or 
below the epithelium of glands (Hansford et al., 2015). Once DGC has advanced, it presents as a poorly 
differentiated diffuse carcinoma that often causes a stiffening of the gastric wall (linitis plastica) 
(Hansford et al., 2015). 
The genetic characteristics of sporadic DGC tumours has been well studied, with one study showing 
42.2% of early onset DGC tumours carry somatic pathogenic CDH1 variants (Cho et al., 2017). Within 
this set, a number of somatic variants were also identified in TP53, ARID1A, KRAS, PIK3CA, ERBB3, 
TGFBR1, FBXW7, RHOA, and MAP2K1 (Cho et al., 2017). TCGA data was previously analysed to 
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identify molecular characteristics of sporadic gastric cancer samples, distinguishing the tumours into 
those that were positive for Epstein-Barr virus (9%: 26 out of 295 samples), had a high occurrence of 
MSI (22%: 64 out of 295 samples), were genomically stable (20%: 58 out of 295 samples), and those 
that exhibited chromosomal instability (50%: 147 out of 295 samples)(Bass et al., 2014). Within a 
subset of hypermutated tumours from this analysis, the genes TP53, ARID1A, KRAS, and PIK3CA were 
also somatically mutated (Bass et al., 2014). This suggests that these genes are important in driving the 
development of invasive gastric carcinomas.  
The sporadic diffuse cases within this set lie primarily in the genomically stable subtype. This subtype 
was enriched for a known fusion between CLDN18 and ARHGAP6 or ARHGAP26 that have been 
shown to cause a loss of epithelial integrity, leading to stomach H+ leakage (Bass et al., 2014; Yao et 
al., 2015). Interestingly, within this subtype, 30% of cases had either a CLDN18-ARHGAP gene fusion 
or a RHOA pathogenic variant, however the two were never seen simultaneously, suggesting two main, 
distinct mechanisms of cancer progression that produce one phenotype (Bass et al., 2014). 
 Aims 
This study describes the whole exome sequencing of HDGC families with no identified pathogenic 
CDH1 variants to identify DGC predisposition genes. The aims are as follows: 
1. To explore the sequencing data of affected and unaffected individuals in HDGC families and 
identify likely disease associated variants. 
2. To identify new genes or functional gene groups associated with risk of HDGC which hope to 
provide more accurate risk estimates for CDH1-negative DGC families.  
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3.4 Materials and Methods: 
 Study Population 
Twenty-eight individuals diagnosed with DGC and eleven unaffected relatives were recruited from 22 
DGC families (table 3.1) that had tested negative for CDH1 pathogenic germline variants as part of an 
ethically approved study (MREC 97/5/32). Families (including first and second degree relatives) were 
categorised as having DGC syndrome based on the current criteria (Caldas et al., 1999; Fitzgerald et 
al., 2010; van der Post et al., 2015). No individuals within this study were known to be heavy drinkers 
or smokers. As part of routine clinical testing, immunohistochemistry (IHC) staining for mismatch 
repair proteins was performed on tumours. 
 Whole exome sequencing and variant filtering 
Germline DNA was extracted from blood or saliva and prepared for PE125 WES using the Nextera 
Rapid Capture Exome enrichment kit (Illumina). Sequencing was performed on HiSeq-4000 machines. 
VCF files were generated using a standard pipeline following GATK best practice recommendations 
for whole exome data (see Chapter 2: Methods for further details). Optimised hard filters were applied, 
including a VQSR truth sensitivity of 99.5% for SNPs and 97% for INDELs, an average 10x depth 
(variant DP) per sample and a QUAL threshold of 200. The QUAL threshold corresponded to a Ti/Tv 
ratio of 2 as calculated by Samtools VCF-Stats. Multi-allelic variants were flagged and excluded for 
the purpose of this analysis. Only genotypes with quality (GQ) >20 and individual depth (genotype DP) 
in sample < 500 were retained for further analysis. 
The dataset was filtered to select 3,973 different uncommon (AF <0.05 in 1000 genomes), protein-
affecting variants (loss of function, predicted deleterious and damaging missense (as flagged by SIFT 
and PolyPhen respectively) and inframe indels) that were observed in the 28 affected HDGC samples 
(HDGC affected allele count > 0). These intuitive filters aimed to remove variants that were least likely 
to be affecting HDGC predisposition. All candidates were manually examined for allele frequency (AF) 
in healthy controls, allele count (AC) in affected and unaffected individuals within families and protein 
affect further downstream. 
Variants were aggregated into 2,847 genes which were filtered to select those that contain at least one 
loss of function variant. The top 1% most variable genes were also removed; this was determined by 
the number of rare, protein-affecting variants each gene contains within the set. A set of 732 genes 
(1,228 different variants) were retained for analysis. Variant and gene filtering steps are summarised in 
figure 3.1. 
Scripts generated for all analysis downstream of VCF generation can be found at the following link 
(https://github.com/elliefewings/Fewings_HDGC_exome_2018). VCF data can be downloaded from 
the following repository (https://doi.org/10.17863/CAM.17181). 
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Family Family ID Number of samples 
sequenced 
Diagnosis of proband (age) Other cancers diagnosed in first or second degree relatives (age) Candidate gene 
Affected Unaffected 
1 GPQ_045 2 0 DGC (41)* DGC (44)*, GC (57) 
 
2 GPQ_047 2 4 DGC (27)* PnC, OvC (22), DGC (24)*, DGC (28) 
 
3 GPQ_048 1 0 DGC (40)* GC (28), DGC (48) 
 
4 GST_172 1 2 DGC (55)* BC, LC, LxC, DGC (44), DGC (52) PALB2 
5 GST_230 1 0 DGC (36) and CRC (47)* DGC (37), LC (54), CRC (57), BC (50), DGC (61), DGC (79), LC (83)  
 
6 GST_256 1 0 DGC (37)* BC, GC (63), GC (64) RECQL5 
7 GST_257 2 0 DGC (36)* CRC, BC (43) and DGC (55)* 
 
8 GST_275 1 0 DGC (47) and LBC (36)* GC (44) MSH2 ** 
9 GST_296 1 0 DGC (44)* DGC (28) 
 
10 GST_345 1 2 DGC (28)* BC, GC (44), GC (47) 
 
11 GST_349 4 1 DGC (23)* SR*, SR*, BC (40s), DGC (45)*, PC (60s), CRC (75) ATR, NBN 
12 GST_358 1 0 DGC (68)* LC, GC (49), GC (50), GC (76) MSH2 ** 
13 GST_368 1 0 DGC (47)* GC, GC (50s), GC (60s) 
 
14 GST_440 1 0 DGC (23)* DGC (40s), DGC (46), ThyC (30) 
 
15 GST_441 1 0 DGC (53)* GC (49), GC (67), GC (71)  
16 GST_444 1 0 DGC (37)* GC, BC (54), BC (65), CRC (66)  
17 GST_446 1 0 DGC (45)* DGC (42)  
18 GST_455 1 0 DGC (48)* GC (44), GC (54)  
19 GST_459 1 1 DGC (35)* LC, UtC (65)  
20 GST_460 1 0 DGC (55)* GC (51), CRC (76)  
21 GST_463 1 1 DGC (28)* GC (53), BC (76), GC (80)  RECQL5 
22 GST_464 1 0 DGC (30)* GC, DGC (67)  
Table 3.1: The 22 families sequenced within this study, including diagnoses of the 28 affected individuals sequenced across the 22 families. First or second 
degree relatives of each proband that were diagnosed with cancer are described and those that were sequenced within this study are marked with *. In total, 39 
individuals were sequenced, including 28 affected and 11 unaffected relatives. 
* indicates sequenced affected individuals. ** No microsatellite instability was detected in tumour. Cancers described include: breast cancer (BC), colorectal 
cancer (CRC) , diffuse gastric cancer (DGC), gastric cancer (GC), laryngeal cancer (LxC), lung cancer (LC), ovarian cancer (OvC), peritoneal cancer (PnC) , 
prostate cancer (PC), signet ring cells (SR) , thyroid cancer (ThyC), uterine cancer (UtC) 
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Figure 3.1: Variants filtering and analysis  
A) variant filtering, B) gene filtering and C) gene clustering.  
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 Gene interaction network analysis: 
Gene interaction network analysis was used to identify variant-enriched candidate genes with 
interacting protein products; non-antagonistic, physically interacting proteins may have a similar effect 
on cell function and therefore may produce a shared phenotype when mutated. The 732 filtered genes 
were put through the Cytoscape GeneMania plugin, placing physically interacting genes into clusters 
for further analysis (Montojo et al., 2010). A cluster was defined as a set of five or more physically 
interacting genes. 
The Gene Ontology (GO) Consortium enrichment analysis web tool was used to apply GO terms to 
clusters using the PANTHER Overrepresentation Test (version 13.0) including the default Bonferroni 
correction for multiple testing (Blake et al., 2015). Of the significant terms highlighted by the analysis, 
the most significant term that encompasses between ten and 200 genes was selected, in compliance with 
previous studies (Milne et al., 2017).  
Allelic counts of all 1,228 different filtered, loss of function variants (regardless of GeneMania 
clustering) within the selected GO terms were aggregated and contingency tables were drawn. Variants 
were also aggregated for each GO term over a comparably filtered set of 503 Europeans from phase-3 
of the 1000 genomes study (Auton et al., 2015). A one-tailed Fisher’s exact test was performed using 
the R Stats package to test for an enrichment of loss of function variants within each selected GO term 
in HDGC in comparison to the European 1000 genomes set. For this test, only one occurrence of a 
variant was counted per family in the HDGC set. 
The 1000 genomes project was used as a control set to test for an enrichment of loss of function variants 
under selected GO terms in HDGC. Variants from European phase-3 1000 genomes data were filtered 
to select 28,833 different uncommon (European AF <0.05 in 1000 genomes), protein-affecting variants 
(loss of function, predicted deleterious and damaging missense and inframe indels). Variants were 
aggregated into 11,796 genes, which were filtered to select those with at least one loss of function 
variant and remove the top 1% most variable genes. Variability was measured by the number of rare 
protein-affecting variants each gene contains; 3,634 genes containing 4,601 different loss of function 
variants were retained. Aggregated allele counts for each selected GO term were generated using these 
loss of function variants for further analysis. 
 Validation by Sanger sequencing 
Candidate variants were validated by Sanger sequencing. Germline DNA from blood was quantified 
using the Qubit dsDNA HS kit (Invitrogen) and custom flanking primers were designed for each variant. 
DNA fragments were amplified by PCR and the products were sequenced on an ABI Genetic Analyser 
(Applied Biosystems) using BDT V3.1 (Invitrogen) according to the manufacturer’s instructions for 
Sanger sequencing (see Chapter 2: Methods for further details). Due to their proximity, both RECQL5 
variants (c.2806-2T>C and c.2828C>T) were covered by one pair of primers. 
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Tumour DNA from the father of family 11 was extracted from formalin-fixed paraffin embedded 
(FFPE) scrolls using a covaris ultrasonicator (Covaris). Identified germline candidates were checked 
for loss of heterozygosity within tumour DNA via Sanger sequencing as above. 
 Tumour immunohistochemistry and microsatellite instability analysis 
The Ventana Benchmark mismatch repair panel (MLH-1 (M1), PMS2 (EPR3947), MSH2 (G219-1129) 
and CONFIRM anti-MSH6) was used to perform IHC analysis for known mismatch repair genes within 
selected tumours. 
To perform MSI analysis, 5µm FFPE sections were mounted on glass slides for dewaxing and manual 
microdissection. DNA was extracted with the QIAamp DNA FFPE Tissue kit. Five standard 
microsatellite markers were used to evaluate the DNA (BAT-25, BAT-26, NR-21, NR-24, and MONO-
27) using the Promega MSI Analysis System (v1.2). Poorly and moderately differentiated gastric tissue 
were compared to adjacent tumour-free tissue. 
 Analysis of PALB2 and BRCA2 variants in published studies 
We searched PubMed without language restrictions between Jan 1, 2015, and Dec 31, 2017, using the 
term “hereditary diffuse gastric cancer” to identify sequencing studies reporting loss-of-function 
variants in PALB2 and BRCA2 in HDGC probands with no detected pathogenic CDH1 variants. Only 
publications released after the initial report of PALB2 and BRCA2 in HDGC by Hansford et al were 
used (Hansford et al., 2015). For each of the four identified publications (Hansford et al., 2015; 
Sahasrabudhe et al., 2017; Slavin et al., 2017; Vogelaar et al., 2017) and this current study, allele counts 
of loss of function PALB2 and BRCA2 variants were aggregated. The same counts were performed 
across the 503 European 1000 genomes samples and 27,173 non-TCGA non-Finnish Europeans from 
the ExAC control dataset (Lek et al., 2016). Within all tested sets, the well-characterised BRCA2 
polymorphic stop codon in c.9976A>T was removed. A one-tailed Fisher’s exact test was performed 
using the R Stats package to test for an enrichment of loss of function PALB2 or BRCA2 variants in 
HDGC in comparison to either control set. 
 Copy number variant analysis 
All cases within this study were analysed for potential copy number variants (CNV). The XHMM 
algorithm, using principle component analysis (PCA) to normalise read depth over exomes and a hidden 
Markov model (HMM) to identify regions of increased or decreased reads that might indicate a CNV, 
was applied to the set of HDGC samples (Fromer et al., 2012). All samples were analysed within their 
sequencing libraries to decrease the likelihood that CNVs were called due to variations in read depths 
generated during sequencing runs. Variable regions were annotated with the gene and exon that they 
covered for further analysis. Deletions were examined in BAM files to look for stretches of 
homozygosity within the called regions, as would appear if one allele had been lost. For duplications 
and deletions, the read depth of the called region was examined in comparison to surrounding regions 
and samples that were run in the same sequencing library. Around a 50% read drop or increase was 
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required for the variant to be considered for further analysis. CNVs were further explored in selected 
samples using an Affymetrix CytoScan 750K genotyping array according to clinical protocol. 
 Analysis of external data relating to candidate gene 
Independently from the gene interaction analysis, variants that meet the above filters were manually 
explored to identify any additional candidates. One candidate variant was identified in CLDN18, which 
is implicated somatically in gastric cancer. Sequencing data from a study describing occurrences of the 
CLDN18-ARHGAP26 fusion gene were downloaded using the SRA Toolkit, splitting files into two 
paired end FASTQs per sample (Leinonen, Sugawara and Shumway, 2011; Yao et al., 2015). FASTQ 
files from three germline samples that were identified as carrying the somatic fusion gene were run 
through an in-house pipeline to generate aligned BAM files merged from multiple lanes of sequencing 
(see Chapter 2: Methods for further details). One sample failed analysis, BAM files from two others 
were explored manually in IGV to look for any variants in CLDN18 that could be associated with a 
somatic CLDN18-ARHGAP26 fusion gene.  
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3.5 Results 
 Gene interaction network analysis 
A WES dataset of 39 individuals from 22 CDH1-NPV HDGC families (table 3.1) was filtered to select 
3,973 different uncommon, protein-affecting variants that were aggregated into 2,847 genes. Genes 
were further filtered to select non-variable genes with at least one loss of function variant, creating a set 
of 732 genes (1,228 different variants). The presence of affected and unaffected family members within 
this set allowed for the selection of variants downstream that segregate with phenotype on a per family 
basis. 
The set of 732 filtered genes was input into gene interaction network analysis, clustering 18 genes into 
two physical interaction clusters, shown in figure 3.2, to which GO terms were applied. A cluster of 
eight genes was identified (figure 3.2a) which was associated with the ‘double strand break repair’ 
(GO:0006302) GO term (PANTHER Overrepresentation Test p = 0.000000355). A second cluster of 
ten genes (figure 3.2b) was associated with the GO term ‘negative regulation of extrinsic apoptotic 
signaling pathway via death domain receptors’ (GO:1902042) (PANTHER Overrepresentation Test p 
value = 0.00517). 
Loss of function variants within the filtered set of 1,228 different variants were aggregated under the 
two significant GO terms. This allowed the inclusion of related candidate genes that were not clustered 
by GeneMania. A one-tailed Fisher’s exact test was applied to aggregated allelic counts for each GO 
term in the HDGC set and a comparably filtered European 1000 genomes set to look for an enrichment. 
The ‘double strand break repair’ term was significantly enriched in HDGC (p = 0.000512). In 
comparison, the ‘apoptotic signaling pathway’ term was not enriched in HDGC (p = 0.186), suggesting 
that the differences in allele counts seen in double strand break repair cannot entirely be explained by 
the technical differences that arise when using an externally produced control dataset. 
The significantly enriched double strand break repair set was further explored to select candidate genes. 
BRCA2 was a part of this set but was disregarded from further study as it contained the well-
characterised, benign polymorphic stop codon c.9976A>T (Higgs et al., 2015). Other genes in this set 
include PALB2, MSH2, RECQL5, ATR, and NBN, all of which were shown to be physically interacting 
in GeneMania. Candidate variants are summarised in table 3.2. 
  
 




Figure 3.2: Gene clusters identified via gene interaction analysis 
 Pink lines indicate a physical interaction as assigned by the GeneMania plugin for Cytoscape 
(Montojo et al., 2010). GO terms assigned to the clusters: a) ‘double strand break repair’ 
(GO:0006302), b) ‘negative regulation of extrinsic apoptotic signaling pathway via death domain 
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4 3 DGC (55) Breast, Lung, 
Larynx 
PALB2 c.757_758delAG Frameshift 
deletion 
p.Leu253fs* 0 0 NA NA 
6 1 DGC (37) Breast RECQL5 c.2806-2T>C Splice acceptor 
variant 
 0 0 NA NA 
8 1 DGC (47) Breast MSH2 c.967_968insCTCA Frameshift 
insertion 
p.Ser323fs* 0 0 NA NA 
11 5 DGC (28) Prostate ATR c.6075A>T Stop gain p.Tyr2025* 0 0 NA NA 
NBN c.1124+1G>C Splice donor 
variant 
 0 0 NA NA 
12 1 DGC (68) Lung MSH2 c.1A>C Start loss p.Met1? 0 0 Deleterious Benign 
21 2 DGC (28) Breast RECQL5 c.2828C>T Missense variant p.Arg943His 0.002 0.014332 Deleterious Probably 
damaging 
Table 3.2: Candidate variants identified via gene interaction analysis on WES data of HDGC families. 
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 Candidate variants in HDGC families 
A heterozygous 2bp frameshift deletion was identified in PALB2 (NM_024675.3: c.757_758delAG, 
p.Leu253fs, rs180177092). This loss of function variant at amino acid position 253 is predicted to result 
in an early stop codon seven amino acids downstream. Family 4 (figure 3.3), in which this PALB2 
variant was found, has a history of breast, lung, and laryngeal cancer as well as DGC. Exome sequencing 
was performed on three siblings from this family; a proband with DGC at the age of 55 years, and two 
unaffected siblings. The variant was identified in the affected proband and in one of the siblings. The 
affected proband had previously received treatment for a H. pylori infection but had tested negative at 
all subsequent biopsies. 
The mismatch repair gene MSH2 is a member of the Lynch syndrome associated gene set. Within this 
gene, two loss of function variants were identified; a start loss (NM_000251.2: c.1A>C, p.Met1?, 
rs267607911) in family 12 and a frameshift insertion of 4bp (NM_000251.2: c.967_968insCTCA, 
p.Ser323fs) in family 8. Both variants were seen in families with a strong history of DGC, however 
only DNA from the probands was available for sequencing and segregation analysis could not be 
performed. Clinical IHC staining for mismatch repair proteins was performed on tumours from both 
cases, with both tumours showing normal expression levels of the MSH2 protein. Both families tested 
negative for H. pylori. 
Variants in DNA repair genes ATR and NBN were seen within family 11 (figure 3.4). The proband of 
this family was diagnosed with DGC at age 28, two siblings underwent risk-reducing gastrectomies and 
were found to be signet ring cell positive. For the purpose of this analysis, these individuals are treated 
as affected family members. The family had an unusual history, with both parents being likely affected 
with DGC; the father was diagnosed with DGC and the mother had metastatic disease characterised by 
signet rings which were likely from a gastric primary. All individuals sequenced within this family 
tested negative for H. pylori infection. The proband and both siblings were double heterozygotes for 
loss of function variants in ATR and NBN. A splice donor variant (NM_002485.4: c.1124+1G>C) in 
NBN was seen in the three siblings but not the father and so was presumed to have been inherited 
maternally (DNA was only available for the father). A predicted stop gain variant (NM_001184.3: 
c.6075A>T, p.Tyr2025*) in ATR was seen in all three siblings and the father. Therefore, the three 
siblings carried the loss of function variants in both NBN and ATR. An unaffected second-degree relative 
within family 11 did not carry either variant. There were no other strong candidates within this family 
and a clinical Affymetrix CytoScan 750K SNP genotyping array to detect copy number changes in the 
father revealed no clinically relevant variants. DNA from tumour tissue from the father of family 11 
was analysed for loss of heterozygosity of the ATR stop gain variant. The variant was confirmed as 
appearing within the tumour but remained in heterozygous state. 
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Figure 3.3: a) The pedigree for family 4. b) Chromatograms showing the frameshift variant in sample 
1 and sample 2 against control DNA. Whole exome sequencing was performed on the circled 
samples, where shading indicates an affected and white indicates an unaffected individual. 
  
 




Figure 3.4: a) The pedigree for family 11 showing the segregation of variants in NBN and ATR 
amongst the four affected family members for which DNA was available for sequencing. b) 
Chromatograms showing the NBN and ATR variants in sample 2 against control DNA. Whole exome 
sequencing was performed on the circled samples, where shading indicates an affected individual.  
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Two variants were identified in the helicase gene RECQL5 in different families; one missense variant 
(NM_004259.6: c.2828C>T, p.Arg943His, rs200535477) in family 21 and one loss of function splice 
acceptor variant (NM_004259.6: c.2806-2T>C, rs201841487) in family 6. In both families, gastric 
cancer and breast cancer can be seen across three generations. The proband of family 6 tested negative 
for H. pylori. The H. pylori status of the proband from family 21 is unknown. Within family 21 
sequencing was performed on both an affected and unaffected individual, with the missense variant 
only appearing in the affected individual.  
Other genes within the GeneMania cluster were not explored further as the genotype of individual 
variants did not segregate with the phenotype in families containing affected and unaffected members. 
 Loss of function variants in PALB2 and BRCA2 in published HDGC studies 
The enrichment of loss of function PALB2 and BRCA2 variants in HDGC was assessed using previously 
published studies (Hansford et al., 2015; Sahasrabudhe et al., 2017; Slavin et al., 2017; Vogelaar et al., 
2017). In total, five HDGC probands were identified with loss of function PALB2 variants, out of 312 
tested families across the four studies (table 3.3). In these studies, PALB2 variant carriers account for 
1.5% of HDGC families; in comparison to 0.096% of non-TCGA, non-Finnish European ExAC samples 
(Fisher’s Exact Test, p = 1.43x10-9) and 0.2% of European 1000 genomes samples (p = 0.039). In 
contrast, there was no enrichment of BRCA2 loss of function variants in HDGC probands in comparison 
to ExAC (p = 0.47) and 1000 genomes (p = 1). 
 Germline copy number variants in HDGC 
CNVs were called across the HDGC set and variants that lie in DNA repair or known cancer genes were 
further analysed. A duplication of exons 19 to 27 of DNA repair gene ATM was called in the one 
individual from family 9 and the affected individual from family 20 was called with a duplication of 
exons 1 to 15 of HDGC predisposition gene CDH1. A deletion of 16 exons within FANCD2 was called 
in the one individual in family 13 however was later removed as a candidate due to the identification of 
heterozygous variants in called regions which are not consistent with a deletion. 
The called duplications were explored in BAM files, neither showed a 50% gain in reads across the 
region in comparison to other germline DNA samples sequenced within the library. However, the link 
between CDH1 and HDGC predisposition and its potential clinical implications warranted further 
validation of this variant within family 20 using a clinical grade SNP genotyping array. The CDH1 
duplication was not reproduced within this sample however a gain of approximately 83KB within 
22q11.23 was identified. 
The father from family 11 was also put forward for a SNP array to detect CNVs due to the likely 
inherited nature of disease within this family. A gain of approximately 1.5MB, spanning 2q12.2 and 
2q12.3, and a hemizygous loss of 71Kb within Xp11.22 were detected. Neither covered regions were 
deemed clinically relevant to the phenotype. 
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Hansford 2015 European P124 DGC (45) No c.1193AC>A Frameshift 
deletion 
p.Val398fs 0 0 
Sahasrabudhe 
2017 
European CG-12 IGC (69) Yes c.1240C>T Stop gain p.Arg414Ter 0 0 
Sahasrabudhe 
2017 
European CG-008 DGC (48) No c.1240C>T Stop gain p.Arg414Ter 0 0 
Sahasrabudhe 
2017 
European GM037589 NA (46) No c.1240C>T Stop gain p.Arg414Ter 0 0 
Sahasrabudhe 
2017  






European CG-039 DGC (47) No c.1882_1890delAAGTCCTGC Inframe 
deletion 
p.Lys628_Cys630del 0 0 
Sahasrabudhe 
2017 
Latin_american CG-028 IGC (81) Yes c.1882_1890delAAGTCCTGC Inframe 
deletion 
p.Lys628_Cys630del 0 0 
Sahasrabudhe 
2017 
Latin_american 3CG-103 Mixed 
(79) 
Yes c.2753C>A Missense p.Pro918Gln 0 0 
Fewings 2018 European GST_172_301 DGC (55) No c.757_758TAG>T Frameshift 
deletion 
p.Leu253fs 0 0 
Teixeira 
(unpublished) 
European GM048157 DGC (56) No c.1438A>T Stop gain p.Lys480Ter 0 0 
Table 3.3: PALB2 variants identified by in HDGC sequencing studies 
DGC= Diffuse Gastric Cancer, IGC = Intestinal Gastric Cancer 
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 Analysing candidate variants in external data 
Two affected individuals within family 7 were identified as carrying a germline start loss of gene 
CLDN18 (NM_001002026.2: c.1A>G, p.Met1?, rs138856042). The gene was selected as a candidate 
due to the frequency of CLDN18 fusion genes identified in gastric tumours (Bass et al., 2014; Yao et 
al., 2015). Three germline DNA samples from external data that were known to contain somatic 
CLDN18 fusion genes were downloaded. One sample failed analysis, likely due to insufficient 
coverage, and the two other samples were explored for germline CLDN18 variants. No variants were 
identified in CLDN18 exonic regions of these two samples. It was therefore assumed that somatic fusion 
genes involving CLDN18 were not a result of genomic instability in this gene caused by germline 
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3.6 Discussion 
This study analysed the sequencing data of 28 individuals affected with HDGC. The number of affected 
individuals recruited to this study and therefore the statistical power to detect disease associated variants 
was greatly limited by the rarity of the disease. The inclusion of unaffected relatives made it possible 
to discern whether variants of interest segregated with the phenotype. However to add statistical 
evidence to the identified candidate variants, larger sample numbers would need to be sequenced to 
generate an extensive affected disease cohort. This could be achieved through the recruitment of 
additional affected individuals but this may not be achievable to any great number within a reasonable 
time frame. Alternatively, externally sequenced data can be combined into one analysis, allowing the 
benefit of larger sample sizes but introducing ethnic genetic differences that would need to be accounted 
for in association analyses.  
Predicted pathogenic germline variants in known cancer predisposing genes or DNA repair genes, 
including PALB2, MSH2, ATR, NBN, and RECQL5, were found in 25% of HDGC families analysed 
in this study and these findings reflect the on-going expansion of cancer phenotypes in existing 
predisposition genes as genomic analyses extend to rarer cancer subtypes. Genes that were once seen 
as causing predisposition in one or two specific cancer types are now being further identified in the 
context of other cancers. This is largely the case for DNA damage repair genes, although specific repair 
pathways are closely associated to a few predominant cancer types. For example, mismatch repair genes 
were initially associated with colorectal cancer, but then subsequently associated with a risk of 
developing gastric and pancreatic cancer, amongst others (Lynch et al., 1985; Oliveira et al., 2015). 
However, simply identifying predicted pathogenic variants in known cancer predisposing genes does 
not imply causality. For this, larger studies with matched controls are required, which is not always 
feasible for rare diseases.  
The generation of large exome/genome datasets, such as ExAC and 1000 genomes, can be used to 
strengthen possible associations as we have illustrated in the case of PALB2. When combining our data 
with those from previously published relevant studies, including those where no PALB2 variants were 
found, we saw a significant overrepresentation of PALB2 (but not BRCA2) pathogenic variants 
compared to ExAC and 1000 genomes controls. The discrepancies in p values seen in both controls is 
likely due to differences in sample size. In addition to these published families, another HDGC family 
with a strong family history of DGC with a PALB2 stop gain variant (NM_024675.3: c.1438A>T, 
p.Lys480*) was reported to us by collaborators during the time course of this study. In a number of the 
cases described by Sahasrabudhe et al, tumour molecular profiling was also performed, showing that 
PALB2 pathogenic variant carriers had mutational signatures indicative of homologous recombination 
defects (Sahasrabudhe et al., 2017). The PALB2 protein plays a critical role in homologous 
recombination during double strand break DNA repair by recruiting BRCA2 and RAD51 to DNA 
breaks. Pathogenic variants in this gene are associated with an increased risk of breast and pancreatic 
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cancer (Antoniou et al., 2014; Pauty et al., 2014; Easton et al., 2015). Even within PALB2 families, 
cases of DGC are likely to be rare and could be masked by a larger number of sporadic gastric 
adenocarcinomas, which means that associations with cancer subtypes may be missed in 
epidemiological studies of PALB2 families unless the pathology on all reported cancers is known. An 
analogous development has recently occurred with BRCA1 where a rare serous subtype of endometrial 
cancer has shown to be overrepresented in BRCA1 variant carriers, an example of a novel cancer 
association in a gene has been intensively studied for over 20 years (Saule et al., 2018). 
ATR and NBN are involved in initiating the response to double strand DNA breaks. The DNA repair 
signalling gene NBN produces one of three proteins that form the MRN complex, alongside MRE11 
and RAD50. The MRN complex is involved in the activation of the ataxia proteins ATM and ATR, 
both of which play roles in the further recruitment of DNA damage repair proteins, cell cycle regulation, 
and apoptosis. Loss of function variants are seen in NBN and ATR independently of each other in the 
parents of family 11, both of which had DGC or suspected DGC. The variants are co-inherited in all 
three siblings within the family. Independently, these variants may be conferring a risk to DGC, 
although an extensive maternal and paternal family history show no other incidences of gastric cancer 
and only one instance of late-onset prostate cancer. Slavin et al also identified a stop gain variant in 
ATR in an individual with intestinal type adenocarcinoma and a strong family history of gastric cancer 
(Slavin et al., 2017). 
Nijmegen breakage syndrome (NBS) is a recessive condition that is associated with homozygous 
variants in NBN. One specific founder variant, c.657del5 is homozygous in more than 90% of patients 
with NBS, and in heterozygous form has been linked to stomach, colorectal and pancreatic cancer 
predisposition (Seemanová et al., 2007). Other heterozygous variants in NBN have also been linked 
with an increased risk of lung, ovarian, and breast cancer (Rainville and Rana, 2014; Maria Kałużna et 
al., 2015; Ramus et al., 2015). A large case-control study of a Chinese population identified a haplotype 
of three SNPs within the 3’ untranslated region of NBN that confers a protective effect on gastric cancer 
(P. Sun et al., 2015), suggesting that there is increased likelihood that NBN plays a role in gastric cancer 
susceptibility.  
The unusual cancer pattern seen in family 11 could be attributed to multi-locus inherited neoplasia 
alleles syndrome (MINAS), in which pathogenic variants are inherited in multiple cancer predisposing 
genes, leading to a distinct or severe phenotype (Whitworth, Skytte, Sunde, Derek H Lim, et al., 2016). 
The close relationship between NBN and ATR in double strand break repair could indicate a potential 
combinatorial effect of these loss of function variants. An indication of this could be the young age of 
onset of DGC or signet ring cells seen in the three siblings. However, the combinatorial effect of double 
heterozygosity of variants in DNA repair genes has been studied extensively in BRCA1 and BRCA2, 
and this appears to be no more deleterious to breast cancer predisposition than a single pathogenic 
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variant (Leegte, 2005). Nevertheless, double heterozygosity may have implications for genetic 
counselling that should be considered.  
Within families such as this, that show a similar phenotype in both parents, and within all three 
offspring, careful consideration of the inheritance is required for counselling. In a heterogenous 
population, it is unlikely that both parents are carrying the same predisposition variant, and therefore 
predisposition is unlikely to be conferred by a homozygous variant within the three siblings. With the 
exome sequencing of one parent, compound heterozygous variants can be examined, with one variant 
inherited from each parent. Within this family, no compound heterozygosity was seen in genes that 
could be linked to cancer predisposition. The inheritance of two variants in interacting genes is a 
phenomenon that has been described in several cases, including combinations of BRCA2/NF1 in breast 
ductal carcinomas with multiple other neoplasms (Whitworth, Skytte, Sunde, Derek H Lim, et al., 
2016), and APC/MSH2 pathogenic variants in colorectal cancer (Uhrhammer and Bignon, 2008). As 
more information is made available about gene interactions and cancer predisposing pathways it is 
likely that more families such as this are identified, and knowledge of cancer predisposition gene 
interactions will be broadened.  
Genetic variants in the mismatch DNA repair pathway are associated with Lynch syndrome. There were 
two variants identified in MSH2, a frameshift insertion and a start loss variant. A similar MSH2 initiation 
codon variant (c.1A>G) has been previously described as having a mild effect on protein function and 
so should not be treated as a loss of function variant (Kets et al., 2009). However, the function of MSH2, 
measured by the presence of MSI, has been shown to be reduced in cases and tumours with this variant 
(Kets et al., 2009). However, both cases shown here have normal expression of MSH2 after IHC 
staining and no MSI within the tumours. While it is most likely that these cases represent phenocopies, 
with neither tumour appearing to be caused by a mismatch repair deficiency, a novel (non-mismatch 
repair mediated) mechanism of MSH2-related carcinogenesis in DGC cannot be ruled out. 
The helicase RECQL5 is important for preventing aberrant homologous recombination and preventing 
the accumulation of double strand DNA breaks and preserving genome stability (Saponaro et al., 2014). 
Two individuals were sequenced within family 21, with the missense RECQL5 variant segregating 
between the affected proband and the unaffected father. The splice acceptor variant in family 6 was 
seen in an individual diagnosed with DGC at age 37. Both families have a history of breast and gastric 
cancer. 
3.7 Summary 
Previous studies have explored the role of known cancer predisposition genes in CDH1-NPV HDGC. 
Sahasrabudhe et al identify PALB2, BRCA1, and RAD51C germline variants in DGC families 
(Sahasrabudhe et al., 2017). Hansford et al describe variants in ATM, BRCA2, MSR1, and STK11, a 
frameshift deletion in PALB2, as well as uncovering a role for CDH1 related adhesion gene CTNNA1 
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(Hansford et al., 2015). Although our study found no variants of interest in ATM, BRCA1, BRCA2, 
CTNNA1, MSR1, RAD51C, or STK11, an exploration of PALB2 variants in all HDGC families 
sequenced within recent literature showed an enrichment of loss of function variants in comparison to 
control sets. The results of these studies make a case for including PALB2 in genetic testing for CDH1-
NPV HDGC families and it is possible that PALB2 pathogenic variant carriers with DGC may benefit 
from platinum-based chemotherapy and treatment with PARP inhibitors. On the other hand, the 
evidence is not yet strong enough to recommend DGC surveillance in PALB2 pathogenic variant 
carriers, as the absolute level of risk is likely to be low in the absence of a family history. 
Sporadic cancers, including a stomach adenocarcinoma subset had been analysed as part of a TCGA 
study, looking for rare germline variants in various cancer types (Lu et al., 2015). This study identified 
an association between truncating PALB2 variants and sporadic stomach adenocarcinoma (Lu et al., 
2015). To supplement this study, TCGA data were analysed, selecting 88 DGC individuals as described 
by Bass et al (Bass et al., 2014). No truncating PALB2 variants were seen within sporadic DGC samples, 
suggesting that the described association with PALB2 truncating variants is seen within intestinal gastric 
cancer samples and so may also play a role in sporadic intestinal gastric cancers. 
The rarity of CDH1-NPV HDGC makes the collection of large datasets challenging. This study 
employed gene interaction network analysis to prioritise candidate variants that are most likely to be 
involved in HDGC predisposition based on prior biological knowledge. This does not overcome the 
problem of low statistical power due to the small sample size that is often seen with rare cancer datasets. 
However, this method allows for the selection of the most plausible candidates from the available data.  
An additional analysis of CNVs within this dataset was attempted using the XHMM algorithm (Fromer 
et al., 2012). Although it has not proposed any plausible candidates, the CNV analysis on germline 
WES data is currently not validated and therefore some causal CNVs could have been missed within 
this study. 
In summary, DNA damage repair genes were found to be enriched for rare protein-affecting variants 
within HDGC families with no detected pathogenic CDH1 variants (CDH1-NPV). Further studies of 
these genes in similar families are required to gather more evidence on these potential associations, 
increasing knowledge about the genetic basis of these families to make better informed decisions about 
risk reduction and possibly influence management in affected family members. Lastly, many CDH1-
NPV families remain unexplained even after WES, and while WGS may identify some further 
candidates in regulatory elements or structural variants it seems unlikely that a second high-impact gene 
implicated in HDGC will be discovered beyond CDH1. With this in mind, focusing on moderate or low 
impact cancer genes such as PALB2 may be the way forward for studies into CDH1-NPV HDGC 
predisposition. 
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4 MALTA (MYH9 Associated eLasTin Aggregation) syndrome: 
germline variants in MYH9 cause rare sweat duct proliferations 
and irregular elastin aggregations 
4.1 Introductory statement 
The work described in this chapter is the culmination of clinical and bioinformatics research. The 
separation of this phenotype from previously described sweat duct proliferative phenotypes was noted 
by Schaller et al (Schaller et al., 2010). Cases 1, 2-1, and 2-2 were described by Jörg Schaller and Ed 
Rytina. WES on these samples was performed by the Cancer Research UK Cambridge Institute 
Genomics Core. Data were processed to VCF by an in-house WES pipeline (written by Alexey 
Larionov) and analysed by me. Family 3 was identified, sequenced and analysed by Mirjana Ziemer, 
Konstanze Hörtnagel, and Kerstin Reicherter who highlighted a number of candidate genes. Data were 
then shared with me for joint variant calling and analysis. The candidate gene was sequenced in families 
4 and 5 by Mirjana Ziemer, Konstanze Hörtnagel, and Kerstin Reicherter. All in silico functional work 
on the identified variants was designed and performed by me.  
4.2 Abstract 
In the present study we investigate the germline whole exome sequencing data of several individuals 
with an irregular distribution of elastin fibres and benign sweat duct proliferations who were initially 
diagnosed with microcystic adnexal carcinoma, Rombo or Nicolau-Balus syndrome. Germline DNA 
was extracted from the blood of six affected individuals from three families with a history of sweat duct 
proliferations. Whole exome sequencing was performed across these individuals to select candidate rare 
protein-affecting variants that co-segregate with phenotype. The candidate gene MYH9 was Sanger 
sequenced in a further two affected families. Analysis of the germline variants within these individuals 
provides evidence that these disorders represent a single entity, characterised by variants in non-muscle 
myosin gene MYH9. Non-muscle myosins take part in a diverse range of cellular functions including 
cell migration and invasion, protein and organelle localisation and cell signalling. Pathogenic variants 
in MYH9 have been previously described in patients with thrombocytopaenia and giant platelets. None 
of the affected individuals in this study presented with any phenotypic features of the previously 
described MYH9-related platelet disorder (MRPD). Four out of the five identified variants were located 
within the myosin head ATP binding pocket. The amino acids modified by these variants are conserved 
across eight different classes of myosin. We provide evidence that sweat duct proliferations with 
abnormal elastin aggregations are associated with germline pathogenic variants in MYH9 and therefore 
suggest the name MALTA (MYH9 Associated eLasTin Aggregation) syndrome to reflect this 
underlying genetic basis. The identified MYH9 variants are located in different gene regions and appear 
to have a different effect on myosin function to those previously associated with MRPD. Understanding 
the genetic basis of MALTA syndrome will aid the diagnosis and management of this disease by 
providing a way of differentiating its associated skin lesions from sweat duct tumours that have very 
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similar histopathological characteristics but are clinically aggressive. Importantly, our findings point to 
a novel disease mechanism for non-muscle myosins in tumorigenesis and skin diseases.  
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4.3 Introduction 
In 1961 Nicolau and Balus described individuals with benign cutaneous lesions including 
atrophodermia vermiculata, multiple syringomata and milia which become known as Nicolau-Balus 
syndrome and, amongst other histopathological features, was characterised by irregular distribution of 
elastin fibres (Nicolau and Balus, 1961). A similar phenotype was later described as Rombo syndrome 
by Michaelsson et al (Michaelsson, Olsson and Westermark, 1981), with elastin distribution in these 
cases appearing like “swathes of steel wool” in some areas of the dermis (Van Steensel, Jaspers and 
Steijlen, 2001). In 2010, Schaller et al described a number of cases with the same abnormal elastin 
tissue, with the additional feature of sweat duct proliferations that are morphologically similar to those 
found in microcystic adnexal carcinoma (MAC) patients (Schaller et al., 2010). MAC is a locally 
aggressive disease composing of sweat duct proliferations that invade perineurally and require surgical 
resection in many cases (Goldstein, Barr and Santa Cruz, 1982). In contrast, the condition described by 
Schaller et al followed a benign course with no perineural invasion (Schaller et al., 2010) and the two 
described cases showed no disease progression 19 years after partial excision of the lesions (Schaller et 
al., 2010). This suggests that while the ductal proliferations seen in these cases mimic MAC, the disease 
progression and histopathological features are more closely related to Rombo syndrome. A summary 
of these phenotypically related syndromes is given in figure 4.1. 
Sweat duct proliferations and related cutaneous tumours pose a challenge for diagnosis and treatment 
as they have multiple overlapping histopathological features. Understanding the genetic landscape of 
these complex skin lesions would aid diagnosis, particularly in distinguishing them from more 
aggressive neoplasms, thereby altering the treatment and management. We provide evidence that sweat 
duct proliferations with abnormal elastin aggregations are associated with germline pathogenic variants 
in MYH9 and suggest the name MALTA (MYH9 Associated eLasTin Aggregation) syndrome to reflect 
this. 
 Microcystic adnexal carcinoma associated cutaneous neoplasia 
MAC is a cutaneous neoplasm that was first described in 1982 by Goldstein et al (Goldstein, Barr and 
Santa Cruz, 1982). Goldstein described the disease as a distinct clinicopathologic entity and detailed 
the histological differences between MAC and other known adnexal tumours (Goldstein, Barr and Santa 
Cruz, 1982). In contrast to other described adnexal tumours, MACs exhibit highly local aggressive 
behaviour, as well as being largely invasive into skeletal muscle and perineural spaces (Goldstein, Barr 
and Santa Cruz, 1982). This perineural involvement and the propensity for the lesions to appear on the 
upper lip distinguish MAC from other similar adnexal tumours (Goldstein, Barr and Santa Cruz, 1982). 
However, differential diagnosis of sweat gland tumours has remained problematic due to the lack of 
consensus in classification which is often due to inadequate biopsy size (Smith et al., 2001; Cardoso 
and Calonje, 2015). In particular, desmoplastic trichoepithelioma (dTE), sclerosing and morphea-type 
basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and syringoma are frequently and 
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incorrectly diagnosed (Goldstein, Barr and Santa Cruz, 1982; Crowson, Magro and Mihm, 2006). 
However, MACs display ductal structures which differentiates them from dTE and are also unique in 
their invasion both perineurally and subcutaneously (Goldstein, Barr and Santa Cruz, 1982).  
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Figure 4.1: A timeline showing the identification of cutaneous neoplasms displaying atrophodermia 
vermiculata and elastin aggregations. 
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In spite of this, the literature suggests misdiagnosis is still a concern with related diseases, with one case 
study reporting that seven MAC cases were not diagnosed with MAC after an initial clinical 
examination (Gabillot-Carre et al., 2006). Of these, six cases were misdiagnosed after further 
pathological examinations (Gabillot-Carre et al., 2006). 
MAC-like ductal structures have also been observed without such perineural invasion, and in 
combination with other features such as syringomata, atrophodermia vermiculata, milia and keratotic 
cysts (Schaller et al., 2010). One main histopathological characteristic of these cases is an unusual 
aggregation and distribution of elastin fibres which have been described as ball like or wiry in various 
cases (Van Steensel, Jaspers and Steijlen, 2001; Schaller et al., 2010). Such features are also described 
in Rombo and Nicolau-Balus syndrome however these cases have not been described with MAC-like 
ductal structures (Michaelsson, Olsson and Westermark, 1981; Van Steensel, Jaspers and Steijlen, 2001; 
Schaller et al., 2010). Although these described cases have some overlapping features, such as elastin 
aggregations, other features are markedly less common. For example, the family described by 
Michaelsson et al were also identified with a number of BCC cases, developing at around the age of 35 
(Michaelsson, Olsson and Westermark, 1981). Whilst other cases appear to be affected mainly 
superficially, causing social impairment in otherwise healthy individuals (Van Steensel, Jaspers and 
Steijlen, 2001). The spectrum of identified features in individuals with elastin aggregations can cause 
differential diagnosis. Within cases described by Schaller et al. a mother and daughter presented with 
different combinations of the above features and so were diagnosed with different diseases (Schaller et 
al., 2010). In cases such as these, it is likely that the disease is inherited in an autosomal dominant 
manner and so, if possible, genotypic characterisation would more informative for diagnosis and 
management.  
Case studies of Nicolau-Balus and Rombo syndrome described abnormal elastin distribution as a key 
diagnostic factor (Michaelsson, Olsson and Westermark, 1981). In these cases, in contrast to the 
families described within this study, no sweat duct proliferations were described (Michaelsson, Olsson 
and Westermark, 1981; Van Steensel, Jaspers and Steijlen, 2001; Schaller et al., 2010). However it is 
possible that these were missed in the original biopsies, as was the case with one family described within 
this study within which sweat duct proliferations were identified upon retrospective review (Van 
Steensel, Jaspers and Steijlen, 2001). In contrast to this, Chiller et al (Chiller et al., 2000) collated data 
from 48 MAC cases which were identified as having small keratinizing cysts and ductal proliferations 
but with no mention of elastin distribution. Therefore, although MALTA syndrome shows great 
similarities to MAC, and in some cases could be diagnosed as such, the irregular elastin distribution, 
relative benign nature of disease progression, and lack of MAC-like ductal proliferations in otherwise 
affected family members suggests this is a distinct entity.  
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Within this study we describe a benign syndrome that differentiates itself in its characteristic 
aggregations of elastin fibres and underlying genetic factor. Although the MAC-like ductal structures 
are a distinct cutaneous feature of this syndrome, they are not entirely descriptive of the disease as a 
whole and are not present in all cases. The common features that appear within described families 
include the keratinizing cysts and irregular distribution of elastin as is described in a mother and 
daughter by Schaller et al (Schaller et al., 2010). The MAC-like ductal proliferations identified by 
Schaller et al (Schaller et al., 2010) were only present in four of the five tested families. 
 Occurrences of adnexal neoplasms – Age, environment, gender and family history 
The differential diagnoses of adnexal neoplasias limits the ability to generate a large scale 
epidemiological study of age and environmental factors. Such studies have been done for more specific 
phenotypes such as MAC, however these rely heavily on case studies to provide information about the 
clinical attributes of patients. Using case study clinical and histopathological information to study 
syndromes poses the challenge of making sure that all samples were correctly diagnosed and share the 
same phenotypic features. The MAC-like syndrome described within this study may be encompassed 
within some of the MAC cohorts, as at the time of diagnosis irregular distribution of elastin may have 
been missed by pathologist or noted as a sample irregularity during MAC diagnosis. Therefore, 
understanding the epidemiology of this and other similar adnexal neoplasms may give an indication of 
the occurrences of the described MAC-like syndrome.  
A large scale epidemiological study of MAC occurrences has yet to take place. As such, individual case 
studies are heavily relied upon to provide information about the clinical attributes of patients. Some 
studies have collated individual sweat duct proliferation case studies to try and define groups at greater 
risk and to discuss the efficiency of treatments among these groups (Chiller et al., 2000; Gabillot-Carre 
et al., 2006; Schaller et al., 2010). One benefit of such collation is that individual diagnoses can be 
discussed with reference to histopathological information from all participants, limiting differential 
diagnosis. An example of this is shown by Schaller et al. (Schaller et al., 2010) in a table of patients 
from various studies shown in combination with their clinical and histopathological features. Another 
benefit is that factors such as gender, age of diagnosis, familial history and environmental exposures 
can be analysed to provide information which may aid in the diagnosis and management of the disease. 
The average age of MAC patients is extremely diverse across studies. One large scale American study 
of 48 cases states the median age of diagnosis to be between 60 to 69 years (Chiller et al., 2000). 
However they do note that their study includes one Male of 19-years-old and suggest a trend towards a 
younger diagnosis in male patients (Chiller et al., 2000). Another report of seven cases similarly state 
their patients to be middle aged (Gabillot-Carre et al., 2006). Interestingly, a summary of MAC-like 
cases by Schaller et al. gives an age of disease onset between 2 to 15 years of age (Schaller et al., 2010). 
Another case study describing MAC on the axilla of an 18-year-old discusses this age difference 
between studies, suggesting that some lesions have been initially reported many years before a diagnosis 
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was ascertained (Green et al., 2014). They go on to venture that the asymptomatic and indolent nature 
of MAC may lead to it being overlooked in children and young adolescents; and perhaps not be reported 
or diagnosed until later in life (Green et al., 2014). This is emphasised by the presence of paediatric 
cases of MAC, with some being congenital (Green et al., 2014), which suggests that genetic factors 
may be more influential than age and environmental exposure. 
As with many cutaneous carcinomas, UV exposure is speculated to be a driving factor of MAC 
development. This speculation is coupled with the fact that MAC, as well as Rombo and similar 
syndromes, is often identified on the head or neck, and less frequently on the axilla (Crowson, Magro 
and Mihm, 2006). When this is considered along with a median diagnosis age of middle to late in life, 
it seems reasonable to suggest that the onset of the disease is coupled with an environmental factor or 
linked to aging. One American epidemiological study has suggested that a propensity for the lesion to 
occur on the left side of the face may be linked to increased UV exposure whilst driving (Chiller et al., 
2000). However there are noted occurrences of sweat duct proliferative lesions in regions that are not 
commonly UV exposed, including on the breast (Cardoso and Calonje, 2015) and buttocks (Schaller et 
al., 2010). There are also several childhood and adolescent case studies (Schaller et al., 2010; Green et 
al., 2014), which suggests that genetic factors may contribute to risk in some cases.  
In 2010 it was reported that fewer than 300 MAC cases had been described worldwide (Inskip and 
Magee, 2015). The rarity of this disease means that a wide scale study of the effects of UV exposure 
and genetic factors on MAC predisposition and development is currently not possible; although the 
effects of UV are often alluded to in the literature, with some case studies labelling exposure as a known 
predisposing factor (Inskip and Magee, 2015). When studying the effect of UV and genetic factors on 
MAC development it is important to make distinctions between middle to late life cases with no family 
history of cutaneous neoplasms, which are more likely to be sporadic and linked to environmental 
factors, and early onset cases or those with a family history of cutaneous neoplasms within which 
genetic factors are likely to play a role. 
In contrast to many of the MAC cases, cases of Rombo syndrome were diagnosed during late childhood 
or adolescent years (Michaelsson, Olsson and Westermark, 1981; Van Steensel, Jaspers and Steijlen, 
2001). Of the limited number of cases currently described, one is part of a family with a strong history 
of Rombo, with the syndrome being observed through four generations (Michaelsson, Olsson and 
Westermark, 1981). Cases within this family were first observed with skin conditions including 
atrophodermia vermiculata and milia-like papules that developed in late childhood (Michaelsson, 
Olsson and Westermark, 1981). A spontaneous case was presented by Van Steensel et al., this individual 
first presented with irregular facial skin at 15 years of age however the patient claimed to have begun 
noticing changes to the skin at around 6 years of age (Van Steensel, Jaspers and Steijlen, 2001). 
Ashinoff et al also identified a spontaneous Rombo patient who presented with atrophodermia 
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vermiculata, plaques on the left and right cheeks and no eyelashes, as was seen in previous cases 
(Michaelsson, Olsson and Westermark, 1981; Ashinoff, Jacobson and Belsito, 1993). Unusually, this 
patient was diagnosed at the age of around 94, and had apparently normal skin at the age of 35 (Ashinoff, 
Jacobson and Belsito, 1993). It has been further speculated that the case described by Ashinoff et al was 
not affected with Rombo syndrome due to a lack of described atrophodermia vermiculata as well as 
different histological features to those described by Michaelsson et al and Van Steensel et al 
(Michaelsson, Olsson and Westermark, 1981; Van Steensel, Jaspers and Steijlen, 2001).  
For this study, which aims to identify an underlying genetic cause to MAC-like sweat duct proliferations 
in combination with irregular elastin aggregations, all samples were identified with an early age of onset 
or strong family history. This increases the likelihood that the identified phenotype is caused by 
underlying genetic causes. The development of similar disease characteristics later in life and with no 
family history may be indicative of spontaneous genetic variants or that these phenotypes can be 
mimicked by environmental predisposing factors. 
 Histopathology of MAC and MAC-like adnexal neoplasms 
A report by Public Health England stated that there were 109 cases of MAC within the region from 
2010 to 2013 (Public Health England, 2015). The rarity of such cancers means that each case study 
provides a large contribution to the field and a new insight into the disease. Consequently, the pathology 
of MAC is not singularly defined, but rather a collection of observations from various case studies. 
However, Goldstein et al (Goldstein, Barr and Santa Cruz, 1982) identified some core features of MAC 
that can distinguish this entity from its differential diagnoses, including the appearance of lesions on 
the upper lip and both perineural and subcutaneous involvement (Goldstein, Barr and Santa Cruz, 1982). 
MAC-like adnexal neoplasms may present with a number of the following features and may 
subsequently have been diagnosed as a different disease or syndrome. 
MAC often presents as a plaque or subcutaneous nodule, which is usually within, but not limited to the 
head or neck region (Gabillot-Carre et al., 2006; Cardoso and Calonje, 2015). Patient biopsy usually 
reveals keratocysts which present superficially and in the mid-dermis, alongside infiltrating ductal 
structures (Schaller et al., 2010). These structures are surrounded by 2 layers of cuboidal cells in the 
deep dermis (McKinley et al., 2014). Both MAC and MAC-like ductal proliferations are often also 
surrounded by myxoid connective tissue or collagenous stroma, giving an appearance that has been 
described as ‘onion-like’ (Schaller et al., 2010; McKinley et al., 2014).  
One additional feature that has been described in the cases studied here is the aggregation of elastic 
tissue in the dermal papillae (Schaller et al., 2010). Specifically, a number of cases show ball-like elastin 
structures within the papillary dermis (Schaller et al., 2010). These aggregations are a feature of 
Nicolau-Balus syndrome and are often accompanied by reduced distribution of elastic fibres in the deep 
dermis which was shown in cases by Schaller et al. (Schaller et al., 2010) with the addition of MAC-
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like ductal proliferations. Interestingly, such distinct histopathological features which have been 
described in Rombo and Nicolau-Balus cases, have not been noted in previous MAC studies, where 
diagnosis is focused on the appearance of more classical ductal proliferations (LeBoit and Sexton, 1993; 
Chiller et al., 2000; Cardoso and Calonje, 2015). 
Additionally, MAC and MAC-like cases have been identified with syringomas (Schaller et al., 2010; 
McKinley et al., 2014; Cardoso and Calonje, 2015). These benign neoplasms of eccrine origin have 
been described as yellow or flesh coloured papules and can appear as an individual entity or in 
conjunction with another disease (Lau and Haber, 2013). It has been proposed that some patients with 
MAC-like ductal proliferations may instead be suffering from a rare form of ‘plaque-like’ syringoma, 
such is the similarity of the histopathology (Schaller et al., 2010). This is supported by the presence of 
cuboidal epithelial cells with sclerotic collagen (Schaller et al., 2010) as seen in cases of eruptive 
syringoma (Cannon, 1981; Lau and Haber, 2013). 
Cases of Rombo syndrome have been described with similar histopathological features. One case study 
reports cysts in the middle dermis containing vellus hairs and horny material, with a general thickening 
of the stratum corneum identified from biopsies and described as hyperorthokeratosis (Van Steensel, 
Jaspers and Steijlen, 2001). Similar to the MAC-like cases, irregular distribution of elastin fibres has 
been observed in individuals with Rombo syndrome, however these have been described as similar to 
‘swathes of steel wool’ (Van Steensel, Jaspers and Steijlen, 2001). This is noticeably different from the 
‘ball-like’ aggregations described in MAC-like cases (Schaller et al., 2010), however similarities can 
be drawn in the inability for cells to regularly distribute elastin. More Rombo, MAC and MAC-like 
cases would need to be specifically observed for elastin distribution to identify whether these 
differences are distinct features that differentiate MAC from Rombo and MAC-like ductal 
proliferations. 
 Sweat duct morphology 
Human sweat glands can be largely defined as apocrine or eccrine. Apocrine glands are involved in 
secretion into hair ducts; specialised apocrine glands include the ceruminous gland which produces 
cerumen (earwax) in the external auditory canal and the mammary gland (Cardoso and Calonje, 2015). 
Eccrine glands secrete directly to the skins surface and are expansive in their localisation in human skin 
in comparison to other mammals where they are mainly found on the palms and soles of the feet (Murota 
et al., 2015). Both eccrine and apocrine sweat glands change in activity during puberty, particularly in 
their joint involvement in response to psychological stress (Harker, 2013). Eccrine glands show an 
increase in sweat secretion, induced by acetylcholine, at around the age of 12, particularly on the axilla, 
whereas apocrine glands remain inactive until puberty (Harker, 2013; Murota et al., 2015). 
Apocrine and eccrine sweat glands do share some morphological similarities. For instance, both glands 
are composed of a secretory unit and a ductal epithelium (Hibbs, 1958). However the ducts of eccrine 
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glands are long and thin, in comparison to the shorter and thicker ducts of the apocrine gland (Lu and 
Fuchs, 2014). In contrast, the larger gland region of the apocrine glands allows it to be positioned in the 
same region of the middle dermis to the smaller eccrine gland, in spite of their difference in duct length. 
The secretory region of eccrine glands constitutes an inner layer of secretory cells surrounded by 
myoepithelial cells, both of which are encircled by a basement membrane (Lu and Fuchs, 2014). 
Traditionally, various malignant sweat gland tumours were classified by whether they originate from 
eccrine or apocrine glands (Cardoso and Calonje, 2015). MAC was originally reported as being of 
eccrine origin, due to the identification of intact eccrine glands and morphologically similar tumour 
cells (Goldstein, Barr and Santa Cruz, 1982). Immunohistochemical studies into MAC origin propose 
that the presence of S-100 and CF-1 positive cells is a suggestion of its eccrine origin (Ongenae et al., 
2001). However it has also been reported as having sebaceous differentiation and is now believed to 
have diverged from follicular apocrine glands (Cardoso and Calonje, 2015). 
The contrasting evidence for the cellular origin of MAC may once again be explained by the range of 
clinical and histopathological features and diagnoses represented by MAC and MAC-like adnexal 
neoplasms. It could be the case that some clinical features grouped under the term MAC could be 
derived from multiple causes and cellular origins and should as such be treated as separate diseases. 
Some studies suggest that, as well as the more common differential diagnoses, syringoid eccrine 
carcinoma could be grouped with MAC (Cardoso and Calonje, 2015). As the name suggests, this eccrine 
tumour would stand apart from MAC in its histology; this may give weight to the argument that, instead 
of distinct clinicopathological entities, multiple malignant sweat gland tumours could be placed on a 
spectrum from the development of individual syringomas to a locally invasive neoplasm (Schaller et 
al., 2010; Cardoso and Calonje, 2015). 
The identification of one underlying genetic or environmental cause to these rare adnexal neoplasms 
could answer questions about how to categorise such diseases. Importantly, collating cases of the same 
genetic origin and describing the histopathological and clinical features will help to create a clear 
diagnostic and treatment path. It would also allow for larger combined datasets of individuals with a 
definitive diagnosis that is not subject to individual pathological review. 
In this paper we describe five families with clinical and histopathological features that show similarities 
to MAC, Nicolau-Balus and Rombo syndromes (figure 4.1) and provide evidence that the described 
syndrome is a manifestation of germline variants in MYH9. Accordingly, we propose the term MALTA 
(MYH9 Associated eLasTin Aggregation) syndrome to reflect the underlying genetic basis of this 
disease.  
 Aims 
This study gathered the sequencing data from five families with a rare but specific clinical and 
histopathological diagnosis. The aims were as follows: 
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1. To identify candidate variants linked to the development of irregular elastin aggregations and 
sweat duct proliferations. 
2. To explore identified variants and identify any existing genotype-phenotype correlation with 
regards to this syndrome. 
3. To describe a novel genetic syndrome associated with the development of sweat duct 
proliferations and irregular elastin aggregations. 
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4.4 Materials and methods 
 Study population 
Families were identified by clinicians from collaborating centres following pathological review. 
Families 1 and 2 were recruited as part of the ethically approved Investigating Hereditary Cancer 
Predisposition (IHCAP) study (REC 12/EE/0478). Informed consent was obtained from all participants 
in accordance with institutional review board policies and local practices.  
Three participants within two families (families 1 and 2) were selected for WES based on a diagnosis 
of sweat duct proliferations resembling MAC and irregular elastin aggregations as described by Schaller 
et al (Schaller et al., 2010). Three additional cases from a third family were later recruited for WES 
analysis, with additional family members (including those unaffected with the disease) being used for 
further segregation analysis. Members of a further two Rombo families underwent Sanger sequencing 
for variants in the likely causal gene. 
 Clinical information  
Family 1 
Case 1 is a 44 year old male who first presented with swelling and hardening of the left temple region 
at the age of 19; an initial biopsy identified benign eccrine sweat duct proliferations which were 
classified as syringoadenoma (Schaller et al., 2010). The individual has since presented swelling on 
both sides of the face with eczematous lesions on the neck and erythematous maculae on both elbows. 
Histopathological examination of biopsies taken from the facial lesions showed that ductal 
proliferations extended through the middle and deep dermis, infiltrating the connective tissue septa but 
not invading perineurally. Abnormal aggregations of elastic fibres were seen in additional biopsies. 
Several attempts were made to surgically remove the tumours, but these were unsuccessful and further 
surgical treatment was refused. This individual had no family history of skin tumours or cancer.  
Family 2 
Case 2-1 is a female who was diagnosed with Nicolau-Balus syndrome as a child after presenting with 
syringomata, milia and atrophodermia vermiculata (Schaller et al., 2010). At age 26 she developed an 
indurated plaque on the right cheek, 6 cm in size, with an apparent punctum on its surface. Excision 
biopsy of the lesion showed it was deeply infiltrative and composed of sweat duct proliferations in a 
fibrous stroma. The proliferating ducts extended deep into the subcutis but, like case 1, did not display 
any perineural invasion. The mother of case 2-1 (case 2-2) similarly presented with atrophodermia 
vermiculata, syringomata on the neck and anterior chest with some infundibular facial cysts that showed 
evidence of ruptures and lesions on the buttocks. Biopsies from both cases showed the same abnormal, 
round aggregations of elastic fibres in the papillary dermis (figure 4.2A), however biopsies from case 
2-2 did not show any ductal proliferation. There was no other family history of skin tumours or cancer.  
Family 3 
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We identified three additional cases from one family (figure 4.3). Two are siblings (case 3-1 and case 
3-2; male and female respectively) and the third is their male cousin once removed (case 3-3). Although 
these three individuals were diagnosed with Rombo syndrome and presented with atrophodermia 
vermiculata and further irregular elastic fibre distribution, the identification of sweat-duct proliferations 
during biopsies suggests that these are not classical Rombo cases. There are reported to be additional 
affected individuals across three generations, although the exact pathology of these individuals is 
unknown.  
Family 4 and Family 5 
A further six individuals from two additional families underwent targeted sequencing of the candidate 
gene. Family 4 were previously reported by Michaelsson et al in the first paper describing the clinical 
and histopathological features of Rombo syndrome (Michaelsson, Olsson and Westermark, 1981). The 
individual from family 5 had no family history of skin disorders but presented with atrophodermia 
vermiculata and multiple milia on the face as well as abnormal distribution of elastin. He was diagnosed 
with Rombo syndrome, with sweat duct proliferations identified during retrospective review of his 
histology (Van Steensel, Jaspers and Steijlen, 2001). 
 Germline whole exome sequencing and variant filtering 
DNA from families 1 and 2 was extracted from blood and prepared for PE125 WES using the Nextera 
Rapid Capture Exome enrichment kit (Illumina). Sequencing was performed on Illumina HiSeq-4000 
machines. Cases 3-1, 3-2 and 3-3 underwent PE100 WES on a HiSeq-2500 and were added to the 
dataset as FASTQ files. VCF files were generated using a standard pipeline following GATK best 
practice recommendations for whole exome data (see Chapter 2: Methods for further details). 
Variants were filtered to select 732 rare (AF < 0.01 in 1000 genomes), protein-affecting variants (loss 
of function, predicted deleterious and damaging missense (by SIFT and PolyPhen respectively) and 
inframe indels). An in-house sequenced control set of 187 non-skin disorder related samples was used 
to select novel variants. Genes were selected that contain different variants within each family and that 
segregated with the phenotype where possible. None of the candidate variants summarised in this study 
have been identified in 1000 genomes, gnomAD or the in-house control set.  
 Validation and genotyping by Sanger sequencing 
Candidate variants were validated by Sanger sequencing. Qubit dsDNA HS kit (Invitrogen) was used 
to quantify DNA. Custom flanking primers were designed for each variant and DNA fragments were 
amplified by PCR. The products were sequenced on an ABI Genetic Analyser (Applied Biosystems) 
using BDT V3.1 (Invitrogen) according to the manufacturer’s instructions for Sanger sequencing. 
The exons of candidate gene MYH9 were analysed by Sanger sequencing in probands from families 4 
and 5. Once a candidate variant was identified, genotyping was performed in other family members   
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Figure 4.2: Elastin aggregation and MYH9 staining in MALTA cases. (A) irregular distribution of elastic fibres 
in case 2-1; (B) superficial keratocysts stained for MYH9 in case 1. The glandular component of this 
case’s tumour showed a similar staining pattern 
 
Figure 4.3: The pedigree for family 3. Red arrows indicate individuals that underwent WES. Blue arrows indicate 
individuals that underwent genotyping for the MYH9 variant c.5492_5499delGGCTGCCT. Green stars indicate 
individuals who were heterozygous for this variant.  
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where available using Sanger sequencing to sequence the surrounding region. An additional three 
members of family 3 (one unaffected and two affected) and five members of family 4 (one unaffected 
and four affected) were genotyped using this method to allow for further segregation analysis.  
 Spatial analysis of MYH9 variants  
The protein structure of the MYH9 product (non-muscle myosin IIA (NMMIIA)) was analysed using 
the mechanistic protein prediction tool Mechismo (Betts et al., 2015), to assess variants in the context 
of key functional elements of the protein, including the ATP binding site. The NMMIIA amino acid 
substitutions identified in this study and their effect on protein interactions was studied. Each assessed 
variant generated a Mechismo score (sum of (1 + maximum absolute change in pair-potential)) to 
predict the effect it has protein-protein, protein-chemical and protein-DNA/RNA (Betts et al., 2015). 
With the aim of ascertaining how MYH9 variants may produce multiple non-overlapping phenotypes, a 
comparable analysis was performed on the previously published pathogenic variants in MYH9. A set of 
60 variants (Althaus and Greinacher, 2009; Saposnik et al., 2014) described in the literature as causing 
MRPD, which may be coupled with renal impairment, hearing loss, and cataracts, were analysed for 
their effect on protein interactions.  
 Conservation of myosins at mutated regions 
The amino acid sequences of myosin genes from the ten major classes were downloaded in the form of 
FASTA files and aligned using CLUSTALW to identify conserved regions. Myosin genes explored 
included class I MYO1A and MYO1D, class II MYH1 and MYH9, class III MYO3A, class V MYO5A, 
class VI MYO6, class VII MYO7A, class IX MYO9A, and class X MYO10. Aligned files were viewed 
in BioEdit. Amino acid changes identified in MALTA samples and MRPD samples (Althaus and 
Greinacher, 2009) were analysed for conservation across different myosin classes. This was further 
expanded to look specifically at the class II conventional myosins encoded by the genes MYH1, MYH3, 
MYH7, MYH9, MYH10, MYH11, MYH13, MYH14, and MYH15. 
 Tumour immunohistochemistry 
Tumour blocks were available for case 1, IHC was performed for NMMIIA using mouse monoclonal 
antibodies ab117572 and ab122978 (Abcam). Neither antibody targeted the mutated region identified 
within this individual. 
 Tumour whole exome sequencing and variant filtering 
Tumour DNA for case 2-1 was extracted from cut scrolls of FFPE using an ultrasonicator (Covaris). 
Tumour and germline DNA (from blood) for this case were prepared for sequencing using Agilent 
SureSelect Human All Exon 50Mb kit following manufacturer’s instructions and were sequenced on 
the Illumina HiSeq-4000 as previously described (Tarpey et al., 2013). Raw sequencing data were 
analysed with a somatic variant calling pipeline using Mutect2 (GATK v3.7) to generate a VCF file of 
somatic variants (see Chapter 2: Methods for further details). 
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Variants were filtered to select those with a somatic variant allele frequency (VAF) of no less than 10%. 
Protein-affecting variants (loss of function, predicted deleterious and damaging missense (by SIFT and 
PolyPhen respectively), and inframe indels) were selected, creating a set of 245 somatic variants. These 
were manually searched for their occurrence in known oncogenes as well as in skin related cancers 
(which were histologically categorised into carcinoma, malignant melanoma, adnexal tumour or other) 
according to the COSMIC database (Forbes et al., 2017). 
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4.5 Results 
 Germline whole exome sequencing 
The WES data from six individuals were analysed using an optimised in-house VCF generation pipeline 
to create a set of 732 different high confidence rare protein-affecting variants. Only one gene, MYH9, 
harboured protein-affecting variants in all families, with each variant appearing in all affected family 
members. The NMMIIA gene MYH9 contained a missense variant (NM_002473:c.2012C>T, 
p.Cys671Tyr) in case 1 that was predicted to be deleterious and damaging to protein function. An 
inframe deletion (NM_002473: c.1767_1769delTCC, p.Met589_Asp590delinsIle) in cases 2-1 and 2-2 
of family 2 and a frameshift deletion (NM_002473: c.5492_5499delGGCTGCCT, p.Gln1831Leufs*20) 
in cases 3-1, 3-2 and 3-3 (figure 4.3) were also identified in this gene. None of the three variants had 
previously been observed in phase 3 1000 genomes (Auton et al., 2015) or gnomAD (Lek et al., 2016). 
Three additional members from family 3 were recruited for genotyping, including two individuals that 
were affected with the described phenotype and a third unaffected individual. The identified frameshift 
deletion segregated completely with the MALTA phenotype within this family (figure 4.3). No 
unaffected members of families 1 or 2 were available for segregation analysis. 
Upon the identification of a candidate gene for MALTA predisposition, two additional families 
underwent targeted sequencing of the MYH9 gene. Both families were diagnosed with Rombo syndrome 
and presented with irregular distribution of elastin fibres. A missense variant (NM_002473:c.706G>T, 
p.Gly236Cys) was identified in family 4 and an inframe indel (NM_002473:c.694_695delinsAA, 
p.Ser232Asn) was observed in family 5. Both variants result in a one amino acid change which is 
predicted to be deleterious to protein function and neither have been previously observed in phase 3 
1000 genomes (Auton et al., 2015) or gnomAD (Lek et al., 2016). Additional members of family 4 
were recruited for segregation analysis, with the missense variant fully segregating with phenotype. All 
identified MYH9 variants are described in table 4.1. 
 Spatial analysis of MYH9 variants  
Variants were mapped to the predicted NMMIIA protein structure generated by Mechismo. Four of the 
five identified variants clustered in the myosin head (figure 4.4). It was predicted that the variant 
c.694_695delinsAA identified in family 5 affects the binding of ADP to myosin and generated a 
Mechismo score of 1, where scores of 1 or greater indicate a disruption to protein interactions. The 
generated model also indicates that the missense variants c.2012C>T and c.706G>T also lie within the 








Table 4.1: MALTA Families analysed and MYH9 variants identified in each family. 
Family 
Proband Gender 
(age at diagnosis) 
Diagnosis of Proband 





















1 Male (9) 
MAC-like ductal 
proliferations 
Yes Yes Yes Yes Normal 1 c.2012C>T p.Cys671Tyr Missense variant Sporadic WES 









Inframe deletion Not available WES 
3 Male (17) Rombo syndrome Yes Yes Yes Yes Normal 6 
c.5492_5499del
GGCTGCCT 
p.Gln1831Leufs*20 Frameshift deletion Yes WES 
4 Male (7) Rombo syndrome No Yes Yes Not described 
Not 
described 
5 c.706G>T p.Gly236Cys Missense variant Yes 
Targeted 
sequencing 
5 Male (24) Rombo syndrome Yes Yes Yes No Unknown 1 
c.694_695delins
AA 
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Figure 4.4: Identified MYH9 variants mapped to the head domain of non-muscle myosin IIa. Three of the identified 
variants fall within the ATP binding pocket (inset). 
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In contrast to other motor domain variants identified, the inframe deletion c.1767_1769delTCC appears, 
according to the 3D protein structure, to affect the actin binding region. The frameshift variant identified 
is positioned at the end of the tail domain, resulting in the loss of key acetylation and phosphorylation 
sites. 
To further understand how variants in MYH9 could be creating two distinct phenotypes, variants that 
have been known to be linked to MRPD were also analysed using Mechismo to predict their effect on 
protein interactions. In contrast to variants detected in our study, most of which were located in the 
ATP-binding region of the myosin head, most of the MRPD-associated variants were located in myosin 
tail (figure 4.5). Importantly, unlike the variants identified in the MALTA syndrome families, the 
MRPD variants identified in the myosin head did not lie in either the ATP or actin binding sites which 
are key to myosin function. Six of the 60 MRPD variants that were analysed were predicted with high 
confidence to be within the binding regions for S100 calcium binding proteins A4, A5 or P. Only one 
of these variants, p.Arg1933* was predicted to interrupt the interaction. Another variant, p.Lys850Glu 
was predicted to affect the formation of both heterodimers with NMMIIB (MYH10 gene product) and 
homodimers. 
 Conservation of myosin classes 
The conservation of NMMIIA was observed across eight other myosin classes and specifically within 
class II (containing NMMIIA, B, and C). Amino acid regions that were substituted in the MALTA 
phenotype were shown to be highly conserved across all classes of myosin (table 4.2), with ten different 
myosins showing the same amino acid at all affected sites. The frameshift variant identified in the 
myosin tail is the exception to this, with three other myosins having shorter tail regions that would not 
encompass this variant and others not being conserved. 
In comparison, seven amino acids that are substituted in MRPD did not show conservation across the 
ten tested myosins. No tested amino acid showed complete conservation across tested myosins from all 
classes. These regions were conserved within the nine tested class II myosins, with four sites showing 
complete conservation (table 4.2).  
 Tumour immunohistochemistry 
Two tumours from case 1 were stained for NMMIIA. The variant identified in case 1 was a 
heterozygous missense and MYH9 was expressed in the tumours (figure 4.2B). Staining in the tumour, 
in healthy skin and in other benign adnexal lesions was ubiquitous.  
 Tumour whole exome sequencing 
Somatic variants identified in case 2-1 were analysed for known oncogenic genes and variants. One 
identified candidate variant was a heterozygous missense variant in the receptor tyrosine kinase proto-
oncogene RET (c.2269G>A, p.Val757Met). This variant has not been previously described in the 
COSMIC database, however variants described in COSMIC within this exon and the surrounding exons 
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have been identified in three facial adnexal sebaceous adenoma tumours (including one sample 
diagnosed with Muir-Torre syndrome). 
BAM files were manually searched for loss of heterozygosity of the identified MYH9 variant. The 
variant, c.1767_1769delTCC, appeared to remain heterozygous within the tumour. There were no other 
protein-affecting variants seen in MYH9 within the tumour sample. 
The low DNA quality of the sequenced tumour sample (as confirmed by checking BAM files manually) 
meant any calculated mutation rate is likely to be highly inaccurate. However the general low rate of 
variants seen in this tumour sample (8.2 per Mb) is not representative of highly UV damaged DNA 
which can have a mutation rate upwards of 20 variants per Mb, suggesting that these lesions are not 
linked to UV damage (Mar et al., 2013). 
  
 





Figure 4.5: MALTA variants identified within this study and MYH9-related platelet disorder variants 
were mapped to the exons of MYH9. All variants are missense or inframe aside from those indicated by 
* which are protein truncating. When placed into the context of the non-muscle myosin structure, the 
differential distribution of variants according to disease can be seen across the head and tail regions. 
ELC: essential light chain, RLC: regulatory light chain 
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Myosin Amino acid position 96 232 236 371 589 590 671 702 1165 1424 1831 1841 1933 
Class I MYO1A S S G V N D C R ~ ~ ~ ~ ~ 
MYO1D E S G V K D C R ~ ~ ~ ~ ~ 
Class II MYH1 A S G A K D C R R D V E ~ 
MYH3 A S G A K D C R R D T E E 
MYH7 A S G A K D C R R D A E ~ 
MYH9 S S G A M D C R R D Q E R 
 MYH10 S S G A M D C R R D A E R 
 MYH11 S S G A M D C R R D Q D R 
 MYH13 A S G A K D C R R D A E ~ 
 MYH14 S S G A M D C R R D I E V 
 MYH15 S S G A K D C R Q D A E ~ 
Class III MYO3A T S G L R D C R ~ ~ Q ~ ~ 
Class V MYO5A A S G L K D C R L G G ~ ~ 
Class VI MYO6 T S G L N D C D ~ ~ ~ ~ ~ 
Class VII MYO7A G S G L R D C R I P I L T 
Class IX MYO9A T S G L T D C R Q Q I E G 
Class X MYO10 S S G L R D C R Q I K E Q 
Variants MYH9 L N C N I Y C/H C N/H fs K X 
   
** ** * 
 
** ** * 
 
* 
   
Table 4.2: Conservation of amino acid sites shown to be substituted or truncated in MALTA (grey) and MRPD (white) across eight classes of myosins, focusing 
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4.6 Discussion 
All five MALTA families analysed within this study carried variants in the NMMIIA gene MYH9. 
There are 15 different class II myosins, three of which do not appear in muscle cells and are so called 
non-muscle myosins (NMMs). These are encoded by the genes MYH9 (NMMIIA), MYH10 (NMMIIB), 
and MYH14 (NMMIIC). The three NMMs are expressed in different cell types, with NMMIIA and 
NMMIIB being expressed in epithelial and endothelial cells and NMMIIA being expressed in 
circulating platelets (Betapudi, 2014).  
NMMs have previously been linked to a diverse range of cellular functions including cell migration and 
invasion, protein and organelle localization, and cell signalling (Ouderkirk and Krendel, 2014), making 
them key interactors in many of the hallmarks of cancer. Pathogenic variants in the unconventional 
myosin MYO1A have been previously seen in a high proportion of colorectal and gastric tumours 
(Mazzolini et al., 2012, 2013) and the gene has since been labelled a tumour suppressor gene (Ouderkirk 
and Krendel, 2014). Similarly the myosin XVIIIB gene MYO18B has been classed as a candidate tumour 
suppressor gene and has been shown to be deleted or carrying somatic pathogenic mutations in lung, 
ovarian and colorectal cancers (Nishioka et al., 2002; Yanaihara et al., 2004; Nakano et al., 2005). The 
NMM gene MYH9 has been described as a tumour suppressor gene in SCCs and functional work has 
identified a specific role for NMMIIA in p53 localisation and stabilisation (Schramek et al., 2014). 
Within this study, all tested individuals with the MALTA phenotype, including a combination of MAC-
like sweat duct proliferations, irregular distribution of elastin, atrophodermia vermiculata, and 
syringomas, carried a novel protein-affecting MYH9 variant. Families 1 and 5 contained just one 
sporadic individual, with no available family members for further testing. Families 2, 3 and 4 had strong 
histories of MALTA histopathologic features, allowing multiple affected, and in some cases unaffected, 
individuals to be genotyped, with variants segregating fully with phenotype. Based on the current data, 
the identified MYH9 variants appear to be fully penetrant. 
Variants in MYH9 have been previously associated with MRPD. No participants identified in this study 
exhibited any of the features of MRPD, with all individuals displaying normal platelet size and count 
and no hearing impairment. Similarly, publications on the characteristics of MRPD suggest no skin 
abnormalities (Althaus and Greinacher, 2009; Saposnik et al., 2014). This suggests that MYH9 is 
producing two distinct phenotypes. The majority of MRPD variants fall in the tail region of NMMIIA 
(25 variants out of 42) (figure 4.5). In comparison, 4 of the 5 MALTA variants identified in this study 
lie within the head region, which contains both the ATP and actin binding regions. Only one exon, exon 
39 in the tail region, contains a variant in both MALTA and MRPD. The exon 39 MALTA variant is a 
frameshift variant which is predicted to cause an early stop codon. In contrast, loss of function variants 
in MRPD are only seen in the final exon of the gene. 
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By mapping the identified variants onto the predicted 3D protein structure of NMMIIA, four of the five 
MYH9 variants can be seen in the head region, with three clustering in the ATP binding pocket. Only 
one of the three variants, p.Ser232Asn (c.694_695delinsAA), was predicted to interrupt the ATP/ADP 
interaction, however the close proximity of the other two missense variants to the binding pocket may 
also suggest they are causing a deficiency in ATP binding or in the resulting conformational change 
that is key to the motor function (Betapudi, 2014). 
To further study the two distinct phenotypes produced by MYH9 variants, MRPD variants were also 
plotted into Mechismo to identify any disruption to protein interactions. A number of the variants input 
were predicted to interrupt the interaction with S100 calcium binding proteins A4, A5 and S100P. These 
proteins are required for controlling myosin II phosphorylation and filament assembly (Clark et al., 
2008). This corroborates previous findings that the MYH9 variants described in MRPD disrupt filament 
assembly by affecting the α-helical coiled-coil tail structure (Kriajevska et al., 2000). Additionally, 
variants were predicted to interrupt binding of NMMIIA to NMMIIB and to itself thereby preventing 
the formation of hetero and homodimers.  
By looking at the conservation of myosins, it was observed that sites with variants in the MALTA 
phenotype were conserved across all tested eight myosin classes. This suggests that the MYH9 variants 
identified within this study interrupt a function that is integral to all myosins such as ATP binding. 
Whereas MRPD variants were in regions that are only conserved in the class II myosins, also known as 
conventional myosins, which encompasses the three NMMs NMMIIA, NMMIIB, and NMMIIC. We 
can hypothesise that, in contrast to the MALTA MYH9 variants, the MRPD variants interrupt a function 
that is not integral to all myosins, but key to class II myosins specifically. Such class II specific functions 
include the formation of intracellular hexameric monomers, which was suggested to be interrupted by 
MRPD variants in Mechismo. 
The MRPD phenotype extends beyond platelet abnormalities to affect a wide range of tissues and cell 
types including leukocytes, the kidney and the cochlea. It remains unknown how the disruption of 
MYH9, a gene that is so essential to cell function in many human tissues, leads to very specific 
phenotypes such as deafness and cataracts. One study found that expression of combinations of the 
three NMM isoforms in a tissue specific manner drives differential myosin functions, showing evidence 
of partial co-localization of the two proteins suggesting some overlap in function in addition to some 
unique cellular roles (Marini et al., 2006). 
The expression of more than one NMM in most cell types suggests that these proteins play similar if 
not identical roles in these cells. In platelets, only NMMIIA is expressed which likely explains the 
phenotype in MRPD. It is possible that within the areas of the dermis affected by MALTA syndrome, 
NMMIIA plays a unique role that cannot be recovered by the presence of another NMM. Within skin 
fibroblasts, NMMIIA expression was shown to increase during dermal wound healing and scar tissue 
 
97 | P a g e  
 
remodelling, while expression of NMMIIB remains stable, suggesting differential roles for the two 
proteins (Bond et al., 2011). During this healing process, the extra-cellular matrix (ECM) components 
including elastin are secreted by fibroblasts and the elasticity of the ECM plays a role in the regulation 
of NMMIIA and NMMIIB during scar formation and fibroblast migration (Bond et al., 2011; Almine, 
Wise and Weiss, 2012). It could be through this damage driven signalling cascade that MYH9 variants 
in MALTA syndrome are affecting elastin secretion and distribution.  
Loss of MYH9 has been previously studied by knockouts and RNAi in the context of tumour 
development in head and neck SCC (Schramek et al., 2014). Human and mice keratinocytes were used 
to further understand MYH9 function and identified that as well as its well characterised role as a motor 
protein with actin, it played a key role in stabilizing p53 (Schramek et al., 2014). Blebbistatin was used 
as a NMMIIA inhibitor to block the ATPase activity and show that p53 did not accumulate in the 
nucleus after DNA damage as it does without blebbistatin treatment (Schramek et al., 2014). This 
suggests that MYH9 could play an important role in the DNA damage response, and the link between 
MALTA proliferations and UV damage could be the result of a lack of this damage response. 
A missense variant was identified in the tumour of case 2-1 in the proto-oncogene RET. Single 
nucleotide variants in RET are typically associated with multiple endocrine neoplasia and medullary 
thyroid cancers (Plaza-Menacho, Mologni and McDonald, 2014). However a number of other cancers 
including papillary thyroid cancer, non-small cell lung cancer, breast cancer, pancreatic cancer, and 
prostate cancer have all been associated with somatic RET fusions or overexpression of the gene (Plaza-
Menacho, Mologni and McDonald, 2014). Within COSMIC, skin tumours were analysed for RET 
variants, with particular emphasis on facial adnexal tumours of which 15% of those tested carried 
somatic single nucleotide variants in RET. Other skin cancers with RET single nucleotide variants 
included malignant desmoplastic melanomas of the head, neck and arm. The identification of RET 
variants in a MALTA tumour may indicate that tyrosine kinase inhibitors could be explored as a new 
treatment option for affected individuals. 
4.7 Summary 
The in-depth analysis of MALTA individuals has provided a new insight into the genetic landscape of 
sweat duct neoplasms. Identifying and understanding these genetic factors has a strong impact on 
diagnosis and disease management. The rarity of such diseases has previously lead to a lack of research 
into predisposition and oncogenesis. Grouping together case studies that were previously diagnosed 
with a range of diseases under one genetic syndrome will help to provide studies into the wider group 
of MYH9-related sweat duct tumours. This study also shines a light on NMMs which may play a closer 
role in DNA damage response and cancer predisposition than previously thought. 
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5 Exploring the genetic landscape of early onset Adrenocortical 
carcinoma. 
5.1 Introductory statement 
The adrenocortical carcinoma patients described in this work were identified and recruited by Dr Ruth 
Casey who also provided extensive clinical information. Tumour immunohistochemistry analysis for 
available tumours was performed by Dr Alison Marker. Library preparation and sequencing of the 
germline DNA samples described in this chapter was performed by James Redman and the Department 
of Medical Genetics Stratified Medicine Core Laboratory. Sequencing data were downloaded and 
processed by me using an in-house WES pipeline generated by Alexey Larionov. The results published 
here are in part based on data generated by The Cancer Genome Atlas (TCGA), managed by the National 
Cancer Institute and the National Human Genome Research Institute. Controlled access data were 
requested and downloaded for the TCGA-ACC dataset. The RNA-sequencing data from TCGA were 
analysed using an RNA-sequencing analysis pipeline generated by myself. All downstream data analysis 
was designed and performed by me. 
In recent years, there has been an increased focus on the histological classification of ACC tumours. The 
oncocytic variant of ACC is now recognised as a distinct subtype and shall herein be referred to as 
‘oncocytic ACC’. Another type of ACC, often called normal ACC or just ACC itself, shall be referred to 
as ‘usual type ACC’ in accordance with current terminology used in the literature and to distinguish it 
from all ACCs. Where neither an oncocytic nor usual type is specified, it should be assumed that text is 
referring to ACC as a whole. 
5.2 Abstract 
Adrenocortical carcinoma (ACC) is an endocrine cancer with a poor prognosis as it often presents at an 
advanced stage. Li Fraumeni syndrome, caused by germline pathogenic variants in the tumour suppressor 
gene TP53, is associated with a predisposition to adrenal tumours, particularly childhood cases. However, 
the genetic factors associated with ACC development outside the realms of TP53 are largely unknown. 
The oncocytic subtype of ACC is comprised of oncocyte cells which can be defined by an increased 
number of mitochondria causing a granular cytoplasm. These tumours have been previously described as 
having a low malignant potential, however prospective analysis has shown that this distinct histological 
subtype can be malignant and aggressive. This study describes the germline whole exome sequencing of 
eight oncocytic and usual type ACCs. Gene interaction network analysis was used to identify clusters of 
related candidate genes. Additional analysis was completed to identify candidate variants within genes 
that interact with TP53. TCGA ACC germline data were examined for variants in any of the identified 
candidate genes. Additionally, RNA-sequencing data from TCGA were used to perform differential 
expression analysis to identify genes that may influence the development of an oncocytic phenotype in 
comparison to usual type ACC. MAPK pathway related G-protein coupled receptor genes whose products 
interact physically with TP53 were identified with protein-affecting variants within the described set and 
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within the TCGA-ACC set and could influence ACC risk. RNA sequencing analysis revealed that cAMP-
PKA pathway genes had a change of gene expression in the oncocytic subtype of the TCGA-ACC data. 
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5.3 Introduction 
 Adrenocortical carcinoma 
Adrenocortical carcinoma (ACC) is an extremely rare endocrine tumour with variable malignant 
potential. The incidence of ACC is predicted to be around 2 per million people per year globally and the 
disease accounts for around 0.2% of cancer deaths globally (Schteingart et al., 2005).  
The prognosis of ACC is generally poor as patients typically present with advanced disease (Bilimoria et 
al., 2008). For patients with localised disease, surgical resection is the only potentially curative treatment, 
however recurrence after resection is common and management strategies are not well defined (Gonzalez 
et al., 2007). Within one study, distant metastases were identified in 66% of patients during follow-up 
after surgery (Ayala-Ramirez et al., 2013). Early diagnosis in ACC facilitates complete surgical resection 
and offers the best chance for prolonged disease free survival (Xiao et al., 2015). This emphasises the 
need to understand the genetic landscape of ACC, allowing individuals at greater risk to undergo 
personalised surveillance strategies and enable earlier diagnoses. 
 Epidemiology of adrenocortical carcinoma 
The occurrences of ACC are well documented in the literature. One American study notes not just sex 
and race as patient characteristics but also median income and level of education received (Bilimoria et 
al., 2008). Several studies have noted a preponderance for the disease amongst women, who account for 
between 55-67% of cases (Gonzalez et al., 2007; Bilimoria et al., 2008; Fassnacht, Kroiss and Allolio, 
2013). The average age of diagnosis varies, and studies indicate that peak the incidence is between 40-55 
years of age (Bilimoria et al., 2008; Fassnacht, Kroiss and Allolio, 2013). Paediatric cases of ACCs have 
been described although these are extremely rare and are diagnosed with an incidence of 0.3 to 0.4 per 
million children (Michalkiewicz et al., 2004). Cases of ACC in children are much higher in a south 
Brazilian population due to a high prevalence of the p.Arg337His allele of the TP53 tumour suppressor 
gene (Ribeiro et al., 2001; Wasserman et al., 2015). It has since been suggested that between 50 and 80% 
of childhood occurrences of ACC are associated with pathogenic variants in TP53 (Gonzalez et al., 2009; 
Wasserman et al., 2015). A younger age of cancer diagnosis is often associated with genetic 
predisposition factors. This has also been seen in ACC, with ~51% of cases diagnosed below the age of 
20 being TP53 pathogenic variant carriers (35 carriers out of 69 cases) in comparison to ~4% of cases 
diagnosed above the age of 20 (7 carriers out of 157 cases) (Herrmann et al., 2012; Raymond, Else, et al., 
2013; Wasserman et al., 2015). 
 Clinical Features of adrenocortical carcinoma 
The large size, higher density, and heterogeneous enhancement of ACC tumours on computed 
tomography (CT) imaging often allows them to be distinguished from smaller adenomas. Tumours 
present bilaterally in 1-10% of cases (Latronico and Chrousos, 1997; Bilimoria et al., 2008; Else et al., 
2014), with one large American study being on the lower end of this range with 1.1% of cases having 
bilateral tumours upon diagnosis (Bilimoria et al., 2008). The description of ACC samples within TCGA 
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identified 56% (51 out of 91) of tumours involving the left gland (Zheng et al., 2016). ACCs have been 
shown to commonly metastasise to the liver, lung, and bone, with the liver and lung each corresponding 
to around 10% of distant metastasis identified (Bilimoria et al., 2008). 
Approximately 50% of ACCs can be described as clinically functioning or hormone secreting 
(Schteingart et al., 2005); meaning the tumours are autonomously secreting adrenal hormones including 
cortisol and androgens. The biochemical secretory pattern of a tumour is important for diagnosis and 40-
60% of patients first present with hormonal excess (Luton et al., 1990; Allolio and Fassnacht, 2006; 
Fassnacht, Kroiss and Allolio, 2013), of which 50-80% present with hypercortisolism (Else et al., 2014). 
Presenting symptoms can include diabetes mellitus, osteoporosis, and hypokalemia or hypertension as a 
result of glucocorticoid-mediated mineralocorticoid receptor activation (Else et al., 2014). Other 
commonly produced hormones reported by Gonzalez et al include androgens in 17% (12 out of 72 cases), 
aldosterone in 7% (5 out of 72 cases), estrogen in 1% (1 out of 72 cases), and mixed hormone production 
in 21% of tumours (15 out of 72 cases) (Gonzalez et al., 2007). Adrenal androgen secretion has been 
identified in larger proportions of hormone secreting ACCs in other studies, with the percentage of 
secreting tumours reaching up to 60% (Else et al., 2014). Symptoms of excess androgen secretion include 
male pattern baldness, hirsutism, virilization, and menstrual irregularities (Else et al., 2014).  
For tumours that are not hormone secreting, disease presentation is often due to ‘mass effect’ symptoms, 
for example abdominal or flank pain due to large tumour size (Bharwani et al., 2011). For this reason, 
patients with non-functioning tumours are more likely to present at a late stage which could be a causal 
factor in the ~20-30% of cases who present with distant metastases (Gonzalez et al., 2007; Bilimoria et 
al., 2008; Else et al., 2014). However, cortisol producing ACCs have been shown to have a reduced 
overall survival in comparison to non-functioning and androgen-producing tumours (Gonzalez et al., 
2007). 
 Histological subtypes 
Of the non-usual type ACCs, the most common histological subtype is the oncocytic variant, which is 
predominantly composed of oncocytes (Else et al., 2014). These oncocytes can be defined an increased 
number of mitochondria causing the epithelial cells to have a granular cytoplasm. As of 2010 only 17 
cases of oncocytic ACC had been described in the literature (el-Naggar, Evans and Mackay, 1991; 
Alexander and Paulose, 1998; Kurek et al., 2001; Hoang, Ayala and Albores-Saavedra, 2002; Seo, Henley 
and Min, 2002; Bisceglia et al., 2004; Sang et al., 2004; Tanaka et al., 2004). Although oncocytic tumours 
have been suggested to act less aggressively than usual type ACCs, distant metastases have been identified 
in a number of cases (Tanaka et al., 2004). This disparity may be a reflection of the small number of 
described cases leading to an inaccurate picture of the aggressiveness of the disease; for example, the 
oncocytic ACCs identified within this study were malignant and more aggressive than expected from 
previous clinical case studies. Additionally, diagnosing the malignant potential of these tumours has been 
noted as difficult in a number of studies due to the solid growth pattern of oncocytic tumours (Kurek et 
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al., 2001; Sang et al., 2004; Else et al., 2014), creating challenges for disease management (De Krijger 
and Papathomas, 2012). 
The myxoid tumour variant of ACC is named due to their abundant production of extracellular myxoid 
material (Else et al., 2014). This rare subtype has been described a number of times in the literature, both 
in a benign setting and with distant metastasis (Brown et al., 2000). Interestingly one study described a 
myxoid case which had a distinct gene expression pattern, separating it from other high-grade ACCs 
(Giordano et al., 2003). However, the rarity of this subtype means that this finding has not been replicated. 
The sarcomatoid subtype is used to describe tumours with sarcomatous and carcinomatous features (Coli 
et al., 2010). This tumour type has been diagnosed between the ages of 29 and 79, and diagnosis is often 
made postoperatively (Coli et al., 2010). Behaviour of these tumours is often extremely aggressive and 
usually portends to a poor prognosis (Coli et al., 2010; Else et al., 2014). 
 Treatment 
For non-metastatic ACC patients, surgery is widely accepted as the most curative therapeutic approach 
(Icard et al., 1992; Allolio and Fassnacht, 2006; Fassnacht, Kroiss and Allolio, 2013), and is the most 
commonly used strategy, either alone or in combination with chemotherapy or radiotherapy (Gonzalez et 
al., 2007; Bilimoria et al., 2008). For individuals with hormone excess producing tumours, the levels of 
cortisol need to be closely monitored and controlled prior to surgery as elevated cortisol levels have been 
associated with poor wound healing and infection (Else et al., 2014).  
As well as being the primary therapeutic agent for ACCs, mitotane can be used to control cortisol levels 
in hormone-excess tumours by increasing mitochondrial function and therefore affecting the extra-adrenal 
metabolism of cortisol and androgens (Luton et al., 1990; Latronico and Chrousos, 1997). Mitotane was 
developed from the insecticide dichlorodiphenyltrichloroethane which was described with adrenolytic 
activity in dogs in 1948 (Nelson and Woodard, 1948). An isomer of this compound was isolated and used 
by Bergenstal et al in 1960, showing patient response to this type of therapy (Bergenstal et al., 1960). 
Mitotane is still considered the most effective chemotherapeutic agent for ACCs despite its low response 
rate (Berruti et al., 2005; Gonzalez et al., 2007; Bilimoria et al., 2008). It is more commonly used as an 
adjuvant therapy alongside radical resection and in these contexts has been shown to have a significant 
effect on recurrence-free survival (Terzolo et al., 2007). Mitotane has also been used in combination with 
chemotherapy regimens including cisplatin and etoposide, and cisplatin, etoposide and doxorubicin. 
Within one study, ~19% of patients (13 out of 67) treated with mitotane had a complete or partial response 
to treatment. Although, those who responded to mitotane had been treated with this alone and none of the 
patients treated with additional chemotherapy had shown a response (Gonzalez et al., 2007).  
 Genetics of adrenocortical carcinoma 
Li Fraumeni syndrome is a well-studied, highly penetrant, cancer predisposition syndrome that confers 
an increased risk to a number of early onset cancers. It was first described in 1961 by Li and Fraumeni, 
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whose analysis of families with childhood rhabdomyosarcoma identified cases of sarcoma, leukaemia, 
brain tumours, breast cancer, and ACC (Li and Fraumeni, 1969). Amongst the 44 early onset cancer cases 
(diagnosis at less than 15 years of age) identified in this study of four families, 9% had adrenal tumours 
(Li and Fraumeni, 1969). Li Fraumeni syndrome is associated with germline pathogenic variants in the 
transcription factor gene TP53, and it has been recommended that all ACC cases should be tested for 
germline pathogenic TP53 variants (Herrmann et al., 2012). 
As previously discussed, germline pathogenic TP53 variants associated with childhood ACC are 
particularly prominent in a south Brazilian population (Wasserman et al., 2015). The main pathogenic 
TP53 variant hotspots are p.Arg175His, p.Gly245Ser, p.Arg248Gln, p.Arg248Trp, p.Arg273His, and 
p.Arg282Trp (Wasserman et al., 2015) which affect the DNA binding domain and loops opposing the 
protein-DNA interacting surface coded for in exons 4-8 (Petitjean et al., 2007). The Brazilian 
p.Arg337His allele in exon 10 is not one of these common germline pathogenic TP53 variants, however 
in a study of 36 paediatric ACC cases in 34 families from the state of Paraná, the pathogenic variant was 
seen in 97.2% of cases (35 out of 36) (Ribeiro et al., 2001). This high frequency of germline pathogenic 
TP53 variants in childhood ACCs has been replicated in other studies, with one predicting an 80% 
probability that any case diagnosed with ACC before the age of 18 carries a pathogenic TP53 variant, 
regardless of family history (Gonzalez et al., 2009). This led to questions about the prevalence of germline 
pathogenic TP53 variants in adult ACC cases. Herrmann et al analysed the prevalence of pathogenic TP53 
variants in cases that were diagnosed above 18 years of age (Herrmann et al., 2012). This study identified 
germline pathogenic TP53 variants in 3.9% of cases (4 cases out of 103, with age of diagnosis ranging 
from 21 to 71 years of age), affecting the DNA binding domain (a previously described hotspot region) 
and tetramerization domain of exon 10 (Herrmann et al., 2012).These studies suggest that pathogenic 
TP53 variants are highly penetrant and more likely to have an oncogenic affect early in life. 
In contrast to this, Varley et al studied a number of families with childhood adrenocortical tumours and 
identified inherited TP53 protein coding variants in unaffected family members (Varley et al., 1999). In 
addition to this, some variants were identified in family members with late onset cancer. One family 
identified carried a germline protein coding TP53 variant in the proband with ACC diagnosed before the 
age of two years and multiple sarcomas, and in 3rd and 4th degree relatives with breast and stomach cancer, 
both diagnosed above the age of 40 years (Varley et al., 1999). This study suggests that some low 
penetrance alleles in TP53 do exist in ACC cases, and that these might explain some ACC cases without 
a family history of typical Li Fraumeni syndrome cancers. Additionally, other factors could be 
contributing to the risk of developing childhood ACC in some TP53 protein coding variant carriers. 
The association between germline pathogenic variants in TP53 and ACC is by far the most well studied. 
However, in recent years, germline and somatic pathogenic variants in Lynch syndrome genes have been 
identified in ACC families. Lynch syndrome is typically associated with an increased risk of colorectal 
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cancer and is characterised by pathogenic germline variants in DNA mismatch repair genes MLH1, 
MSH2, MSH6, and PMS2. In one study, germline pathogenic variants in Lynch syndrome genes were 
identified in 3.2% of tested ACC families (3 out of 94 probands), with IHC showing a loss of mismatch 
repair gene expression in the extracted tumours from these families (Raymond, Everett, et al., 2013). This 
percentage of ACC affected individuals identified with these germline Lynch syndrome variants is 
comparable to the prevalence of these variants in colorectal and endometrial cancers, which is estimated 
to be around 2% and 5% respectively (Raymond, Everett, et al., 2013). The impact of Lynch syndrome 
in ACC was corroborated by the pan-cancer study of TCGA data, identifying two pathogenic MSH6 
variants and one pathogenic MSH2 variant in germline DNA from individuals with ACC (Zheng et al., 
2016). Additionally, a study of the multiple endocrine neoplasia gene MEN1 has identified some ACC 
cases with pathogenic germline variants (Waldmann et al., 2009). However somatic variants in this gene 
are more common in adrenal tumours, with loss of heterozygosity and copy number variant events being 
described (Skogseid et al., 1995; Heppner et al., 1999; Zheng et al., 2016). 
 Aims 
This piece of work describes the whole exome sequencing and exploration of variants in germline DNA 
from individuals diagnosed with ACC. It also explores the gene expression patterns linked to the 
development of the oncocytic subtype of ACC from TCGA adrenal tumour RNA-sequencing data. The 
aims are as follows: 
1. To identify candidate genes containing germline variants that may affect predisposition to ACC 
in patients who are negative for pathogenic variants in the known cancer-predisposing gene TP53. 
2. To identify gene expression changes in RNA-sequencing data from oncocytic ACC tumours that 
may drive the oncocytic phenotype in comparison to usual type ACCs. 
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5.4 Materials and Methods 
 Study Population 
Eight individuals diagnosed with ACC were recruited as part of ethically approved studies (REC 
12/EE/0478 and REC 14/EE/1059). Five individuals were affected with oncocytic ACC, the remaining 
three were diagnosed with usual type ACC.  
The set is gender balanced (four males and four females); three of the five oncocytic ACC germline 
samples are from males and the remaining two are from females. The average age at diagnosis was 45 
years and was younger for females (35 years of age) than for males (55 years of age). Table 5.1 shows 
the clinical details for the individuals studied in this analysis. 
 Germline whole exome sequencing and variant filtering 
For all individuals, DNA was extracted from blood and prepared for PE125 WES using the Nextera Rapid 
Capture Exome enrichment kit (Illumina). Sequencing was performed on HiSeq-4000 machines. The set 
was called and filtered as part of the in-house dataset and VCF files were generated using a standard 
germline pipeline following GATK best practice recommendations for WES data (see Chapter 2: Methods 
for further details). 
Common variants that appeared in greater than 5% of European 1000 genomes population were removed 
from analysis. Protein-affecting variants (loss of function, inframe indels and predicted deleterious and 
probably damaging missenses (as flagged by SIFT and PolyPhen respectively)) were selected. A total of 
1,178 different variants in 1,041 genes appeared in the whole set. An oncocytic specific set was also 
created for further analysis which included 954 of the above filtered variants in 855 genes. 
 Variant prioritisation and candidate selection 
Variants that passed filtering were manually examined and prioritised to select candidates, removing 
those that appear in five or more samples from an in-house control set. A literature search was performed 
for the variant containing gene to identify any known link between that gene and cancer predisposition or 
the phenotype of interest. The Human Protein Atlas (HPA) (www.proteinatlas.org) (Uhlen et al., 2017) 
which compiles expression data from GTEx, FANTOM5, and HPA datasets, was used to determine the 
expression of candidate genes in adrenal tissue. Where data are available for a candidate gene, knockout 
or allele trapped mouse models were explored for a cancer or adrenal related phenotype using the Mouse 
Genome Database (www.informatics.jax.org)(Blake et al., 2017). Known cancer predisposing genes 
including Lynch syndrome genes and TP53 were searched for protein-affecting, rare variants and any 
identified were selected as candidates. 
  
 





diagnosis Sex ACC subtype Mismatch repair Immunohistochemistry 
ACC1 67 M Oncocytic ACC MSH2/6 preserved 
ACC2 33 M Oncocytic ACC abnormal pattern 
ACC5 55 F Oncocytic ACC abnormal pattern 
ACC6 45 F Oncocytic ACC MSH2/6 preserved 
ACC7 63 M Oncocytic ACC Not tested 
ACC8 21 F Usual type ACC Not tested 
ACC9 58 M Usual type ACC Not tested 
ACC10 18 F Usual type ACC Not tested 
Table 5.1: Details of the oncocytic and usual type ACC samples that underwent WES in this study 
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 Gene interaction network analysis 
To perform computationally intensive gene interaction network analysis, more stringent filters were 
applied to variants to speed up processing time. The variant allele frequency threshold in 1000 genomes 
European controls was reduced from 5% to select only variants with an allele frequency of less than or 
equal to 1%. Variants that are rare in 1000 genomes control set but appear with more than four alternative 
alleles within in-house control data were removed. Additionally, the top 1% most variable genes within 
in-house data were removed. This was determined by the number of rare protein-affecting variants each 
gene contains within the set. The set of 348 different variants were aggregated into 339 genes and input 
into the Cytoscape GeneMania plugin (Montojo et al., 2010). 
Interaction networks were drawn and genes that interacted physically according to GeneMania were 
clustered. Clusters of four or more genes were further explored. The GO Consortium enrichment analysis 
web tool was used to apply GO terms to clusters using the PANTHER Overrepresentation Test (release 
20171205) including the default false discovery rate (FDR) correction for multiple testing (Blake et al., 
2015). Of the terms highlighted by the analysis, the most significant term that encompasses between ten 
and 200 genes was selected, in compliance with previous studies (Milne et al., 2017).  
Allelic counts of all 348 different filtered protein-affecting variants (regardless of GeneMania clustering) 
within the selected GO terms were aggregated and contingency tables were drawn. Variants were also 
aggregated for each GO term over a comparably filtered set of 503 Europeans from phase-3 of the 1000 
genomes study (Auton et al., 2015). Variants from European phase-3 1000 genomes data were filtered to 
select 25,021 different rare (European AF <0·01 in 1000 genomes), protein-affecting variants (loss of 
function, predicted deleterious and damaging missense, and inframe indels). Variants were aggregated 
into 11,360 genes, which were filtered to remove the top 1% most variable genes. Variability was 
measured by the number of rare protein-affecting variants each gene contains. Aggregated allele counts 
were generated for each selected GO term. In total a set of 11,422 genes with variants in 1000 genomes 
Europeans and the ACC set were analysed for an enrichment of variants in each of the identified GO 
terms. A one-tailed Fisher’s exact test was performed using the R Stats package to test for an enrichment 
of protein-affecting variants within each selected GO term in ACC in comparison to the European 1000 
genomes set. 
 TP53 gene interaction analysis 
The 339 genes were analysed to identify any that may be closely related to TP53. The Cytoscape 
GeneMania plugin was used to identify genes that cluster with TP53 via physical interactions. The cluster 
included genes that were first degree interactors with TP53 (predicted to have a direct physical 
interaction) and those that interacted with TP53 through partner genes, including ‘result’ genes that were 
introduced by the Cytoscape GeneMania plugin due to close interactions with the input set. All clustered 
genes had between one and five degrees of separation (five interaction ‘edges’) between the candidate 
 
108 | P a g e  
 
gene and TP53. Each gene within the TP53 cluster was further examined to prioritise candidate variants 
as above. 
A set of 11,360 comparably filtered genes with rare, protein-affecting variants in the 1000 genomes 
European set (503 individuals) was also analysed for interactions with TP53. Of genes input into 
Cytoscape GeneMania from both the ACC set (339 genes) and the 1000 genomes European set (11,360 
genes), the numbers of first and second-degree interactors with TP53 were counted. A one-tailed Fisher’s 
exact test was used to test for an enrichment of 1st degree interactors with TP53, and 1st or 2nd degree 
interactors with TP53 in the ACC set. The 2nd degree interactors included those that interacted via a 
‘result’ partner gene which did not have a variant within the input gene set. No ‘result’ partner genes were 
counted as first or second-degree interactors. 
 Tumour immunohistochemistry 
The Ventana Benchmark mismatch repair panel (MSH2 (G219-1129) and CONFIRM anti-MSH6) was 
used to analyse known mismatch repair genes within tumours. IHC was performed on 4µm sections of 
paraffin embedded tumour tissue in accordance with the manufacturer’s guidelines and interpreted by an 
experienced pathologist (Dr Alison Marker, Department of Histopathology, Addenbrookes Hospital). 
 The Cancer Genome Atlas – Adrenocortical Carcinoma  
The results here are in whole or part based on data generated by TCGA, managed by the National Cancer 
Institute and the National Human Genome Research Institute. Controlled access data were requested and 
downloaded for the TCGA-ACC dataset. Aligned germline WES data generated from the blood or tissue 
derived normal cells of 91 ACC cases as described by Zheng et al (Zheng et al., 2016) were downloaded 
from TCGA database. FASTQs were generated from BAM files and realigned to hg19 reference genome. 
Data were run through an in-house VCF generation pipeline and filtered to select rare (1000 genomes 
European AF < 0.01) protein-affecting variants (loss of function, predicted deleterious and damaging 
missense variants, and inframe indels). This TCGA set was explored to provide further evidence of the 
role of candidate genes in this study in ACC predisposition. 
To identify any unique gene expression patterns in the oncocytic subset of ACCs, RNA-sequencing data 
from TCGA were downloaded and run through a purpose-built RNA-sequencing analysis pipeline (see 
Chapter 2: Methods for further details). The samples were aligned with TopHat (v2.1.1) prior to 
processing and QC. Differential expression analysis was performed comparing expression levels in the 
three TCGA oncocytic samples (cases) for which RNA-sequencing data were available, to 74 usual type 
ACC samples (controls). For each group of cases and controls, an FPKM (fragments per kilobase of 
transcript per million mapped reads) is calculated by creating a dispersion model which tests if the 
variance in the group is beyond what is expected from a Poisson distribution model. The model used to 
calculate the group FPKM value is identical to that used by DESeq (Simon Anders and Wolfgang Huber, 
2010). Genes with a significantly different expression value, with an FDR corrected p value (q value) of 
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less than 0.05, and with a difference in FPKM between the two groups of greater than 1 were further 
explored. Due to the small number of available cases for this analysis, each sample’s FPKM value was 
manually examined for candidate genes to ensure that the group FPKM is representative of the set. 
To understand the functional processes of candidate genes, the GO Consortium enrichment analysis web 
tool was used to apply GO terms to the set using the PANTHER Overrepresentation Test (version 13.0) 
web tool. Terms were examined to identify those that might be relevant to the oncocytic subtype. 
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5.5 Results 
 Germline whole exome sequencing and variant filtering 
After sequencing, a VCF was generated containing 66,447 different variants in the eight ACC individuals. 
Of these, 60,373 different variants were in the five samples with the oncocytic subtype of ACC. After 
genotype filtering to remove low quality or potentially misaligned variants (see Chapter 2: Methods for 
further details), 64,747 different variants were retained in all ACC samples, with 58,922 being retained 
in the oncocytic subset. A set of 1,178 different rare, protein-affecting variants were retained after variant 
filtering, of which 954 were in oncocytic samples. These variants were further filtered and aggregated 
into genes for further analysis. 
 Gene interaction network analysis 
The filtered set of 339 genes input into the Cytoscape GeneMania plugin were aggregated into seven 
clusters of three or more genes linked by a physical interaction of gene products. Cluster 1 was the largest 
and consisted of 22 genes, 11 of which were directly interacting with CUL9 (figure 5.1). The genes were 
run through GO enrichment analysis to identify a term that could be applied to the set. Cluster 1 was not 
significantly enriched for any GO term after FDR correction, however the most significantly enriched 
term with between ten and 200 genes was ‘regulation of gene silencing by miRNA’ (GO:0060964) (p = 
0.00337) which was applied to the set. This term contained 81 genes overall, of which only two were seen 
in cluster one (NUP153 and NCOR2). 
Cluster 2 was a smaller interacting set consisting of four genes; CXCR1, BRAT1, TTC1, and SEC13. The 
set also contained the genes GNAI2 and ACY1 which were not candidates but were added as interacting 
partners to the cluster by the Cytoscape GeneMania plugin to allow for the identification of genes that are 
2nd degree interactors. No GO terms were identified that contained between ten and 200 genes overall and 
more than one of the cluster genes. The closest term to matching these criteria was ‘organelle localization’ 
(GO:0051640) which contained 577 genes overall, including cluster 2 genes SEC13 and BRAT1. 
However, this was not applied to the set due to the large overall number of genes included in the term. 
Cluster 3 contained eleven genes which centred around an interaction with the ERBB2 interacting protein 
encoded by ERBIN. No significant GO term was identified after multiple testing correction using FDR, 
however the most significant term prior to correction was ‘cell junction assembly’ (GO:0034329) (p = 
0.0000476) which contained 139 genes in total including PATJ, OCLN, and ITGB4 which were identified 
in cluster 3. 
Smaller clusters of three genes were also identified and included within this study. Cluster 4 consisted of 
genes GRM1, GRK2, and MAPK8IP3 with the addition of MAP3K1 as an interacting partner gene 
(containing no variants within the ACC set). The most significantly enriched term, containing two of the 
three genes in cluster 4, was ‘activation of MAPK activity’ (GO:0000187) (p = 0.000141). This   
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Figure 5.1: Cluster 1 from the gene interaction network analysis showing genes containing rare protein-
affecting variants in the ACC set. Interacting partner genes that were not identified with variants in the 
ACC set are in grey.  
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term consists of 143 genes including GRM1, and MAPK8IP3. The three genes in cluster 5 (SGCB, SGCZ 
and RANGRF), were enriched within the term ‘muscle cell development’ (GO:0055001) (p = 0.000135), 
with two of the 140 genes in this set being the sarcoglycan genes SGCZ and SGCB. Cluster 6 (MEOX2, 
TDO2, and ASMTL) and cluster 7 (ERC2, DGUOK, and MAPT) were not associated with any GO terms 
with between ten and 200 genes. 
The four identified GO terms (GO:0060964, GO:0034329, GO:0000187, and GO:0055001) were further 
explored for an enrichment of rare, protein-affecting variants across the whole ACC set in comparison to 
a 1000 genomes European control set. Of the 81 genes in the ‘regulation of gene silencing by miRNA’ 
(GO:0060964) term, 38 (46.9%) contained variants in either 1000 genomes Europeans or the ACC cases. 
Across the genes in the term, two variants (aggregated allele count of 2) were identified in ACC and 145 
were seen in the control set. This term was not significantly enriched for variants in ACC in comparison 
to controls (p = 0.695). The term ‘cell junction assembly’ (GO:0034329) contained variants in 91 of the 
139 genes described under the term (65.5%) in the combined case-control set. Five variants were 
identified in these genes in ACC cases in comparison to the 419 in controls. The set was not statistically 
enriched for variants within cases (p = 0.864). In the combined set, variants were identified in 80 of the 
143 genes (55.9%) in the ‘activation of MAPK activity’ (GO:0000187) ontology term. This term was not 
significantly enriched in cases with a combined allele count of 3 in comparison to 280 in controls (p = 
0.864). The final tested term, ‘muscle cell development’ (GO:0055001), was also not significantly 
enriched in the ACC cases (p = 0.839). The set contained 86 of the 140 genes described under this term 
and had a combined allele count of 4 in cases and 338 in controls.  
None of the identified terms were enriched for variants in ACC cases in comparison to 1000 genome 
European control samples. However due to the known link between the MAPK pathway and oncogenesis, 
variants within the cluster termed ‘activation of MAPK activity’ (GO:0000187) were further explored. 
Within this cluster, gene GRM1 contained a rare, protein-affecting missense variant 
(NM_001278065.1:c.1643C>T, p.Thr548Met, rs201399008). Although this gene contains only one loss 
of function variant in the ExAC non-TCGA set, it does contain 453 missense variants. A splice donor 
variant in MAPK8IP3 within this term was excluded upon manual examination of BAM files due to a 
lack of reads supporting the variant call, implying that the variant was a sequencing artefact. The G 
protein-coupled receptor gene GRK2 (also called ADRBK1) was also identified within the cluster however 
was not in the MAPK related ontology term.  
 TP53 gene interaction analysis 
Of the 339 input genes, ~12% formed an interaction cluster with TP53. A set of 50 different variants were 
identified in 42 genes whose products were predicted to directly or indirectly physically interact with p53. 
The cluster of TP53 related genes (figure 5.2) included those with up to five degrees of separation from 
TP53 and those that interacted via partner genes. These partner genes are introduced by the Cytoscape 
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GeneMania plugin to bridge the gap between two secondary interacting genes and are displayed in grey 
in figure 5.2. None of the identified partner genes were included in the 339 genes used in this analysis, 
however they allowed other genes to become part of the TP53 cluster. For example, the protein product 
of the synaptic membrane exocytosis regulator RIMS3 interacted physically with the product of the 
partner gene BANP, which directly interacts with TP53. Other partner genes introduced to the cluster that 
act as a direct link between candidate genes and TP53 included TAF9 which interacts with GALNT6, 
COX17 which interacts with KATNAL1, and MAP3K1 which links GRK2 and MAPK8IP3 to TP53. 
The majority of genes in the cluster (29 out of 42, 69%) were first or second-degree interactors with TP53, 
meaning they interacted directly or via another gene. A further seven genes were third degree interactors, 
with the remaining six genes being fourth, fifth or sixth degree interactors (4, 1, and 1 gene respectively). 
The number of first and second-degree interactors were counted in comparison to a comparably filtered 
1000 genomes European control set. Of the set of 339 input genes with variants in ACC, 11 (~3.2%) were 
first-degree interactors with TP53, 29 (~8.6%) were first or second-degree interactors. The 503 European 
individuals from phase 3 1000 genomes carried 25,021 different filtered variants in 11,360 genes. Of 
these input genes, 277 (~2.4%) were first-degree interactors, 3,053 genes (~26.9%) were first or second-
degree interactors. There was no statistical enrichment of first or second-degree interactors to TP53 in the 
ACC set (p value for 1st interactors: 0.22, 1st and 2nd interactors: 1.00). 
Although an enrichment of TP53 interactors was not seen in the ACC set, individual rare protein-affecting 
variants within TP53 interacting genes were further explored to identify any that may confer a risk of 
ACC development. Within the identified genes, 50 different variants were identified and explored to 
prioritise candidates that were rare in an in-house control set and were not seen in ExAC or 1000 genomes 
control sets; 15 different prioritised variants were manually checked in BAM files, of which 11 could be 
validated. These 11 variants were further explored for a potential role in ACC predisposition. A summary 
of the 11 different variants identified in TP53 interacting genes, including counts of missenses and loss 
of function variants within these genes within the ExAC non-TCGA non-Finnish European (taken from 
the ExAC non-TCGA control data browser; see Chapter 2: Methods for further details) can be seen in 
table 5.2.  
A germline, loss of function, splice donor variant (NM_000179.2:c.3438+1G>A, rs267608096) in the 
Lynch syndrome gene MSH6 was identified in one affected individual. The female (sample ID: ACC5) 
was diagnosed with oncocytic ACC at the age of 55 and IHC studies on available tumour showed a loss 
of mismatch repair genes MSH2 and MSH6. This variant has been previously described on ClinVar 
(Landrum et al., 2018) by the International Society for Gastrointestinal Hereditary   
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Figure 5.2: A cluster of genes containing rare, protein-affecting variants in ACC individuals that 
interact directly or indirectly with TP53 (shown in purple). The 11 candidate genes that were rare in an 
in-house dataset and appeared real in BAM files are shown in blue. Interacting partner genes that were 
not identified with variants in the ACC set are in grey.  
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Gene name Variant consequence ID Amino acid change Sample 
AC LoF variants in this 
gene in non-TCGA NFE 
ExAC 
AC Missense variants in this 
gene in non-TCGA NFE ExAC 
GRK2 Missense variant rs201237885 p.Phe85Cys ACC6 3 33 
ENPP2 Missense variant c.1644C>A p.Lys548Asn ACC8 5 632 
INADL Stop gained c.3964G>T p.Gly1284* ACC1 80 16761 
IRF7 Missense variant c.83C>T p.Gly28Glu ACC5 35 100 
MACF1 Missense variant rs376859455 p.Phe3171Val ACC6 7 1505 
MSH6 Splice donor variant rs267608096  ACC5 25 332 
SPEN Missense variant rs749550885 p.Thr1166Met ACC2 4 606 
SUPT3H Inframe deletion rs767570619 p.Cys32_Tyr33del ACC1 64 46 
TANC1 Missense variant rs143668886 p.Arg1313Gln ACC1 18 264 
TFAP2C Missense variant c.1112C>T p.Thr371Ile ACC1 0 26 
ZFAND4 Frameshift variant rs773964968 p.Ser355Cysfs ACC7 101 207 
Table 5.2: Candidate variants identified in the ACC set within genes that physically interact with TP53 according to Cytoscape GeneMania plugin and the 
frequency of loss of function variants in those genes in ExAC non-TCGA non-Finnish European control set.  
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Tumours and has been labelled as a ‘likely pathogenic’ Lynch syndrome variant (ClinVar submission 
accession: SCV000108066.2). 
Other genes containing variants were examined to assess whether the type of variant carried by ACCs is 
frequent in a healthy population. The previously identified (see 5.5.2 Gene interaction network analysis) 
MAPK associated G-protein coupled receptor gene GRK2 (ADRBK1) was also identified as associating 
with TP53 via MAP3K1. The gene carried a rare missense variant (NM_001619.3:c.254T>G, 
p.Phe85Cys, rs201237885) in a female (sample ID: ACC6) who was diagnosed with an oncocytic subtype 
ACC at the age of 45. GRK2 does not frequently contain missense variants in the ExAC non-TCGA non-
Finnish European control population, with only 33 protein-affecting missense variants in the set of 27,173 
individuals. This low number of variants could be due to the smaller than average gene length 
(NM_001619.3, 3466 bp, 689aa) or could suggest that variants are associated with disease phenotypes 
and therefore not present in healthy control populations. This is in contrast to the TP53 interacting gene 
ENPP2, which contains a novel missense variant (NM_006209.4:c.1644C>A, p.Lys548Asn) in germline 
DNA from a female with young-onset ACC (sample ID: ACC8), diagnosed at the age of 21. This 
pyrophosphatase gene is of a similar length to GRK2 (NM_006209.4, 3233bp, 884aa) however it has a 
far larger number of protein-affecting missense variants in healthy controls, with 632 missense variants 
identified in the ExAC non-TCGA non-Finnish European population. 
Apart from the aforementioned MSH6 splice variant, only two other loss of function variants appear in 
the identified TP53 interacting genes. A stop gain variant in tight junction associated gene INADL (also 
known as PATJ) (NM_176877.3:c.3964G>T, p.Gly1284*) was identified in a male (sample ID: ACC1) 
diagnosed with an oncocytic ACC at the age of 67. IHC revealed that this individual had preserved MSH2 
and MSH6 in the tumour tissue. The ExAC non-TCGA non-Finnish European set contained 80 loss of 
function variants in this gene; all of these had an AF<0.01. A frameshift deletion of 2bp in zinc finger 
gene ZFAND4 (NM_001128324.2: c.1064_1065del, p.Ser355Cysfs, rs773964968), was identified in a 
male individual (sample ID: ACC7) diagnosed with oncocytic subtype ACC at age 63. In the ExAC non-
TCGA non-Finnish European population this gene carries 101 rare (AF<0.01) loss of function variants. 
The high prevalence of truncating variants seen within these genes in a healthy population suggests that 
they are not likely to be associated with a disease phenotype. 
Variants in IRF7, MACF1, SPEN, SUPT3H, and TANC1 were also excluded from further analysis due to 
a large number of similar consequence variants seen in a control population. Although genes such as 
TANC1 did have a low number of loss of function variants in the healthy population, the variant identified 
in this study was a missense variant of which there were 264 occurrences in the healthy population. To 
fully understand the function of these missense variants in both a healthy and disease affected population, 
they would need to be assessed in the context of the proteins functional domains. A missense variant in 
transcription factor gene TFAP2C was identified in sample ACC1. No loss of function variants and only 
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26 missense variants have been identified within this gene in the ExAC non-TCGA non-Finnish European 
population, suggesting this gene is well conserved and could play a role in disease pathogenesis. 
 Analysis of candidate variants using publicly available datasets and tools 
The identified MSH6 splice donor variant has a known role in Lynch syndrome and can be linked to 
mismatch repair loss in the tumour of this individual. However, for other identified candidate genes, a 
link between genotype and phenotype is not as transparent. Freely available online tools can be used to 
elucidate this further in some cases. 
The TP53 interacting G-protein coupled receptor kinase candidate gene GRK2 (also known as ADRBK1) 
has not previously been associated with cancer predisposition. Protein and RNA expression data from 
HPA suggests that this gene is most highly expressed in the bone marrow and immune system including 
the appendix, tonsil, and spleen. The protein is expressed at a low level in the adrenal gland and GTEx 
RNA-sequencing data (The GTEx Consortium et al., 2015) summarised by HPA shows an average of 
22.6 RPKM (reads per kilobase million) across 145 adrenal samples. This expression level is relatively 
low, with the highest expression being an average of 153.4 RPKM across 104 spleen samples. 
A database of mouse model gene knockouts was used to assess potential phenotypes caused by variants 
in this gene. A study describing Cre recombination knockout mice showed that deletion of GRK2, resulted 
in developmental retardation and cardiac abnormalities (Matkovich et al., 2006). The variant identified 
in GRK2 in ACC was a missense variant and so the phenotype is likely to be less severe than knockout 
associated phenotypes. 
Protein from the transcription factor gene TFAP2C was not detected in a number of tissues, including 
adrenal glands according to HPA data. RNA-sequencing data from GTEx also reflects this lack of 
expression with an average of 0.2 RPKM across the 145 adrenal samples. This is in comparison to an 
average RPKM of 17 in oesophageal tissue and 29.6 in skin tissue within GTEx data. Mouse models in 
this gene have highlighted a role in early development, specifically proliferation and differentiation of 
trophectodermal cells (Werling and Schorle, 2002). 
 Candidate genes in The Cancer Genome Atlas – Adrenocortical Carcinoma dataset 
The candidate genes GRK2, MSH6, and TFAP2C were further explored in the TCGA-ACC dataset. No 
variants were found in this set in candidate gene GRK2, however one missense was identified in GRK3 
as well as a missense in GRK1, GRK4, GRK5, GRK6, and two missenses in GRK7. 
A frameshift insertion was seen in two unrelated individuals from the TCGA-ACC set in the mismatch 
repair gene MSH6 (NM_000179.2:c.4065-4066T>TTTGA, p.Lys1358Aspfs, rs267608142). Other 
mismatch repair variants were seen in this set in MSH2 (NM_000251.2:c.4G>A, p.Ala2Thr, rs63750466 
and NM_000251.2:c.2156T>G, p.Leu719Trp, rs777933557) and MSH3 (NM_002439.4:c.2732T>G, 
p.Leu911Trp, rs41545019). No variants were seen in candidate gene TFAP2C.  
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 Differential expression analysis in oncocytic The Cancer Genome Atlas data 
RNA-sequencing data from three oncocytic samples within the TCGA subset were analysed in 
comparison to data from 74 usual type ACC samples to identify genes or sets of genes (defined by 
ontology terms) that were differentially expressed. Within this analysis, usual type ACC samples were 
used as controls to identify oncocytic specific expression changes. No RNA sequencing data derived from 
normal tissue was available from these samples to act as an additional ‘true’ control. Expression levels 
across the group were tested for 63,652 genes and RNAs. Of these, 127 were significantly differentially 
expressed between the two sets (FDR corrected p value < 0.05). A set of 61 genes and RNAs had an 
FPKM change of greater than 1. 
These genes were assigned GO terms using the GO Consortium enrichment analysis web tool. A set of 
42 ontology terms were highlighted that contained less than 200 genes in total, with each term carrying 
more than one of the 61 candidate genes. Out of the 42 highlighted terms the candidate gene OXT, which 
codes for the hormone Oxytocin, was in 22 terms and was significantly differentially expressed between 
the tested sets (p = 0.00005). This gene was included in, but was not limited to the terms ‘renal system 
process’ (GO:0003014), ‘response to fatty acid’ (GO:0070542), ‘regulation of blood pressure’ 
(GO:0008217), and ‘regulation of synapse organization’ (GO:0050807). The OXT gene had expression 
levels of 0 FPKM within the oncocytic subset and 1.31 FPKM in usual type ACCs, the significant 
difference between the values is driven by the 0 FPKM. Of the 74 usual type ACCs included as controls, 
44 carried an FPKM of 0 for the OXT gene (figure 5.3A) and therefore it is unlikely to be associated with 
the oncocytic subtype. Similarly, the CART prepropeptide coding gene, CARTPT, is significantly 
differentially expressed in cases and controls (p = 0.00005), with an FPKM of 0 in the oncocytic cases 
and 2.09 in the usual type ACC controls. This gene was identified in 17 of the highlighted GO terms but 
also has an FPKM of 0 in 38 controls. 
One interesting term highlighted through this analysis was ‘negative regulation of Wnt signaling pathway’ 
(GO:0030178) which could have implications in oncogenesis. The two genes identified within this term 
with a significant expression change were SFRP5 (p = 0.00005) and NFATC4 (p = 0.0003). Of these two 
genes, nuclear factor gene NFATC4 had the largest expression change, with an FPKM of 16.67 in cases 
and 118.60 in controls. Two oncocytic ACC tumour samples had extremely low expression of this gene, 
with individual FPKMs of 0.99 and 2.80, the final case had an FPKM of 46.21 which was more 
comparable to the values seen in controls. Gene expression values for NFATC4 in the usual type ACC 
controls ranged from 0.75 FPKM, lower than the minimum FPKM in cases, to 577.39 FPKM, with a 
mean of 118.60 and a standard deviation of 128.20. In spite of this high deviation from the mean, the data 
distribution does vary between the oncocytic ACC subtype and usual ACC controls (figure 5.3B). In 
comparison, SFRP5, had a smaller change in expression with an FPKM of 0 in cases and 2.35 in controls. 
Within this gene, 33 controls also had an FPKM of 0, however one sample did carry an FPKM of 156.31, 
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likely contributing to the high group average. The distribution of FPKM in cases and controls for SFRP5 
can be seen in figure 5.3C. 
 
Figure 5.3 A-F: Candidate genes with a differential gene expression in oncocytic ACC samples (cases) 
in comparison to usual type ACC samples (controls). Gene expression is shown in fragments per 
kilobase of transcript per million mapped reads (FPKM). 
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Another highlighted gene was PDE2A which showed a significant loss of expression in the oncocytic 
ACC subtype cases (p = 0.00005) with an FPKM of 4.40 in cases and 91.06 in controls. In the oncocytic 
ACC cases, expression ranged from 0.94 to 6.93 FPKM; in comparison, expression in the controls ranged 
from 1.12 to 690.37 FPKM (figure 5.3D). This gene was identified in six GO terms; ‘response to purine-
containing compound’ (GO:0014074), ‘response to cAMP’ (GO:0051591), ‘carbohydrate derivative 
catabolic process’ (GO:1901136), ‘response to organophosphorus’ (GO:0046683), ‘organophosphate 
catabolic process’ (GO:0046434), and ‘purine-containing compound catabolic process’ (GO:0072523). 
Of the 61 significantly differentially expressed genes analysed, 57 (~93%) showed a loss of expression 
in the oncocytic ACC subtype case set. Of the loss of expression genes, 48 (~84%) had a value of 0 FPKM 
in the case set. Of the four identified gain of expression genes, two had expression levels of 0 FPKM in 
the usual type ACC control set. The genes AL901608.1 and IGHV1OR16-4 had no expression in any of 
the usual type ACC controls, nor in two of the three cases. Therefore only 11 genes had expression values 
in both cases and controls and are likely to represent true expression changes. These included the two 
candidate loss of expression genes NFAT4 and PDE2A. The two gain of expression genes in this set 
included PKIB (p = 0.00015), with 25.10 FPKM in cases and 2.68 FPKM in controls (figure 5.3E), and 
SH3TC2 (p = 0.0002) with 3.01 FPKM in cases and 0.10 FPKM in controls (figure 5.3F).  
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5.6 Discussion 
Germline WES data from individuals with usual type or oncocytic ACC were analysed to identify any 
predisposing genetic factors. GO analysis was used to highlight clusters of functionally related genes 
containing rare germline protein-affecting variants that could be affecting disease predisposition. Four 
GO terms were identified and further explored for an enrichment in ACC cases. The first Cytoscape 
GeneMania generated cluster consisted of 22 genes, however the GO term assigned to this, ‘regulation of 
gene silencing by miRNA’, was only associated with variants in NUP153 and NCOR2. This GO term did 
not contain the other 20 genes shown to physically interact in the gene cluster, showing a discrepancy in 
genes that share a GO term and those that are interacting physically according to Cytoscape GeneMania. 
None of the identified terms in this analysis, which also included ‘cell junction assembly’, ‘activation of 
MAPK activity’, and ‘muscle cell development’, were statistically enriched for rare protein-affecting 
variants in ACC cases in comparison to 1000 genome European controls. 
The MAPK signalling pathway is often altered in tumours and has been shown to be downregulated in 
adrenal tumours (Rubin et al., 2015). Genes that were identified with variants in the ‘activation of MAPK 
activity’ set were further explored, revealing a rare protein-affecting missense variant in the conserved 
gene (as determined by its variability in control sets) GRK2 which was later also identified as interacting 
with TP53. This G protein-coupled receptor gene has been linked to cancer development and prognosis 
in a number of different settings. The GRK2 gene has been described as a tumour suppressor in thyroid 
cancer, with overexpression showing a reduction in cell proliferation in cell lines (Métayé et al., 2008). 
In contrast to this, an overexpression of this gene has been seen in a number of tumour environments 
including breast, thyroid, pancreatic, and prostate tumours, causing to be linked to an increase in 
proliferation and poor overall survival (Prowatke et al., 2007; Métayé et al., 2008; Nogués et al., 2016; 
Zhou et al., 2016). Although GRK2 has currently only been shown to be somatically altered in cancers, 
the low level of germline variability of this gene in healthy controls suggest it is well conserved, with 
only three loss of function and 33 missense variants identified in ExAC non-TCGA non-Finnish 
Europeans (combined allele count of 36 out of 27,173 individuals) and one missense variant seen in the 
1958 birth cohort. 
GRK2 has low levels of expression in a healthy adrenal mouse gland and mice knockouts were shown to 
cause developmental and cardiac abnormalities (Matkovich et al., 2006). Studies of GRK2 and the related 
gene GRK5 showed that although both products interact with p53, only GRK5 can phosphorylate and 
regulate the tumour suppressor (Wei et al., 2012). In contrast to this, a separate study revealed a dose-
dependent correlation between GRK2 expression and levels of phosphorylated p53, causing a delay to 
cell cycle progression in hepatocellular carcinoma cells (Wei et al., 2012). Interestingly, missense variants 
in other G protein coupled receptor genes including GRK1, GRK3, GRK4, GRK5, GRK6, and GRK7 were 
identified in the ACC set analysed from TCGA data including usual and oncocytic types. 
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Pathogenic germline variants in Lynch syndrome genes have been previously identified in 3.2% of ACC 
cases (Raymond, Everett, et al., 2013). The mismatch repair gene MSH6, the product of which was found 
to directly interact with p53, contained a rare loss of function variant in germline DNA from one 
individual with oncocytic ACC. Tumour material from this individual was also shown to have loss of 
MSH2 and MSH6 via IHC. Although loss of MSH2 and MSH6 have been shown to be caused by germline 
defects in MSH6 in colorectal tumours (Morak et al., 2017), within this study tumour material from a 
second individual revealed loss of MSH2 and MSH6 without the presence of any germline protein-
affecting variants in mismatch repair genes.  
Of the TP53 interacting genes highlighted within this study, only two others (apart from MSH6) contained 
loss of function variants. The variants identified in the genes INADL and ZFAND4 were rare (1000 
genomes European AF < 0.01), however overall the genes carried a high number of loss of function 
variants in the ExAC non-TCGA control population. Genes are described as ‘tolerant’ to loss of function 
variants if they harbour a higher than expected number of these variants, suggesting that they are not 
evolutionarily conserved nor under a high degree of negative selective pressure. Genes may be under 
negative selective pressure if changes to that gene impact key cellular pathways and cause an increased 
risk of disease. Therefore, genes with a high number of loss of function variants in a healthy population 
are less likely to cause an increased risk of disease predisposition. 
A missense variant in the transcription factor gene TFAP2C was identified in ACC1. Although this gene 
does not show high levels of variability in the ExAC non-TCGA non-Finnish European controls, 
suggesting a high level of conservation, it also has very low to no expression in healthy adrenal samples 
(mean RPKM of 0.2 across 145 healthy adrenal samples in comparison to a mean RPKM of 29.6 in 
healthy skin samples) and so a missense variant is unlikely to have a deleterious effect in this tissue. No 
further variants were identified in this gene in the TCGA-ACC subset. 
Analysis of expression data from ACC samples within TCGA revealed a potential role for NFATC4, 
PDE2A, PKIB, and SH3TC2 in oncocytic ACC development. The protein product of the gene NFAT4C 
is involved in the Wnt signalling pathway. Wnt-pathway activation had been previously shown in TCGA-
ACC data in comparison to Wnt wild-type samples, in addition to somatic variants in the Wnt/β-catenin 
pathway in 41% of tested ACC cases (Zheng et al., 2016). The nuclear factor of activated T cells (NFAT) 
family of transcription factors are activated by the Wnt signalling pathway in a calcium dependent 
manner, causing the expression of downstream Wnt target genes (Van Camp et al., 2014). In correlation 
with findings by Zheng et al (Zheng et al., 2016), findings here suggest that there is an increased activation 
of the Wnt signalling pathway in ACC tumour samples, as determined by the high expression of NFATC4 
with an FPKM of 118.60. Interestingly, this high expression is not seen in oncocytic ACC tumour 
samples, with expression in this subset much lower at 16.19 FPKM (comparable to values seen in healthy 
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adrenal samples in GTEx data), suggesting that unlike the usual type ACC, Wnt signalling is not 
hyperactivated during oncocytic ACC oncogenesis.  
Cyclic adenosine monophosphate (cAMP) is a component of the cAMP/PKA signalling pathway that 
regulates cellular differentiation, growth, cell metabolism, and cell death. The phosphodiesterase encoded 
by PDE2A is activated by cyclic guanosine monophosphate (cGMP) and is involved in the degradation 
of both cAMP and cGMP (Stroop and Beavo, 1991). By decreasing phosphodiesterase activity, and 
therefore decreasing degradation of cAMP, one can produce a mild hypercorticosteronemia phenotype in 
mice (de Joussineau et al., 2012). Phosphodiesterases are described as modifiers of abnormal adrenal 
phenotypes instead of being directly causal of adrenal tumours. For example, loss of heterozygosity of 
PDE11A4 has been linked to the development of adrenal hyperplasia in adrenocortical tumour patients 
(Horvath et al., 2006). Additionally, germline exonic variants in PDE11A are a modifying factor for the 
development of testicular and adrenal tumours in individuals carrying germline variants in PRKAR1A 
(Libé et al., 2011). A reduction of phosphodiesterase expression could therefore cause aberrant cAMP 
pathway signalling and in some cases lead to cAMP-regulatory element mediated transcriptional activity 
causing excessive cortisol production (Libé and Bertherat, 2005; de Joussineau et al., 2012).  
Neither of the two candidate genes PKIB or SH3TC2 were associated with a GO term. There is little 
known about the gene SH3TC2 besides its involvement in Charcot-Marie-Tooth disease (Brewer et al., 
2014). In contrast, PKIB is a well-studied protein kinase inhibitor. These genes were highlighted as the 
only two genes to show a gain of gene expression in the oncocytic ACC subset after filtering. The product 
of gene PKIB is also linked to cAMP signalling as a member of the cAMP-dependent protein kinase 
inhibitor family. The cAMP-protein kinase A (PKA) pathway is involved in the control of cell growth 
and differentiation in almost all mammalian tissues (Taskén and Aandahl, 2004). PKIB has previously 
been shown to be overexpressed specifically in aggressive and castration resistant prostate cancer (Chung 
et al., 2009). PKIB is involved in PKA-C nuclear localisation and modification of kinase activity causing 
Akt phosphorylation and activation (Chung et al., 2009).  
The secretion of cortisol is a key diagnostic factor of adrenal tumours. The cAMP pathway is a regulatory 
process of cortisol secretion, with cAMP-PKA activation stimulating cortisol production and release. The 
two genes with a change in expression linked to cAMP appear to collectively and individually promote 
the cAMP-PKA pathway (Zheng et al., 2016), contrary to this, clinical information for these three 
individuals show that the extracted oncocytic adrenal tumours were not hormone secreting. This could 
suggest that cAMP-PKA is contributing to different oncogenic processes being utilised in the oncocytic 
subtype of ACC in comparison to the usual subtype.  
5.7 Summary 
This study contains one of the largest described in-depth analyses of the genetic aspects of oncocytic and 
usual type ACC. In-house generated WES data was utilised to describe a number of germline candidate 
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variants in these samples, although no clearly associated novel candidates were identified. The majority 
of participants in this sequencing study were diagnosed over the age of 40 and none were described with 
a family history of ACC, therefore the probability of finding causal germline mutations in this set and 
comparable sporadic cancer datasets is low and the results are perhaps unsurprising. In addition to using 
in-house WES data to identify potential candidates for ACC predisposition, external data were utilised to 
explore possible pathways of oncocytic subtype development. G-protein coupled receptor genes were 
identified with germline variants within in-house and TCGA ACC data, suggesting a potential role for 
the MAPK pathway in disease predisposition. Analysis of RNA-sequencing data suggested that the 
cAMP-PKA pathway may have a specific role in the oncogenesis of the oncocytic subtype and therefore 
may, be a potential drug target.  
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6 Predisposition to hereditary breast cancer 
6.1 Introductory statement 
The work described in this chapter is the joint effort of myself and other researchers within the group. 
All WES preparation was performed by James Redman and Alexey Larionov and sequenced at the 
Cancer Research UK Cambridge Institute Genomics Core. Data were processed to VCF by an in-house 
WES pipeline written by Alexey Larionov. Sequencing data from the Montreal dataset were processed 
and analysed by me. The WECARE WES data were processed to VCF by Alexey Larionov. Variant 
filtering for the WECARE set was performed separately by both Alexey Larionov and myself. The GO 
enrichment analysis was designed by myself and performed on the Montreal set and on my own 
comparably filtered version of the WECARE set. Statistical tests on the WECARE set were 
recommended by David Conti and performed by Alexey Larionov using his own comparably filtered 
variant set. Further prioritisation, including breast cancer interaction analysis, on a subset of WECARE 
candidate genes was performed by myself. 
6.2 Abstract 
Breast cancer is the most common cancer diagnosed in the UK. Hereditary breast cancers are often 
associated with germline variants in BRCA1 and BRCA2. Although other genes have been identified 
containing breast cancer predisposing variants, these only account for a small minority of the remaining 
BRCA1/BRCA2-negative hereditary breast cancer cases. Individuals with contralateral breast cancer 
have been shown to be enriched for hereditary predisposition in comparison to unilateral breast cancer 
cases. Additionally, ethnically homogenous populations such as the Ashkenazi Jews have been shown 
to be at higher risk of hereditary diseases, largely due to the presence of a number of disease associated 
founder variants. This study explores whole exome sequencing data from the Women’s Environmental 
Cancer and Radiation Epidemiology (WECARE) study, looking at contralateral breast cancer as a 
model for increased breast cancer risk, and from a set of familial and Ashkenazi Jewish breast cancer 
cases recruited via the McGill Cancer Genetics Programme in Montreal. Both datasets were explored 
for an enrichment of loss of function variants in GO terms and individual variants within enriched terms 
were further explored using a manual variant prioritisation approach. Further statistical tests were 
performed on the WECARE set to prioritise candidate genes, which were explored for an interaction 
with known breast cancer predisposing genes. Within the Ashkenazi Jewish families from the Montreal 
set, two different rare, loss of function variants were identified in DNA recombination related gene 
RAD52. Within the whole Montreal familial breast cancer set, four GO terms were significantly 
enriched for loss of function variants in comparison to a 1000 genomes control set and an in-house 
control set including; ‘cysteine-type endopeptidase activity’ (GO:0004197), ‘single-stranded RNA 
binding’ (GO:0003727), ‘magnesium ion binding’ (GO:0000287), and ‘cholesterol binding’ 
(GO:0015485). After statistical prioritisation of the WECARE set, variants were identified in genes that 
interacted with known breast cancer genes. In particular, variants within the gene encoding STK11 
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interacting protein (STK11IP) were seen in both the WECARE and Ashkenazi Jewish individuals in the 
Montreal set. A number of candidate genes have been suggested that, when carrying pathogenic 
variants, could explain some of the missing heritability seen in familial breast cancer cases.  
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6.3 Introduction 
 Hereditary breast cancer syndromes 
Breast cancer is the second most common cause of cancer mortality in women in the UK (Cancer 
Research UK, 2016). Between 5-15% of breast cancers are thought to be hereditary (Carroll et al., 2008; 
Economopoulou, Dimitriadis and Psyrri, 2015). Around 30% of hereditary breast cancers are associated 
with germline pathogenic variants in genes BRCA1 and BRCA2 (Siegel, Naishadham and Jemal, 2013). 
A prospective cohort study reports a wide range of risk estimates for carriers of pathogenic variants in 
these genes, with a cumulative risk by the age of 70 of between 40% to 87% and 27% to 84% for BRCA1 
and BRCA2 respectively (Kuchenbaecker et al., 2017). It has been shown that individuals with a family 
history of breast cancer can carry at least a twofold risk of disease development (depending on the 
strength of the family history), with pathogenic variants in BRCA1 and BRCA2 accounting for around 
15% of this excess risk (Easton, 1999; Antoniou et al., 2008). 
In recent years, other breast cancer predisposition genes including PALB2, CHEK2, and ATM have been 
incorporated into the BOADICEA risk score model which calculates BRCA1 and BRCA2 carrier 
probabilities for individuals with family histories of breast cancer (Lee et al., 2016). Pathogenic variants 
in these genes are predicted to increase risk of breast cancer (by age of 80) to 50% for PALB2, 30% for 
CHEK2, and 28% for ATM (Lee et al., 2016). These three genes, like BRCA1 and BRCA2 are part of 
the DNA damage repair pathway. 
Pathogenic variants in TP53 have been described in Li Fraumeni syndrome, which was originally 
identified as conferring a risk to childhood rhabdomyosarcoma, sarcoma, leukaemia, brain tumours, 
breast cancer, and adrenocortical carcinoma (Li and Fraumeni, 1969). Germline pathogenic variants in 
this tumour suppressor gene are associated with a small fraction of breast cancer cases, although breast 
cancers do account for around one third of cancers in Li Fraumeni syndrome families (Birch et al., 
1998). 
PTEN Hamartoma Tumour Syndrome (PHTS) is associated with germline variants in PTEN. Pathogenic 
variants in this gene increase risk of endometrial, thyroid, renal, and colorectal cancers in addition to 
breast cancer. Lifetime breast cancer risk estimates for germline pathogenic PTEN variant carriers range 
from 67-85% (Tan et al., 2012; Bubien et al., 2013; Nieuwenhuis et al., 2014).  
Despite the multiplicity of breast cancer predisposing genes, including many that have not been 
mentioned, families with a strong history of breast cancer who are negative for germline variants in 
these known cancer genes are often seen. This suggests that there are still more risk associated genes to 
identify. Studies looking to identify novel breast cancer predisposition genes or variants often utilise 
ethnically homogenous populations and those who carry a greater cancer risk such as those with 
multiple primary tumours. The Ashkenazi Jewish population is the largest genetically isolated 
population in the United States and is often used to identify founder variants that are rarer and less 
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easily identifiable in the general population (Rinella et al., 2013; Carmi et al., 2014). An example of 
this is the identification of Crohn’s disease risk variants which were found to have up to 4-fold higher 
prevalence in Ashkenazi Jewish individuals (Kenny et al., 2012). Additionally this technique was 
successfully utilised by Rinella et al, to identify new pathogenic variants in BRCA1 and BRCA2 negative 
Ashkenazi Jewish breast cancer cases (Rinella et al., 2013). 
 Contralateral Breast Cancer 
The development of multiple primary tumours is thought to be indicative of a greater overall 
predisposition for cancer (Cybulski, Nazarali and Narod, 2014). Evidence for this can be found by 
looking at populations of individuals who develop no cancer, one cancer or multiple cancers. This latter 
group of individuals is larger than would be expected by chance (Cybulski, Nazarali and Narod, 2014), 
suggesting that there is a greater probability for some individuals to develop a second primary tumour. 
Additionally, it has often been described that the sites of the second tumour occurrence are specific and 
in these cases can often be linked to a hereditary syndrome (Lynch et al., 1977; Cybulski, Nazarali and 
Narod, 2014). This is particularly the case with multiple breast tumours, which is known as contralateral 
breast cancer (CBC) when the first and second primary tumours appear in different breasts.  
CBC can be described as synchronous, when the second tumour is discovered close in time to the first, 
or asynchronous, when there is a larger (although currently undefined) period of time between the first 
and second diagnosis (Narod, 2014). These differences are important to distinguish between tumours 
that develop as a result of the primary tumour metastasising to the other breast, and those that are a true 
second primary tumour. Synchronous breast cancer is less common, constituting around 30% of 
multiple breast tumour cases (Hartman et al., 2005); they can be further categorised by whether the 
symptoms appear in both breasts or in one breast, the latter of which is usually only discovered as a 
result of staging investigations following the discovery of the first tumour (Narod, 2014). It should be 
noted that within the latter group, some second primary tumours may have not been identified during 
this screening and may therefore have been labelled as asynchronous. There is no standard for 
classifying synchronous or asynchronous BC, however the term synchronous can generally be applied 
to second primary tumours that appear less than a year post-diagnoses of the first tumour (Senkus et al., 
2014). To create a clear distinction between multiple primary tumours and potential metastatic 
secondary tumours, studies exploring CBC often consider only asynchronous cases, with a clear 
distinction in time between diagnosis of the first and second primary tumour (Bernstein et al., 2004). 
Pathogenic variants in BRCA1 and BRCA2 are well described as contributors to hereditary breast cancer 
as previously mentioned (Kuchenbaecker et al., 2017). Pathogenic variants in both genes also confer 
an elevated risk for second primary CBC, with risk estimates of 41% for BRCA1 and 21% for BRCA2 
within 20 years of diagnosis of the first tumour (Kuchenbaecker et al., 2017). However, only 5% of 
CBC patients carry pathogenic variants in BRCA1 or BRCA2 (Hartman et al., 2005; Malone et al., 
2010). Studies have examined genetic risk factors for CBC in BRCA1 and BRCA2 pathogenic variant 
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negative individuals with a strong family history (Bernstein et al., 2004; Sisti et al., 2015). The 
WECARE study identified a modest increased risk to CBC in carriers of a protein-truncating CHEK2 
variant, 1100delC (Mellemkjær et al., 2008). However this variant has been described as rare in most 
populations and unlikely to account for a large proportion of CBC cases (Mellemkjær et al., 2008). 
 Tumour Characteristics and CBC risk 
When describing the relationship between the characteristics of the first tumour and the risk of 
developing CBC, it is important to note that different tumour subtypes are subject to different 
treatments. It can therefore be a challenge to distinguish between the effect of tumour status and the 
effect of differential treatment. For example, estrogen-receptor (ER) positive tumours have been 
associated with a decreased risk for CBC development which is thought to be due to the standard 
treatment of this tumour type with adjuvant endocrine therapy (Lizarraga et al., 2013).  
A similar trend was observed in cases with ER negative and PR (progesterone-receptor) negative first 
primary tumours, who had a higher risk of developing CBC to ER+/PR+ cases (Saltzman et al., 2012). 
It was also shown in the same study that women with HER2-overexpressing or triple negative first 
primary tumours were at higher risk of CBC development in comparison to women with a luminal-A 
subtype (Saltzman et al., 2012). In line with previous suggestions that this difference in risk could be 
linked to the treatment given, the risk became non-significant when analysis was limited to patients who 
were not treated with adjuvant hormonal therapy (Saltzman et al., 2012). Another interesting 
observation with regards to hormone receptor (HR) status is that there is a correlation between the 
molecular subtype seen in the first and second primary tumours; for example, women whose first 
primary tumour is HR-negative are around 10 times more at risk of developing a second HR-negative 
tumour (Kurian et al., 2009). This suggests that similar genetic or environmental factors are contributing 
to the risk and development of the first and second primary tumours (Saltzman et al., 2012).  
Studies have been published looking into the effects of lobular histology, medullary histology and high 
histologic grade on the development of CBC and have shown to slightly increase risk (Lizarraga et al., 
2013). However risk rates with regards to lobular histology of the first primary tumour have been shown 
to differ amongst studies (Lizarraga et al., 2013; Langlands et al., 2016). This could be a result of 
differences in methods of diagnosis, interpretation of histological results, and different degrees and 
methods of surveillance and disease management between study centres as well as general clinical 
approaches in different countries (Langlands et al., 2016). One study suggested that there is no increased 
incidence of CBC in patients with invasive lobular carcinoma or invasive ductal carcinoma (Langlands 
et al., 2016). However when studies were limited to cases of synchronous CBC, there was a higher 
incidence of lobular cancers than seen in UBC cases (Kollias et al., 2001). This result has similarly been 
seen in other population studies (Bernstein et al., 1992) and therefore a lobular histology has been 
described as a risk factor for developing a second synchronous primary breast cancer.  
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The observation that often one BC subtype is reflected in both the first and second primary tumours 
gives further credence to the idea that both tumours are likely to be a result of the same combination of 
risk factors such as predisposition genes. The link between predisposing gene and tumour characteristic 
is best seen in patients with BRCA1 pathogenic variants who are at greater risk of being diagnosed with 
triple-negative breast cancers (Pellegrino et al., 2016).  
 The effect of first primary cancer treatment on CBC risk 
Treatment of the first primary breast cancer has long been thought of as a possible risk or protective 
factor against the development of subsequent tumours. The widespread adoption of tamoxifen as a 
therapy for ER-positive patients in 1985 has been linked to a 3% decrease in cases of CBC each year 
(Lizarraga et al., 2013). In one study the use of hormonal therapy has been linked to a decrease in CBC 
cases by 42% (Schaapveld et al., 2008). Chemotherapy was also shown to decrease CBC risk by 27% 
(Schaapveld et al., 2008). 
The effects of radiotherapy on the development of a second primary breast cancer have been extensively 
studied. Radiation in doses comparable to those delivered by radiotherapy has been shown to induce 
breast cancer, particularly in young women (under 24 years of age) (Boice  Jr. et al., 1991). Therefore 
the dose given to the primary BC has been described as influencing CBC development (Boice Jr. et al., 
1992). The increased risk of developing CBC after radiotherapy was established previously but was 
shown to contribute to less than 3% of CBCs (Boice Jr. et al., 1992). This risk was similarly shown to 
be increased in younger women whose first BC was treated before the age of 45 (Boice Jr. et al., 1992). 
The same relationship between CBC and radiotherapy in younger women was shown in the WECARE 
study (Stovall et al., 2008), which was originally designed with the intention of analysing the interaction 
between radiotherapy, pathogenic variants in known BC predisposition genes and the development of 
CBC (Bernstein et al., 2004). Many of the known BC predisposition genes play key roles in DNA 
damage repair, including the repair of double strand breaks induced by ionizing radiation. It was 
therefore hypothesised that individuals with pathogenic variants in BC associated DNA damage repair 
genes may be more susceptible to radiation induced CBC (Bernstein et al., 2004). The WECARE study 
later showed that radiotherapy for the first BC and specific variants in the double strand break repair 
gene ATM increase the risk of developing second primary breast cancers (Bernstein et al., 2010).  
 Aims 
This study uses high risk breast cancer populations to identify new breast cancer associated 
predisposition genes. The aims are as follows: 
1. To identify candidate variants for an association with a predisposition to CBC development 
2. To explore variants in an Ashkenazi Jewish breast cancer cohort to identify potential founder 
variants with an association with breast cancer risk 
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6.4 Methods 
 Study Population 
Three populations of samples were used for this analysis. In total, 512 germline DNA samples were 
utilised for sequencing from the WECARE (Women’s Environmental Cancer and Radiation 
Epidemiology) study (Bernstein et al. 2004). This included 256 unilateral breast cancer (UBC) and 254 
CBC patients and two patients with an unknown phenotype that were later removed from analysis. 
WECARE was created as a case-control study matching 1,398 patients with UBC as controls to 705 
CBC patients. Participants were recruited through five cancer registries covering Denmark and the US 
within Iowa, California (Los Angeles and San Diego) and Washington; all registries from within the 
US were associated with the Surveillance, Epidemiology and End Results (SEER) registry system 
(Malone et al. 2010). 
Participants were eligible for the WECARE study as cases if they meet the following conditions as 
described in the study design (Bernstein et al. 2004):  
a) The first primary invasive breast cancer did not spread beyond the regional lymph nodes at the 
time of diagnosis.  
b) The second primary breast cancer must be diagnosed at least one year after the diagnosis of the 
first breast cancer. 
c) The participant resided in the same reporting area for both diagnoses. 
d) The participant had no previous cancer diagnosis. 
e) The participant was under the age of 55 at the time of the first primary breast cancer diagnosis. 
f) The participant was alive at the time of contact to provide consent, complete an interview and 
provide a blood sample. 
Participants from WECARE were selected for the study described here if they met the following 
additional criteria: 
a) Participant does not carry any pathogenic variants in BRCA1, BRCA2 or PALB2. 
b) Participant was of white ethnicity with European ancestry. 
c) The germline DNA sample passed quality control in a previous genome wide association study 
(Bernstein et al. 2004). 
d) The germline DNA sample could be matched to a control on the use of radiotherapy on the first 
primary tumour. 
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Clinical information about the study participants was made available including time between diagnosis 
of first and second primary tumour where appropriate and treatment given for first primary tumour. All 
participants were recruited through registries in the USA or Denmark and are ethnically matched to 
generate a group of predominantly American women of European ancestry.  
As an external control, data from 198 female germline DNA samples from phase 3 of the 1000 genomes 
project were aggregated into the WECARE set. Ethnicity tests using eigenvectors were used to confirm 
the ethnicity of the WECARE set and to select non-Finnish European samples from the 1000 genomes 
project that match this ethnicity. In addition to the WECARE study, 63 women with breast, ovarian or 
pancreatic cancer were recruited from centres in Montreal via the McGill Cancer Genetics Programme. 
All recruited individuals had a strong family history of breast cancer. A BRCAPro score, which is based 
on studies of Ashkenazi Jewish and European descent individuals, was generated to predict the 
likelihood of families carrying pathogenic variants in BRCA1 or BRCA2 (Huo et al., 2009). Individuals 
with a BRCAPro score of greater than 10%, but with no pathogenic variants in these genes were 
selected. Of this set, 14 individuals were of Ashkenazi Jewish ancestry, and so in addition to analysis 
across all 63 cases, this small subset was analysed separately. 
 Germline whole exome sequencing 
DNA was extracted from blood and prepared for PE125 WES using the Nextera Rapid Capture Exome 
enrichment kit (Illumina). For the WECARE study, sequencing was performed on HiSeq-2500 
machines by the CRUK CI genomics core facility. Germline DNA from the Montreal breast cancer 
participants was sequenced on HiSeq-4000 machines. 
VCF files for both sets were generated using a standard pipeline following GATK best practice 
recommendations for whole exome data (see Chapter 2: Methods for further details). For the WECARE 
set, FASTQ files from 198 non-Finnish European females from the 1000 genomes project (NFE) were 
integrated for joint variant calling to reduce the likelihood of technical differences affecting association 
testing. Genotypes were filtered to select those with a genotype quality score of greater than 20 and a 
genotype depth of less than 500 to remove incorrectly aligned regions. A variant call rate filter was set 
separately for WECARE samples with NFEs, where each variant had to be present in greater than or 
equal to 85% of WECARE genotypes and 85% of NFE genotypes. A WECARE only set was also 
created with more permissive filters, selecting variants that appeared in greater than or equal to 85% of 
WECARE genotypes only for analysis where the NFE set was not used. 
The WECARE dataset was filtered to select uncommon variants (AF <0.05 or > 0.95 (to allow for rare 
variants that are found in the reference genome) in either the WECARE set only or the WECARE set 
including NFEs), protein-affecting variants (loss of function, predicted deleterious and damaging 
missense (as flagged by SIFT and PolyPhen respectively)) and those that were predicted to be
*The WECARE dataset underwent comparable filtering by bioinformatician Alexey Larionov, prior to statistical 
gene prioritisation as further described which was performed by Alexey Larionov and David Conti. 
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 pathogenic by ClinSig (flags included: “likely_pathogenic”, “risk_factor”, “pathogenic", "association", 
"protective", "drug_response”). Variants that were predicted to be “benign” or “likely_benign” by 
ClinSig were removed regardless of predicted variant consequence*. 
Standard genotype filters were used on the Montreal set, including selecting those with a genotype 
quality score of greater than 20 and a genotype depth of less than 500 to remove incorrectly aligned 
regions, in addition to a variant call rate filter of greater than or equal to 50%. Variants were filtered to 
select uncommon (AF <0·05 in European 1000 genomes), protein-affecting variants (loss of function, 
predicted deleterious and damaging missense (as flagged by SIFT and PolyPhen respectively), and 
inframe indels).  
 Gene ontology enrichment analysis 
Similar to previous analysis on the HDGC dataset (see Chapter 3), GO terms were used to identify 
clusters of genes enriched for variants in each breast cancer cohort in comparison to a 1000 genomes 
control set. A multi-use R markdown script was developed that takes a dataset of interest, filters 
according to parameters set by the user, creates an aggregated count of variants in a specified set of GO 
terms and runs a Fisher’s exact test to compare this count to that of a control set. 
The script accepts Rdata, with one dataframe for VEP annotated variants and another for genotype 
information as is generated by the in-house pipeline. Parameters that need to be set by the user include 
a maximum allele frequency (AF) filter and a population which ethnically matches the case dataset, 
both the case and 1000 genomes dataset are then filtered for variants with an allele frequency below the 
filter in the set population from 1000 genomes. Additionally, users can set a consequence filter of either 
“LOF”, stating that only loss of function variants should be used, or “PAV”, allowing the analysis to be 
performed on all protein-affecting variants (loss of function, predicted deleterious and damaging 
missense variants and inframe indels). The Montreal set was filtered for loss of function variants with 
an AF < 0.05 in the European 1000 genomes population. 
The case and control sets are filtered accordingly, and allele counts for each variant are aggregated into 
GO terms. A GO annotation file (GAF) containing terms and associated gene IDs was downloaded from 
the GO data site. Terms that in total contained between 20 and 200 genes and contained variants within 
these genes in either the case or control set were analysed. A one-tailed Fisher’s exact test was applied 
to select terms that were significantly enriched for variants in the case set, with an FDR corrected p 
value of less than 0.01. Variants identified within the enriched terms are output separately for further 
exploration. 
The same script was applied to test for GO terms associated with breast cancer risk in the Ashkenazi 
Jewish Montreal subset and the WECARE set. All sets were tested for an enrichment of 
† Described statistical tests were recommended by statistician David Conti and implemented by Alexey 
Larionov using variant sets filtered comparably to those previously described. 
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GO terms consisting of aggregated loss of function variants with an allele frequency of less than 0.05 
in the European 1000 genomes cohort. A script was later developed comparing the case set of interest 
to an in-house sequenced control set of mixed cancer types. This script checks that the case set is not 
included in the in-house set (as this consists of all samples sequenced within the local sequencing 
facility) and recalculates allele counts and frequencies of the control set if necessary (excluding variants 
within case individuals) before performing the same enrichment analysis for GO terms. 
Directed acyclic graphs of significantly disease associated GO terms were drawn using the European 
Bioinformatics Institute web tool QuickGO (Binns et al., 2009). 
 WECARE gene prioritisation and targeted sequencing† 
Three types of statistical analysis were performed on the WECARE set to prioritise genes for further 
study; 1) a sequence kernel association test (SKAT) with burden based variant aggregation, 2) a SKAT 
with variance based variant aggregation, 3) a proportional odds logistic regression model. A set of 
filtered variants were input into burden and variance based SKATs (using R SKAT package), using a 
generalised linear regression model to test for an association between variants and risk of CBC. For this 
test, variants were aggregated into 8,649 gene based functional regions using burden SKAT, which 
assumes that all variants detected in one gene have the same direction of effect on the phenotype and 
so are all protective or all risk causing, and variance based SKAT which allows variants to have opposite 
directions of effect. Although burden based SKAT tests harbour more statistical power when all variants 
aggregated affect the phenotype in the same direction with a similar order of magnitude, this power is 
dramatically decreased when aggregated variants have opposing effects on phenotype (e.g. some 
variants increase risk while others are protective) (Lee et al., 2012). In comparison, the variance based 
method tests and aggregates individual variant effects and weights, allowing for the detection of rare 
genes which harbour both protective and risk causing variants which would otherwise remain 
undetected and may be important influencers of CBC predisposition (Lee et al., 2012). Covariates 
included in this analysis include age at diagnosis, number of pregnancies and the top two calculated 
eigenvectors. 
A proportional odds logistic regression (using R MASS package) was performed to test for an 
association between aggregated genes (using burden based SKAT) and CBC in comparison to both 
UBC and unaffected NFE samples. For all tests, genes were ranked by p value. Genes with a p value of 
less than 0.05 in one of the three tests were selected for further analysis. Genes with a p value of less 
than 0.05 in two out of the three tests were automatically selected for targeted sequencing in a greater 
cohort (neither the methods nor results of the additional targeted sequencing will be described within 
this thesis).  
† Described statistical tests were recommended by statistician David Conti and implemented by Alexey 
Larionov using variant sets filtered comparably to those previously described. 
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 Breast cancer predisposition gene interaction analysis 
Gene interaction analysis was performed to identify variants within genes that perform a similar 
function or interact with breast cancer predisposition genes. Twelve breast cancer predisposition genes 
were selected from a consensus paper by Easton et al (Easton et al., 2015) (BRCA1, BRCA2, TP53, 
PTEN, CDH1, STK11, NF1, PALB2, ATM, CHEK2, NBN, and RECQL). These risk genes, in addition 
to the prioritised WECARE genes, were input into the Cytoscape GeneMania plugin (Montojo et al., 
2010). A cluster of genes that either directly or indirectly interacted with the twelve risk genes, either 
by physical interaction or pathway interaction, was selected.
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The filtered variants within the identified directly interacting candidate genes were explored manually 
to identify any potential link to disease predisposition. In particular, the frequency of variants in the 
candidate genes were assessed in the ExAC non-TCGA control cohort. This method was based upon 
the assumption that genes with a low variability in a healthy population are more likely to be disease 
causing when mutated. 
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6.5 Results 
 Germline whole exome sequencing and variant filtering 
The VCF generation pipeline produced a set of 343,824 different variants across the 710 germline 
samples in the WECARE set, including 198 non-Finnish European (NFE) 1000 genomes samples. After 
genotype filtering as described, variants were filtered on call rate across the WECARE set only and the 
WECARE set including the NFE samples, retaining 298,610 different variants and 130,135 different 
variants respectively. Although the WECARE set specifically included individuals without BRCA1, 
BRCA2 or PALB2 variants, a number of protein-affecting variants in these genes were identified, and 
so 11 individuals carrying these variants were removed from analysis, additionally two samples that 
were identified as ethnic outliers after PCA were removed from the study. The variants were filtered 
for consequence and rarity in each set, retaining 18,683 different variants that were in WECARE 
samples and 11,362 different variants in the WECARE and NFE set. 
Raw sequencing data of the 63 Montreal individuals contained 131,895 different variants. Genotype 
and call rate filtering reduced this number to a set of 130,757 different variants which were further 
filtered on variant consequence and rarity to produce a set of 6,074 different variants. 
 Gene ontology enrichment analysis 
Within the WECARE study, the previously filtered set of 18,683 different variants in the WECARE 
only set were input into GO enrichment analysis. Variants were aggregated into 9,087 genes, which 
were compared to filtered 1000 genomes control variants. Within the 1000 genomes control set, 200,693 
different protein-affecting variants were filtered down to loss of function variants with a European allele 
frequency of less than 0.05. After filtering, 20,969 different variants were retained in the control set and 
aggregated into 9,823 genes. 
Variant counts were aggregated into 1,971 GO terms and were tested for an enrichment in cases vs 
controls using a Fisher’s exact test for each term. Tests on the WECARE set revealed no terms that 
were significantly enriched in cases in comparison to the control set. The most significant FDR 
corrected p value was 0.13 for the term “protein binding involved in protein folding” (GO:0044183). 
Variants within the Montreal breast cancer set were further filtered by the GO script to select 478 
different loss of function variants within 447 genes that were aggregated into 1,971 GO terms as before. 
Of the tested GO terms, 14 were significantly enriched (FDR corrected p < 0.01) for loss of function 
variants in the case set (table 6.1). Descriptors of these terms showed three were associated with cell 
adhesion, including ‘cell-cell junction assembly’ (GO:0007043), ‘catenin complex’ (GO:0016342), 
‘cell-cell adhesion mediated by cadherin’ (GO:0044331). 
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GO:0004197 cysteine-type endopeptidase activity molecular function 74 632 0 374 5.34E-15 1.1E-11 
GO:0071556 
integral component of lumenal side of endoplasmic 
reticulum membrane 
cellular component 44 265 24 741 2.05E-10 0.0000002 
GO:0003727 single-stranded RNA binding molecular function 31 150 37 856 8.45E-09 0.0000056 
GO:0032728 positive regulation of interferon-beta production biological process 28 141 40 865 1.51E-07 0.000074 
GO:0000287 magnesium ion binding molecular function 43 322 25 684 3.37E-07 0.00011 
GO:0034080 CENP-A containing nucleosome assembly biological process 12 22 56 984 2.86E-07 0.00011 
GO:0015485 cholesterol binding molecular function 26 142 42 864 2.24E-06 0.00063 
GO:0005882 intermediate filament cellular component 26 148 42 858 4.6E-06 0.0011 
GO:0036126 sperm flagellum cellular component 14 46 54 960 7.68E-06 0.0017 
GO:0007043 cell-cell junction assembly biological process 7 8 61 998 1.29E-05 0.0023 
GO:0016342 catenin complex cellular component 7 8 61 998 1.29E-05 0.0023 
GO:0003725 double-stranded RNA binding molecular function 20 102 48 904 2.17E-05 0.0036 
GO:0004601 peroxidase activity molecular function 24 144 44 862 2.93E-05 0.0044 
GO:0044331 cell-cell adhesion mediated by cadherin biological process 6 6 62 1000 3.54E-05 0.005 
Table 6.1: Gene ontology terms that were enriched for loss of function variants in the Montreal set in comparison to 1000 genomes controls (FDR corrected p 
value < 0.01) 
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The enriched GO terms could be split into three main namespaces (classes of GO terms), biological 
processes, cellular components, and molecular functions although some terms overlap multiple 
namespaces. Directed acyclic graphs were drawn for terms within the three namespaces. The four 
enriched biological processes were ‘positive regulation of interferon-beta production’ (GO:0032728), 
‘CENP-A containing nucleosome assembly’ (GO:0034080), ‘cell-cell junction assembly’ 
(GO:0007043), and ‘cell-cell adhesion mediated by cadherin’ (GO:0044331) (figure 6.1). Enriched 
cellular component terms included ‘catenin complex’ (GO:0016342), ‘integral component of lumenal 
side of endoplasmic reticulum membrane’ (GO:0071556), ‘intermediate filament’ (GO:0005882), and 
‘sperm flagellum’ (GO:0036126) (figure 6.2). Six enriched terms were labelled as molecular functions 
including ‘cysteine-type endopeptidase activity’ (GO:0004197), ‘single-stranded RNA binding’ 
(GO:0003727), ‘magnesium ion binding’ (GO:0000287), ‘cholesterol binding’ (GO:0015485), ‘double-
stranded RNA binding’ (GO:0003725), and ‘peroxidase activity’ (GO:0004601) (figure 6.3).  
The variants identified within these enriched terms were explored and it was discovered that two 
different variants appeared in a number of different Montreal samples and could be driving enrichment 
in their corresponding ontology terms. The two frameshift insertion variants in MIS18BP1 
(NM_018353.4: c.471_472insT, p.Leu158IlefsTer8, rs546807245) (figure 6.4) and MNS1 
(NM_018365.2: c.605delA, p.Lys202SerfsTer9, rs549395315) (figure 6.5) were checked in an in-house 
control set and were found to be carried by other germline non-breast cancer samples. Both variants 
were indels, which occasionally can be sequencing artefacts, often called in repetitive regions. 
Therefore, BAM files were manually checked for these variants in samples where the variant was called 
heterozygous, homozygous reference and missing after genotype filtering. With both variants, the 
presence of insertions and deletions at the base of interest, in addition to the presence of the variant in 
non-called samples and at repetitive regions suggested that these were sequencing artefacts. However, 
the MNS1 variant was present in 43% of reads in the sample in which it was called as heterozygous, in 
contrast to the other two samples where it was not called which had ~7% and ~6% of reads with a 
deletion. Although in the case of this sample, this variant may not have been a sequencing artefact, it is 
possible that variant calling is generating artefacts in this repetitive region. This emphasises the need to 
manually check BAM files for all candidate variants.  
To reduce the enrichment associated with sequencing artefacts, GO enrichment analysis was performed 
comparing to an in-house control set. Four GO terms were enriched both in comparison to the 1000 
genomes control set and the in-house control set. These molecular function terms were ‘cysteine-type 
endopeptidase activity’ (GO:0004197), ‘single-stranded RNA binding’ (GO:0003727), ‘magnesium ion 
binding’ (GO:0000287), ‘cholesterol binding’ (GO:0015485). The 14 different rare, loss of function 
variants identified in these terms are described in table 6.2.  
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Figure 6.1: Directed acyclic graph of gene ontology terms significantly enriched 
for loss of function variants in the Montreal set under the namespace of 
‘biological process’. Significantly enriched terms are shown in cream. 
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Figure 6.2: Directed acyclic graph of gene ontology terms significantly enriched 
for loss of function variants in the Montreal set under the namespace of ‘cellular 
component’. Significantly enriched terms are shown in cream. 
 




Figure 6.3: Directed acyclic graph of gene ontology terms significantly enriched for loss of function variants in the Montreal set under the namespace of 
‘molecular function’. Significantly enriched terms are shown in cream. 
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Figure 6.4: BAM file showing the frameshift insertion called in the Montreal set in gene MIS18BP1 (rs546807245) a) Sample 1 was called heterozygous for the 
variant, b) Sample 2 was called as homozygous for the reference allele c) Sample 3 was unable to call the variant or it was filtered out due to poor quality.  
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Figure 6.5: BAM file showing the frameshift deletion called in the Montreal set in gene MNS1 (rs549395315) a) Sample 1 was called as homozygous for the 
reference allele, b) Sample 2 was unable to call the variant or it was filtered out due to poor quality, c) Sample 3 was called heterozygous for the variant. 
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CHROM POS REF ALT SYMBOL Consequence Existing variation Montreal AC GO ID AF 1000 genomes AF 1000 genomes 
NFE 
19 1795984 G A ATP8B3 stop gained rs187576612 1 GO:0000287 0.000998 0.003 
11 104825726 C CTTTT CASP4 frameshift variant rs555193787 1 GO:0004197 0.001398 0.005 
2 202122956 T C CASP8 start lost rs3769824 6 GO:0004197 0.034545 0.0467 
13 100518634 C T CLYBL stop gained rs41281112 7 GO:0000287 0.021965 0.0268 
17 78396004 A G ENDOV splice acceptor 
variant rs41298712 10 
GO:0000287, 
GO:0003727 0.047125 0.0368 
2 163124596 C T IFIH1 splice donor 
variant rs35732034 1 GO:0003727 0.00619 0.0089 
2 163134090 C A IFIH1 stop gained NA 1 GO:0003727 0.001398 0.004 
2 163136505 C G IFIH1 splice donor 
variant rs35337543 5 GO:0003727 0.005591 0.0189 
1 62676247 GAACT G L1TD1 frameshift variant rs202029696 2 GO:0003727 0.005791 0.0179 
16 77759403 T A NUDT7 stop gained rs200408443 2 GO:0000287 0.000399 0.002 
1 64089432 G A PGM1 splice donor 
variant rs77043134 2 GO:0000287 0.003594 0.0139 
17 74383107 CG C SPHK1 frameshift variant rs549579958 2 GO:0000287 0.002995 0.0089 
18 51880889 G A STARD6 stop gained rs17292725 8 GO:0015485 0.014577 0.0328 
6 41010518 G A TSPO2 splice donor 
variant rs41273356 5 GO:0015485 0.008387 0.0278 
Table 6.2: Variants in the Montreal set that were in enriched gene ontology terms in the Montreal set in comparison to 1000 genomes controls and in-house 
controls (FDR corrected p value < 0.01) 
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The gene IFIH1 contains three different loss of function variants within the term ‘single-stranded RNA 
binding’ (GO:0003727), two splice donor variants (NM_022168.3: c.2807+1G>A, rs35732034 and 
NM_022168.3: c.1641+1G>C, rs35337543) and one stop gain (NM_022168.3: c.1879C>A, 
p.Glu627*). This term also contained a splice acceptor variant within the endonuclease gene ENDOV 
(NM_001164637.2: c.229-2A>G, rs41298712). This ENDOV variant was shared with the enriched 
‘magnesium ion binding’ (GO:0000287) term. This term contained the largest number of different loss 
of function variants, with stop gains in ATP8B3 (NM_001178002.2: c.1804C>T, p.Arg649*, 
rs187576612), CLYBL (NM_206808.3: c.775C>T, p.Arg259*, rs41281112), and NUDT7 
(NM_001105663.2: c.111T>A, p.Tyr37*, rs200408443), a splice donor variant in PGM1 
(NM_001172818.1: c.300+1G>A, rs77043134), and a frameshift deletion in SPHK1 (NM_182965.2: 
c.854delG, p.Arg285Leufs, rs549579958). The term ‘cysteine-type endopeptidase activity’ 
(GO:0004197), was enriched due to the presence of two different loss of function variants in caspase 
apoptotic genes. A frameshift deletion was seen in CASP4 (NM_001225.3: c.9_10insAAAA, 
p.Gly4Lysfs, rs555193787) and a start loss variant was identified in CASP8 (NM_001080125.1: 
c.2T>C, p.Met1Thr, rs3769824). The cholesterol binding term was also only enriched due to the 
presence of two different variants, a stop gain in STARD6 (NM_139171.1: c.55C>T, p.Arg19*, 
rs17292725) and a splice donor variant in TSPO2 (NM_001010873.2: c.-21+1G>A, rs41273356). 
The same GO enrichment analysis was performed on the small Ashkenazi Jewish population within the 
Montreal breast cancer set comparing to both the 1000 genomes and in-house control sets. Of the eight 
terms enriched in this set in comparison to the 1000 genomes controls, six were also significantly 
enriched in comparison to the in-house set. These six terms are ‘cholesterol binding’ (GO:0015485), 
‘integral component of lumenal side of endoplasmic reticulum membrane’ (GO:0071556), ‘DNA 
recombination’ (GO:0006310), ‘base-excision repair’ (GO:0006284), ‘peroxidase activity’ 
(GO:0004601), and ‘metalloaminopeptidase activity’ (GO:0070006). Combined variant counts within 
the base-excision repair term were particularly low in control sets, with counts of 41 in 1000 genomes 
and 1 in the in-house set, in comparison to an allele count of 6 in the Ashkenazi Jewish set. Within these 
enriched terms, peroxidase activity related gene EPX and DNA recombination gene RAD52 both 
contain two different rare loss of function variants. 
 WECARE gene prioritisation and breast cancer predisposition gene interaction 
analysis 
Within the WECARE set, 216 genes were prioritised for targeted sequencing in a larger cohort using 
burden and variance based SKAT association testing and a proportional odds logistic regression. The 
proportional odds logistic regression test identified 94 genes that passed a significance threshold with a 
p value of less than 0.05 for a greater enrichment of variants in CBC individuals than UBC and NFE 
controls consecutively. The burden and variance based SKAT tests highlighted 92 genes each that were 
significantly enriched for variants within CBC individuals in comparison to UBC individuals. A set of 
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54 genes were shown to be associated with CBC by more than one of the three tests, and so were 
selected for further exploration via targeted sequencing. 
The 216 prioritised genes were explored for an interaction with known breast cancer predisposition 
genes (BRCA1, BRCA2, TP53, PTEN, CDH1, STK11, NF1, PALB2, ATM, CHEK2, NBN, and RECQL) 
using the Cytoscape GeneMania plugin (Montojo et al., 2010). Of these genes, 77 interacted either 
physically or via a related pathway with the input known breast cancer predisposition genes (figure 6.6). 
Two of the known breast cancer predisposition genes were within the prioritised gene list. The 
Neurofibromatosis Type 1 gene NF1 was one of eight genes with a p value of less than 0.05 for an 
enrichment of variants within CBC individuals via all three statistical tests. It carried one loss of 
function and two different predicted deleterious or damaging missense variants within the WECARE 
samples. DNA damage checkpoint gene CHEK2 was associated with breast cancer by burden based 
SKAT and proportional odds logistic regression. 
Of the other prioritised genes that interacted with known breast cancer predisposition genes, those that 
directly interacted with BC genes were further explored. Excision repair gene ERCC6 was shown to 
physically interact with both CHEK2 and TP53. ERCC6 was significantly enriched for variants in CBC 
individuals by burden based SKAT. One loss of function and four different deleterious and damaging 
missense variants were identified in this gene in the WECARE set. Further analysis of ExAC non-
TCGA control set revealed that ERCC6 is not commonly mutated in a healthy population, with only 47 
occurrences of loss of function variants identified in non-Finnish Europeans from this cohort. In 
contrast, BRD7 interacted with both BRCA1 and TP53, however only carried one missense variant in 
the WECARE cohort and so was not considered a strong candidate. 
Candidate gene FOXM1 was shown to have a pathway interaction with CHEK2. This gene was 
highlighted as significantly enriched for variants in CBC individuals by proportional odds logistic 
regression and Burden based SKAT. FOXM1 carried one loss of function variant and five different 
deleterious and damaging missense variants in the WECARE population. Only 18 occurrences of loss 
of function variants in this gene were identified in the NFE ExAC non-TCGA control set. 
Another interesting candidate identified was the solute carrier gene SLC9A3R1. Identified as enriched 
for variants within CBC individuals by burden based SKAT, this gene shared a pathway interaction 
with TP53. One loss of function and four different deleterious and damaging missense variants were 
identified in this gene in the WECARE set, whereas only 34 loss of function variants were identified in 
the NFE ExAC non-TCGA control set. A literature search of this gene indicated that it may stimulate 
autophagy in breast cancer cells, and somatic variants have been seen in 25.8% of ovarian cancers 
within one study (Kreimann et al., 2015; Liu et al., 2015). 
Another candidate gene, STK11IP, codes for an STK11 interacting protein and therefore was identified 
as having both a physical and pathway interaction with risk gene STK11. The gene had an enrichment 
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of variants in CBC individuals by burden based SKAT. This gene has a large number of loss of function 
variants in non-Finnish European ExAC non-TCGA set. However, of those 52,384 loss of function 
occurrences, only 83 are rare with an AF of less than 0.01, suggesting that this high number may be 
driven by a smaller number of common variants. This gene has one loss of function variant and three 
different deleterious and damaging missense variants in the WECARE set. 
Variants within the candidate genes NF1, CHEK2, ERCC6, FOXM1, SLC9A3R1, and STK11IP can be 
seen in table 6.3. No variants were identified in the WECARE set in the Montreal GO based candidate 
genes. When the above WECARE candidate genes were queried in the Montreal set three variants were 
identified. A stop gain was found in STK11IP (NM_052902.3: c.718C>T, p.Arg240*, rs201204373) in 
two unrelated Ashkenazi Jewish individuals; this variant was not seen in the 1000 genomes control set. 
A missense variant was seen in one Ashkenazi Jewish individual in ERCC6 (NM_000124.2: 
c.1996C>T, p.Arg666Cys, rs61760163), and a pathogenic (by ClinSig) frameshift deletion was 









Figure 6.6: Cytoscape GeneMania interaction cluster of the 77 candidate genes (orange nodes) that 
interact physically (red line) or via a pathway interaction (blue line) with known cancer genes (blue 
nodes). Known cancer genes NF1, ATM and CHEK2 were also candidate genes (half blue, half 
orange)   
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2 220462640 G T STK11IP start lost rs681747 NA 30 12 19 
2 220470710 G A STK11IP missense variant rs149218768 NA 3 1 0 
2 220473373 T C STK11IP missense variant rs765799088 NA 1 0 0 
2 220473374 T G STK11IP missense variant rs753147630 NA 1 0 0 
10 50678356 A C ERCC6 missense variant rs61760166 NA 2 0 2 
10 50681659 T G ERCC6 intron variant rs4253196 pathogenic 1 0 0 
10 50682279 C T ERCC6 missense variant rs751703364 NA 1 0 0 
10 50690906 G A ERCC6 missense variant rs61760163 pathogenic 1 0 2 
10 50701164 T A ERCC6 missense variant rs200832611 NA 1 0 0 
10 50713929 C A ERCC6 splice donor variant rs371739894 pathogenic 1 1 0 
12 2968078 G A FOXM1 missense variant rs28919870 NA 9 3 5 
12 2968523 G A FOXM1 missense variant rs151053319 NA 1 0 0 
12 2970472 CAAAG C FOXM1 frameshift variant rs773729390 NA 2 0 0 
12 2973547 G T FOXM1 missense variant rs28990715 NA 12 9 9 
12 2973861 G T FOXM1 missense variant rs552495230 NA 1 0 0 
17 29497015 G A NF1 missense variant rs876659079 uncertain significance 1 0 0 
17 29684326 C T NF1 stop gained rs786201367 pathogenic 1 0 0 
17 29687560 T C NF1 missense variant rs752541243 uncertain significance 1 0 0 
17 72758167 G A SLC9A3R1 missense variant rs41282065 pathogenic 3 1 0 
17 72758211 C A SLC9A3R1 missense variant rs373243340 NA 1 0 0 
17 72758239 A G SLC9A3R1 missense variant NA NA 1 0 0 
17 72758301 C T SLC9A3R1 missense variant NA NA 1 0 0 
17 72764377 T C SLC9A3R1 splice donor variant rs138547261 NA 1 0 0 
22 29091226 TA T CHEK2 frameshift variant rs587780174 pathogenic 1 0 0 
22 29091856 AG A CHEK2 frameshift variant rs555607708 pathogenic 4 3 0 
22 29092947 C T CHEK2 missense variant rs730881688 uncertain significance 1 0 0 
22 29095854 T C CHEK2 missense variant rs587780194 uncertain significance 1 0 0 
22 29107962 A G CHEK2 missense variant rs141776984 uncertain significance 0 1 0 
22 29121018 C T CHEK2 missense variant rs137853009 pathogenic 1 0 1 
22 29121087 A G CHEK2 missense variant rs17879961 pathogenic 3 0 0 
22 29121242 G A CHEK2 missense variant rs137853007 pathogenic 2 0 0 
22 29121326 T C CHEK2 missense variant rs28909982 likely pathogenic 0 1 0 
22 29130520 C T CHEK2 missense variant rs141568342 likely pathogenic 1 0 0 
22 29130540 G A CHEK2 missense variant rs730881695 uncertain significance 1 0 0 
 
Table 6.3: Variants identified in candidate genes in the WECARE set, including allele counts in 
contralateral breast cancer (CBC), unilateral breast cancer (UBC) and non-Finnish European Female 
controls (NFE) 
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6.6 Discussion 
The Montreal and WECARE breast cancer sets both utilise the collection of participants who are at 
greater risk of hereditary breast cancer. Within the Montreal set, this is via the selection of individuals 
with a strong family history of breast cancer and those from the homogenous Ashkenazi Jewish 
population. The potential to identify founder variants within this set gives an advantage in identifying 
rare variants that might not be seen in significant numbers in a more heterogenous population. The 
selection of individuals with multiple primary tumours within the WECARE set, and comparison to 
those with single breast cancers also enriches the case population for a potential hereditary risk of breast 
cancer (Cybulski, Nazarali and Narod, 2014). Importantly, care was taken to ensure that the CBC 
individuals were asynchronous, and so the second tumour was likely to be a primary and not a result of 
metastasis. 
The Montreal set was around a tenth the size of the WECARE set and therefore required a more tailored 
approach to identify candidate variants. The use of GO enrichment analysis was developed to aggregate 
variant counts across the set and test for an enrichment of variants in each tested term. In smaller sets 
where the identification of rare variants in more than one individual is unlikely, aggregation of variants 
into genes increases the likelihood of an association being identified. Aggregation of variants into 
ontology terms further increases this likelihood. This technique draws functional links between variants 
that may indicate a shared molecular pathway or biological process and therefore potentially may 
produce a shared phenotype. 
A number of GO terms were identified as enriched with variants in the Montreal set in comparison to 
both 1000 genomes control set and an in-house generated set. Using the 1000 genomes as a control set 
allows for the selection of terms that are significantly enriched in breast cancer cases in comparison to 
healthy individuals. However, using external datasets for association testing is likely generate false 
positive results due to technical and ethnic differences. Within the WECARE set analysis, an ethnically 
comparable subset of 1000 genomes data were downloaded and analysed to reduce technical and ethnic 
differences. Within the GO analysis, to minimise the effect of ethnic differences tests were only run on 
the European subset of 1000 genomes. Although technical differences can be reduced slightly by 
performing comparable genotype filters to remove low quality genotypes, filtering differences upstream 
of this, in addition to other technical differences, may still cause confounding results. By comparing to 
an in-house set, enriched ontology terms in cases in comparison to other (non-breast) cancer controls 
can be selected where both sets have been analysed using almost identical sequencing conditions. 
However, these controls are not healthy individuals, and as many breast cancer genes are also linked to 
other cancers, these cannot be treated as pure controls and so cannot be used as the sole comparator. 
However, as they were sequenced at the same facility, and ran through the same VCF generation 
pipeline and filtering, there will be fewer technical differences. Therefore, where terms are enriched for 
 
153 | P a g e  
 
variants in comparison to both control sets, the statistical significance is unlikely to be due to technical 
differences alone. 
Four molecular functions were found to be enriched for loss of function variants in the Montreal set in 
comparison to 1000 genomes individuals and in-house controls. The term cholesterol binding was also 
associated with the Ashkenazi Jewish set when tested independently. However, this set was only 
comprised of two different variants, both with high allele counts. Although these variants passed rarity 
filters set using 1000 genomes Europeans, they were each present in ~3% of ExAC non-TCGA NFE 
controls and so are relatively common in a second healthy population. 
In contrast, the terms ‘single-stranded RNA binding’ (GO:0003727) and ‘magnesium ion binding’ 
(GO:0000287) contained five and six different variants respectively. Single stranded RNA binding has 
previously been associated with breast cancer survival, with mRNA transporter RBM47 being identified 
as a suppressor of breast cancer progression (Upadhyay et al., 2013; Vanharanta et al., 2014). However 
within this set, variants are predominantly in the interferon induced gene IFIH1, variants within which 
are predominantly associated with encephalopathy in Aicardi-Goutières syndrome (Oda et al., 2014). 
Of the six genes with variants in the ‘magnesium ion binding’ (GO:0000287) term, the majority have 
no previous association with breast cancer. However sphingosine phosphorylation gene SPHK1 has 
been shown to be upregulated in breast cancer, with high expression correlating with poor survival and 
treatment response (Datta et al., 2014; Zhang et al., 2014; Maczis, Milstien and Spiegel, 2016). The 
variant identified in this cohort is a loss of function frameshift deletion of one base pair and so is unlikely 
to cause an overexpression or be linked to the described phenotype in this case. 
The majority of breast cancer predisposition genes currently identified function in DNA repair 
checkpoints and homologous recombination. It is therefore reasonable to hypothesise that variants in 
DNA repair related GO terms might also be strong candidates for a novel association with breast cancer 
risk. Genes that interact with the DNA repair pathway but are not currently known to be DNA repair 
genes would also be strong candidates but would be missed by this GO enrichment analysis. As the 
participants included in this study previously tested negative for known breast cancer genes, it is 
unsurprising that DNA repair terms were not identified as enriched via this analysis. The identified 
candidate SLC9A3R1, is not involved in DNA repair via known mechanisms. However, tools such as 
GeneMania can be used to identify genes that could interact with this pathway, such as SLC9A3R1 
which physically interacts with TP53. This solute carrier gene has been shown to stimulate autophagy 
via the stabilization of BECN1 in breast cancer cells (Liu et al., 2015). Defects in the autophagy process 
have been shown to associated with increased tumorigenesis, and a somatic loss of BECN1 has been 
seen in breast, ovarian, and prostate cancers (Aita et al., 1999; Liang et al., 1999). 
The transcription factor Forkhead Box M1 (encoded by FOXM1), was first associated with human 
cancer by Teh et al, who discovered upregulation of the gene in basal cell carcinoma (Teh et al., 2002). 
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It has since been shown that high expression of this gene is an early progressor of tumour cells, 
providing genomic instability and allowing the accumulation of further DNA damage (Gemenetzidis et 
al., 2010; Jia et al., 2010; Teh et al., 2010). The missense variants identified in the WECARE set in 
FOXM1 could affect gene regulation, however the frameshift deletion in this gene is unlikely to be 
linked to an upregulation in cancer cells. 
Germline variants in serine-threonine protein kinase 11 gene (STK11) were identified as the cause of 
Peutz-Jeghers syndrome in 1998 (Hemminki et al., 1998). Affected individuals often have multiple 
hamartomatous polyps but also carry a greater risk of breast, colorectal, small bowel, pancreatic, gastric, 
and ovarian cancer (Volikos et al., 2006). Currently there is limited research into the STK11 interacting 
protein STK11IP, however within this study it has been suggested as a new breast cancer candidate 
gene in two independently collected datasets. Within the WECARE set multiple missense variants as 
well as a start-loss variant were seen in a number of individuals. Additionally, a rare stop- gain variant 
(NM_052902.3: c.718C>T, p.Arg240*,, rs201204373) was identified in two unrelated Ashkenazi 
Jewish individuals within the Montreal set. This rare variant could represent a founder variant in the 
homogenous population and so may have not been previously identifiable in heterogenous population 
studies. 
6.7 Summary 
This study explores predisposition to breast cancer through the analysis of different datasets that utilise 
homogenous and high-risk patient populations. Variant aggregation into genes and ontology terms was 
used in both sets to provide greater statistical power to association tests. Variants involved in single-
stranded RNA binding and magnesium ion binding have been recommended as potential candidates for 
further exploration in larger sets. A number of candidate genes from the WECARE study have been put 
forward for further study. In particular, STK11IP, was identified in both breast cancer sets. The presence 
of multiple occurrences of a truncating variant within this gene in an Ashkenazi Jewish population could 
be indicative of a founder variant. These studies provide techniques for analysing underpowered 
sequencing data. In particular they emphasise the need to cross reference results between related 
datasets. This provides the opportunity to test candidates under different sample selection criteria and 
often different sequencing and analysis environments. Identifying candidates within two different 
datasets provides a more robust argument for that candidate gene’s involvement in disease 
predisposition. 
 
155 | P a g e  
 
7 Discussion 
The primary focus of this work has been to identify genes that when altered predispose to various cancer 
types, looking specifically at early onset and high-risk cases without known genetic risk factors. In 
studies of common cancers and diseases, larger datasets are easier to obtain, providing increased 
statistical power when looking for risk factors. However gathering large sample sets of rare disease 
affected individuals can prove far more difficult and often statistical tests on the resulting smaller sets 
are underpowered to detect rare variants (Hoffmann, Marini and Witte, 2010). By sequencing multiple 
individuals from families with a strong cancer history and individuals from homogenous populations, 
the frequency of rare variants is increased in comparison to an unrelated population. Therefore, in such 
sets the likelihood of identifying rare candidate variants for rare cancer syndromes is increased. Where 
such groups are not available, selecting individuals with an early age of onset or those with multiple 
primary cancers increases the likelihood that the disease is caused by hereditary genetic factors. 
Careful study design and sample selection has enabled the production of datasets within this study that 
are enriched for genetic risk factors. Sequencing data from multiple affected and unaffected family 
members and subsequent segregation analysis can show whether the identified genotype segregates 
with the phenotype. This has been particularly important where a literature review of candidate genes 
reveals no clear association between the affected pathway and the phenotype such as MYH9 variants in 
MALTA syndrome. As pathogenic variants in MYH9 are already linked to a well described blood 
disorder (Althaus and Greinacher, 2009), it originally appeared unlikely that protein-affecting variants 
in this gene would also prove causal to a distinct skin tumour. However further segregation analysis in 
a number of additional families provided clear evidence that MYH9 was a strong candidate gene. 
The study of sequencing data from a homogenous population of Ashkenazi Jewish heritage allowed for 
the identification of a rare, potential founder variant in more than one unrelated individual that may 
increase breast cancer risk. The gene STK11IP, an interacting partner of Peutz-Jeghers syndrome gene 
STK11, was identified as a potential candidate for CBC predisposition in the WECARE breast cancer 
cohort, prior to the identification of additional variants in the Montreal breast cancer set. The differences 
in the two cohorts, both in terms of study design and ethnicity, meant that they required separate 
analysis. Variant aggregation into genes and statistical prioritisation could be applied to the larger 
WECARE set to select candidate genes for further targeted sequencing. Whereas the smaller Montreal 
set benefited from a GO enrichment analysis, further aggregating variants into terms to increase 
statistical power, which led to the identification of two different rare, loss of function variants in DNA 
recombination and repair related gene RAD52 in the Ashkenazi Jewish cohort.  
This study has also benefited from detailed clinical and tumour histology data. Within the ACC set, the 
histological subtype of the tumours was reviewed by an expert pathologist (Dr Alison Marker) and 
tumour information was provided including size and weight, stage at diagnosis and mismatch repair 
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patterns. Such detailed information is not always readily available when using external datasets. 
However cohort publications on TCGA subsets often provide in depth clinical, tumour, and ethnicity 
information, allowing for subtype specific analysis comparable to work completed on in-house data 
(Bass et al., 2014; Zheng et al., 2016). This makes TCGA data a useful resource for integration into 
local analysis to explore candidate variants or increase sample numbers. 
Even with an increase in sample numbers provided by the integration of external data, a rare disease 
dataset often remains statistically underpowered to detect rare genetic variants (Hoffmann, Marini and 
Witte, 2010). Calculations can be made to estimate the power of a given statistical test, which can then 
be used to predict the sample size required to reach the desired statistical power (Sham and Purcell, 
2014; Wang et al., 2014). However, as previously stated, the recruitment of these rare disease affected 
individuals is the limiting factor in the study design process. To partially overcome the difficulties of 
low statistical power, the analyses described here have made extensive use of variant aggregation into 
genes and functionally related gene groups. Tools such as the GeneMania Cytoscape plugin provide 
information about protein interactions by implementing the GeneMania algorithm (Mostafavi et al., 
2008). The tool uses interaction data from a number of sources including BIOGRID (Chatr-Aryamontri 
et al., 2015), GEO (Barrett et al., 2009), I2D (Brown and Jurisica, 2005) and Pathway Commons 
(http://www.pathwaycommons.org). Protein networks are drawn via co-expression, co-localization, 
genetic interactions, physical interactions, pathway interactions, predicted interactions, and shared 
protein domains. The usage of a variety of heterogenous data by GeneMania provides interactions that 
might be missed in a literature search or using pathway data such as the Kyoto encyclopedia of genes 
and genomes (KEGG) (https://www.kegg.jp/). 
One of the limitations of GeneMania is that it provides no information as to the function of the clustered 
genes. For example, PALB2 and BRCA2 may be described by the tool as physically interacting, however 
users must draw their own conclusions about the involvement of both genes in DNA repair. Within this 
study, GO terms were applied to identified GeneMania interaction clusters, providing a description of 
the biological process within which those genes may be interacting. Within this thesis, the method of 
testing for an enrichment of variants within a biological process was first used in the HDGC set, 
supporting results in the literature describing a number of HDGC cases with DNA repair variants 
(Hansford et al., 2015; Sahasrabudhe et al., 2017; Slavin et al., 2017). The use of GO terms in addition 
to GeneMania allowed for the study and identification of variants in potential candidate genes 
associated with the DNA repair ontology term or interacting with known DNA repair genes. 
GO enrichment analysis is a well-used form of variant aggregation and has been described in multiple 
studies including identifying functionally related differentially expressed gene clusters, identifying gene 
sets that are haploinsufficient, and identifying processes that are often targeted by somatic variants in 
neuroblastomas (Wang et al., 2006; Dang et al., 2008; Sanders et al., 2013). Other sets within this study 
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used GO terms independently of GeneMania clustering. This analysis was utilised in the breast cancer 
cohort due to the larger sample sizes and therefore larger numbers of variant carrying genes in 
comparison to other datasets within this study. Larger networks of genes intuitively had greater numbers 
of interactions within GeneMania and so did not generate functionally informative clusters. Where 
clusters could not be drawn, all filtered GO terms were tested for an enrichment of loss of function 
variants. Although this did not have the benefit of analysing genes highlighted as interacting by multiple 
sources, it still provided informative results about biological processes enriched for rare, loss of function 
variants in case sets.  
Analysis of both the ACC and HDGC cohorts resulted in the identification of loss of function and likely 
disease predisposing variants in DNA repair related candidate genes. Within HDGC, breast cancer gene 
PALB2 and Lynch syndrome gene MSH2 were identified with rare loss of function variants. Tumour 
immunohistochemistry also revealed a somatic loss of Lynch syndrome proteins MSH2 and MSH6 
within two ACC tumours from different individuals, with one individual also carrying a germline loss 
of function MSH6 variant. No clear difference was seen in the predicted loss of function consequences 
of PALB2, MSH2, and MSH6 variants identified in these cohorts in comparison to those pathogenic 
variants seen in the more common PALB2 and Lynch syndrome phenotypes of breast and colorectal 
cancer respectively, nor was there any obvious genotype-phenotype correlation within the limited 
number of pathogenic variants identified. The HDGC family carrying a loss of function PALB2 variant 
also had a history of breast cancer on both maternal and paternal sides, in addition to gastric cancer, 
lung cancer, and laryngeal cancer on the paternal side. Despite this range of cancer phenotypes, three 
of the six siblings in the tested generation were diagnosed with diffuse gastric cancer before the age of 
60, suggesting an increased risk for this specific phenotype within this generation. With no sequencing 
data available from the previous familial generation, one can only speculate that the other identified 
cancers could be influenced by environmental factors, combinations of different genetic factors, or be 
simply due to chance. It is possible that pathogenic variants in DNA repair genes such as PALB2 may 
act as general low-level cancer predisposing genes beyond their role as higher penetrance genes in 
certain cancer types. This concept was reinforced by a recent study of TCGA data showing pathogenic 
BRCA1 and BRCA2 variants in 25 different cancer types (Huang et al., 2018). 
This Huang et al pan-cancer study also identified rare CNVs in cancer genes BRCA1, FH, MSH6, NF1, 
PALB2, and PTEN (Huang et al., 2018). The exome hidden Markov model (XHMM) used to identify 
these CNVs was similarly used in analyses described within this thesis. CNV analysis was undertaken 
in families with a very strong history of early onset disease but no identifiable pathogenic germline 
variants, however no clinically relevant alterations were discovered. Within exome data, CNV detection 
relies on depth of coverage over the covered exons in comparison to breakpoint focused analysis such 
as BreakDancer (Chen et al., 2009), which can be used to detect structural variant breakpoints across 
genomic data. In addition to using the XHMM algorithm on WES data, Huang et al identified half of 
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the reported variants using genotyping SNP-array data. Of the more than 95,000 CNVs detected, less 
than 4,000 were consistent across the two study types, largely due to the genotyping data covering 
intronic regions (Huang et al., 2018). A combinatory approach to identifying CNVs using different data 
sources from the same sample improves the likelihood that variants called are not a result of variation 
in amplification efficiency and sequencing depth. The XHMM algorithm normalises read depth data 
across samples to account for poorly covered regions across the sequencing library (Fromer and Purcell, 
2014). However, within this study, a number of identified CNVs called using this algorithm could not 
be validated. To improve identification of CNVs and other structural variants, a number of studies, 
including research into structural variants in 1000 genomes phase 3 data, used low coverage WGS data 
to increase the range of detectable structural variants (Sudmant et al., 2015). This can be used in 
conjunction with more affordable WES data at a higher coverage to detect structural variants including 
deletions, insertions, duplications, and inversions, alongside single nucleotide variants and short 
insertions and deletions (Tattini, D’Aurizio and Magi, 2015). 
A number of other candidate genes have been identified by work presented in this thesis which have 
not previously been described as affecting predisposition to cancer or tumour development. One key 
example of this was the identification of protein-affecting variants in myosin gene MYH9 in MALTA 
syndrome. The literature currently describes no instances of this gene being involved in cell 
proliferation or the development of sweat ducts. Unlike many known cancer predisposition genes which 
affect cell proliferation in a number of different tissue types, the two phenotypes associated with MYH9 
pathogenic variants are distinct in terms of their cellular effects, with one influencing cell size and the 
other influencing proliferation. Functional work (described in more detail below) would be required to 
fully understand the many roles of this non-muscle myosin in different tissue types and how pathogenic 
variants in different regions can cause two distinct phenotypes. 
Where available, tumour studies were undertaken to provide additional insight into the role candidate 
variants could be playing in disease development. Within the set of MALTA families, only one tumour 
block was available where sufficient DNA could be extracted to perform additional somatic sequencing. 
This limited the ability to determine whether identified somatic variants were unique in this individual 
or common and relevant to the tumour type. Within the HDGC and ACC cohorts, MSI and IHC were 
used to determine if tumours were deficient in mismatch repair. Although such a deficiency could 
suggest the presence of a germline Lynch syndrome variant, this is not always the case, as was shown 
in one individual whose ACC tumour showed a loss of MSH2 and MSH6, but who carried no 
identifiable exonic germline mismatch repair variant (even after a manual search for variants of all 
consequence in mismatch repair genes). In the case of HDGC, IHC and MSI were critical in showing 
that the identified germline MSH2 loss of function variants were not causing a complete deficiency in 
mismatch repair. This tumour information can therefore be used both to ascertain whether a germline 
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variant is having the predicted effect on protein function, and to point to a possible means for disease 
predisposition. 
Both somatic variants and expression data can be used to identify pathways implicated in tumorigenesis. 
Where somatic data show passenger variants and driver variants which have been selected for by the 
tumour microenvironment, RNA sequencing data show the resulting gene expression patterns which 
can elucidate the role of both somatic and germline protein-affecting variants. Within the TCGA-ACC 
cohort, a change of expression of both PDE2A and PKIB suggest that the cAMP-PKA pathway is 
implicated in the development of the oncocytic ACC subtype. These expression changes could be 
caused by many different somatic or methylation events changing regulation of the cAMP-PKA 
pathway; however, it is the end result, the overactivation of this pathway, that is relevant to future 
research. Expression data can therefore in some senses be more informative than somatic data for 
detecting affected pathways and suggesting potential therapeutic targets. 
Although this study has provided insight into rare cancer and disease predisposition, the question of 
missing heritability remains. Particularly in the case of the ACC subset, young onset cases (including 
one described individual diagnosed as young as 18 years of age) are being identified with no obvious 
disease cause, either genetic or environmental. A study by Tomasetti and Vogelstein proposed that 
chance effect is underestimated in disease development, and that the majority of cancers are driven by 
random somatic variants occurring during DNA replication (Tomasetti and Vogelstein, 2015b). 
However this study was rather controversial, with some countering its assertion that such “bad luck” 
driven malignancies would be resistant to preventative methods and others taking issue with the 
statistical methods used (Altenberg, 2015; Ashford et al., 2015; Gotay, Dummer and Spinelli, 2015; 
O’Callaghan, 2015; Potter and Prentice, 2015; Song and Giovannucci, 2015; Tomasetti and Vogelstein, 
2015a; Wild et al., 2015). Others also noted that Tomasetti and Vogelstein did not allow for an 
interaction between extrinsic (such as UV damage) and intrinsic processes (such as DNA replication) 
during their analysis and that these extrinsic processes may cause the same process of damage 
accumulation via stem cell division (Wu et al., 2016).  
The “bad luck” theory may explain some of the missing heritability within this study, however there is 
also a possibility that risk variants were not identified due to limitations in current technology with 
incorrect predictions of variant pathogenicity resulting in the filtering out of pathogenic variants. 
Additionally, some cancer phenotypes could have been a result of the interaction of many different 
genetic factors. Some GWA studies have aimed to generate polygenic risk scores, with one study in 
breast cancer susceptibility describing SNPs that account for around 44% of familial relative risk 
(Michailidou et al., 2017). Although polygenic risk scores have provided informative classifiers for 
complex diseases such as prostate cancer (Szulkin et al., 2015), the statistical power required to define 
such scores is likely to be unachievable in many rare diseases. For such diseases, a similar polygenic 
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risk may be ascertainable by looking at smaller numbers of rare variants in highly conserved genes and 
exons. In particular it would be interesting to look at patterns of rare variant occurrence in pathway such 
as DNA damage repair across various cancer types. This could be further studied using large control 
sets to identify parts of the DNA repair pathways that are highly conserved, and to identify variant 
barcodes that are rare in healthy populations. 
In addition to creating a greater understanding of disease predisposition, this study aimed to create and 
describe new analysis methods for next generation sequencing data and tools for use by researchers 
interested in studying a range of genetic data. The use of control data is imperative when interpreting 
the results of germline sequencing data to determine how often variants appear in a healthy population. 
The majority of control datasets have an online portal to allow researchers to query variation in genes 
and variants of interest. The 1000 genomes data do not have a specific browser but some data including 
variant population frequencies are accessible online through Ensembl (http://www.ensembl.org) (Auton 
et al., 2015). The genome Aggregation Database (gnomAD) and the Exome Aggregation Consortium 
(ExAC), which combine sequencing data from a number of sources including TCGA, 1000 genomes, 
and Myocardial Infarction Genetics Consortium, have web portals which provide summary data for 
genes (including coverage metrics, CNV counts, and lists of identified variants) and variants of interest 
(showing population frequencies and IGV snapshots of the reads containing the variant in BAM files) 
(Lek et al., 2016).  
Although the ExAC/gnomAD browser format is extremely user friendly and informative, it does not 
provide users an opportunity to select or filter by data source and therefore remove data that is linked 
to the researcher’s phenotype of interest; for example, within this study, data from TCGA were 
excluded. ExAC however does provide users an opportunity to download a VCF excluding variants 
from key psychiatric studies and from TCGA. As part of the analysis done in this thesis, a browser was 
created for ExAC non-TCGA data and 1000 genomes release 1 data to allow users to interrogate these 
VCFs in a user-friendly web app. This improves the reproducibility of this study as all results taken 
from the ExAC non-TCGA and 1000 genomes resources are publicly available from a web address 
(https://medgenbrowser.wordpress.com/). It also provides a useful resource for cancer-focussed genetic 
researchers who may not have the required bioinformatics skills to download, filter, and query a raw 
VCF file. At the time of writing, since the web address was published in March 2018, collectively the 
browsers have been used over 100 times by over 40 different users, suggesting that this is a resource 
that is of use to the wider genetics community. 
The results of this study, including tools and data created, have been or will be shared with the genetic 
community through open-access publications, collaborations, and GitHub repositories. Novel next 
generation sequencing datasets are a valuable resource for further studies to build upon. Many studies 
now combine sequencing data from multiple sources to provide larger datasets for greater powered 
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statistical analysis (Rinella et al., 2013; Hansford et al., 2015). The work presented here has generated 
one of the largest completed sequencing studies of the oncocytic ACC subtype. Making data available 
for future studies drastically changes the scope of rare disease research, from what were once individual 
case studies to larger combined cohorts of published data. Additionally, the creation and sharing of 
tools and analysis techniques allows genetics research to be more accessible for the wider community 
and improves the reproducibility and validity of generated research.  
8 Future directions 
Work presented in this thesis could be expanded upon to provide a greater understanding of how 
identified candidate variants are influencing disease predisposition. The studies described here used 
small sample sizes and limited tumour sequencing data. For further genetic and functional analysis of 
variants identified in this study, both sample sizes and tumour analysis could be expanded where 
possible. In some cases, further work would involve an accumulation of available external data or the 
recruitment of additional samples. In sets where strong candidate genes have been suggested, functional 
work would help to understand how these variants are producing or affecting the identified phenotype. 
8.1 Hereditary diffuse gastric cancer 
Due to the established availability of preventative surgery for HDGC, the field would greatly benefit 
from a further understanding of disease predisposition. The identification of loss of function variants in 
PALB2 within this study and external studies suggests that loss of function variants in this gene play a 
greater role in HDGC predisposition than previously thought. Data from this study has since been 
pooled with data from collaborators to create a larger HDGC WES study. This combined study may 
have the statistical power to quantify the lifetime risk of HDGC development in individuals with loss 
of function PALB2 variants. 
An interesting family identified within this study carried germline, loss of function variants in both ATR 
and NBN. Two of the siblings in this family had prophylactic gastrectomies and no tumour was available 
from the affected third sibling or either of the affected parents. Future plans for this work include the 
microdissection of single signet ring cells from tissue collected from the risk-reducing gastrectomies 
performed in two members of this family. If enough cells can be gathered for DNA extraction, Sanger 
sequencing can be performed to look for loss of heterozygosity in the two identified predisposition 
variants. Additionally, depending on the amount of DNA extracted from these cells, somatic WES could 
be used to look for signatures of DNA damage repair deficiency. It would be particularly interesting to 
see if loss of heterozygosity or patterns of somatic variants could be attributed to one of the variants in 
ATR and NBN, or to both of them. 
8.2 MALTA syndrome 
Despite extensive efforts, this study has been unable to clearly elucidate the dual role of non-muscle 
myosin gene MYH9 in MALTA and MYH9-related platelet disorder (MRPD). To fully understand how 
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the two germline variant sets produce these two phenotypes, one would need to study how these variants 
differentially affect non-muscle myosin function. Work could be completed initially using cell lines, 
introducing variants implicated in either MALTA or MRPD to observe the differences in cell growth, 
migration, and proliferation rates. One could also mirror previous work by Hu et al (Hu, Wang and 
Sellers, 2002) who studied the kinetic effects of MRPD variants on myosin motor activity. By 
performing a comparable study using MALTA variants one could compare the ATPase activity and 
motility rate of non-muscle myosin IIA when affected with variants causing each phenotype. 
In silico options for further study on this set include further studying the previously reported post-
transcriptional modifications on MYH9. This idea was originally considered to explain how germline 
variants that appear to disrupt a key motor function do not affect many more tissues throughout the 
body, leading to the suggestion that interrupting a specific post-transcriptional modification pattern may 
affect one tissue type or one specific cellular role. Although the post-transcriptional modification sites 
surrounding these variants have been briefly explored, a full study into this would require the analysis 
of all reported variants in both MALTA and MRPD. 
8.3 Adrenocortical Carcinoma 
The rarity of ACC, specifically the oncocytic subtype, limited the analysis performed on this set to only 
a handful of samples. In spite of this, a number of predisposition genes were recommended for further 
study. One of the future steps on this project will involve the WES of FFPE material from a number of 
samples including two additional oncocytic samples, generating the largest WES cohort of oncocytic 
ACC generated so far. This study aims to further elucidate the role of mismatch repair and the cAMP-
PKA pathway in tumour development of oncocytic ACC and to identify any distinguishing features of 
this rare subtype that may help in diagnosis or treatment. Additionally, this somatic sequencing will be 
analysed to look for loss of heterozygosity (LoH) of candidate variants suggested in the germline data 
presented here. If any candidates present with LoH, the gene containing these variants could be explored 
within other studies such as the tumour and normal sequencing data available from oncocytic ACC 
samples within the TCGA cohort. This could provide further evidence for a role for these candidates in 
oncocytic ACC predisposition. 
8.4 Breast cancer predisposition 
For the WECARE study of contralateral breast cancer predisposition, candidate genes were proposed 
for further targeted sequencing in a larger cohort. This included STK11IP which was identified with a 
potential founder variant in the Montreal Ashkenazi Jewish set. An Ampliseq panel of primers covering 
the coding sequences of candidate genes was designed and sequenced in a further set of germline DNA 
samples from around 500 additional women from the WECARE study with either CBC or UBC. This 
should provide greater statistical evidence to explain the role of candidate genes in disease 
predisposition.  
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9 Summary 
This work has improved the knowledge of rare disease predisposition to enable more accurate disease 
management strategies. As well as identifying a greater role than previously thought for PALB2 in 
HDGC predisposition, the combinatory effect of multiple cancer predisposition variants was explored, 
further adding to the suggestion that cancers should no longer be considered monogenic diseases. The 
new syndrome MALTA was delineated through the identification of rare variants in myosin gene MYH9 
in all identified cases. This warrants further exploration of the role of myosins in cellular proliferation 
with a particular focus on genotype-phenotype correlations which are likely to be important for this 
gene. In addition to the suggestion of possible new candidate genes for ACC predisposition, the cAMP-
PKA pathway was identified as potentially playing a role in the development of the extremely rare 
oncocytic subtype. Candidate breast cancer predisposition genes were identified for further study, in 
particular STK11IP and its potential new founder variant. Finally, this study provided an opportunity to 
explore many genetic analysis techniques for the study of rare diseases. During this process novel tools 
such as the control browser web app were developed for use by the wider research community.
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Summary
Background Germline pathogenic variants in the E-cadherin gene (CDH1) are strongly associated with the 
development of hereditary diffuse gastric cancer. There is a paucity of data to guide risk assessment and 
management of families with hereditary diffuse gastric cancer that do not carry a CDH1 pathogenic variant, 
making it difficult to make informed decisions about surveillance and risk-reducing surgery. We aimed to identify 
new candidate genes associated with predisposition to hereditary diffuse gastric cancer in affected families without 
pathogenic CDH1 variants.
Methods We did whole-exome sequencing on DNA extracted from the blood of 39 individuals (28 individuals 
diagnosed with hereditary diffuse gastric cancer and 11 unaffected first-degree relatives) in 22 families without 
pathogenic CDH1 variants. Genes with loss-of-function variants were prioritised using gene-interaction analysis to 
identify clusters of genes that could be involved in predisposition to hereditary diffuse gastric cancer.
Findings Protein-affecting germline variants were identified in probands from six families with hereditary diffuse 
gastric cancer; variants were found in genes known to predispose to cancer and in lesser-studied DNA repair genes. 
A frameshift deletion in PALB2 was found in one member of a family with a history of gastric and breast cancer. 
Two different MSH2 variants were identified in two unrelated affected individuals, including one frameshift insertion 
and one previously described start-codon loss. One family had a unique combination of variants in the DNA repair 
genes ATR and NBN. Two variants in the DNA repair gene RECQL5 were identified in two unrelated families: 
one missense variant and a splice-acceptor variant.
Interpretation The results of this study suggest a role for the known cancer predisposition gene PALB2 in families 
with hereditary diffuse gastric cancer and no detected pathogenic CDH1 variants. We also identified new candidate 
genes associated with disease risk in these families.
Funding UK Medical Research Council (Sackler programme), European Research Council under the European 
Union’s Seventh Framework Programme (2007–13), National Institute for Health Research Cambridge Biomedical 
Research Centre, Experimental Cancer Medicine Centres, and Cancer Research UK.
Copyright © The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY 4.0 license.
Introduction
Gastric cancer is the fourth most common cancer globally. 
The best characterised inherited gastric cancer is the 
diffuse type, which has the hallmark of multiple foci of 
signet-ring cells.1 The term hereditary diffuse gastric 
cancer is used to describe families with a history of diffuse 
gastric cancer that meet the criteria of at least two cases of 
gastric cancer in first-degree or second-degree relatives 
regardless of age of onset (with one confirmed case of 
diffuse gastric cancer); one case of diffuse gastric cancer 
diagnosed before age 40 years; or a personal or family 
history of diffuse gastric cancer and lobular breast cancer, 
including one case diagnosed before age 50 years.2,3
Germline mutations in the E-cadherin gene (CDH1) 
explain 25–30% of hereditary diffuse gastric cancer 
cases, with more than 100 pathogenic germline variants 
currently described within this gene.4 For families with 
hereditary diffuse gastric cancer and known pathogenic 
CDH1 mutations, guidelines exist for risk assessment, 
disease management, surveillance (including regular 
endoscopies), and risk-reducing therapies (including 
prophylactic gastrectomy).5,6 However, for families with 
no pathogenic variant in CDH1, the risk assessment 
is uncertain and, therefore, making decisions about 
and assessing the efficacy of risk-reducing strategies 
is challenging.
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Other familial cancer syndromes that have been 
linked to gastric cancer predisposition include Lynch 
syndrome, which is characterised by mutations in DNA 
mismatch repair genes; Peutz-Jeghers syndrome caused 
by mutations in STK11; and Li-Fraumeni syndrome, 
which is associated with germline TP53 mutations.2,7–9 
Diffuse gastric cancer does not appear to be 
over-represented in these syndromes, although this 
association has not been comprehensively studied.
Predicted pathogenic variants in the DNA double-strand 
break repair genes ATM, BRCA2, and PALB2 have been 
identified in several families with hereditary diffuse gastric 
cancer.4,10 However, given the rarity of these variants, the 
associated risk of diffuse gastric cancer is hard to quantify, 
and these variants are not used in routine clinical testing to 
aid management of these families.
We aimed to identify new candidate genes for 
predisposition to hereditary diffuse gastric cancer in 
families without pathogenic CDH1 variants.
Methods
Study design and participants
In this whole-exome sequencing study, we recruited 
28 individuals diagnosed with diffuse gastric cancer and 
11 unaffected relatives from 22 families with hereditary 
diffuse gastric cancer that had tested negative for CDH1 
pathogenic germline mutations as part of the Familial 
Gastric Cancer study (MREC 97/5/32) and for whom 
blood and tumour samples were available. Families 
(including first-degree and second-degree relatives) were 
categorised as having hereditary diffuse gastric cancer on 
the basis of existing criteria.2,3,6
Whole-exome sequencing and variant filtering
DNA was extracted from blood or saliva and prepared 
for 125-bp paired-end whole-exome sequencing using 
the Nextera Rapid Capture Exome Enrichment Kit 
(Illumina, San Diego, CA, USA). Sequencing was done 
on HiSeq-4000 or HiSeq-2500 platforms (Illumina, 
San Diego, CA, USA). Variant Call Format files were 
generated with a standard pipeline following Genome 
Analysis Toolkit (GATK) Best Practices recommendations 
for whole-exome data (appendix). The dataset was filtered 
to select uncommon (allele frequency <0·05 in the 
1000 Genomes Project European sample) protein-affecting 
variants, including loss-of-function variants (stop site 
gained, stop site lost, start site lost, splice acceptor, splice 
donor, or frameshift), deleterious (predicted with Sorting 
Intolerant From Tolerant version 5.2.2) and damaging 
(predicted with Polymorphism Phenotyping version 2.2.2) 
missense variants, and inframe indels, that were observed 
in at least one of the 28 affected individuals. These filters 
were chosen to remove variants that were least likely to 
affect predisposition to hereditary diffuse gastric cancer. 
We considered the 11 unaffected family members 
separately on a per-family basis as a control group on 
which we did segregation analysis for identified candidate 
variants. We determined the allele frequency of all 
candidate variants in healthy controls (with no history of 
cancer) and allele counts in affected and unaffected 
individuals within families, and predicted downstream 
effects on the protein product.
Variants were aggregated into unique genes, which 
were then filtered to select those that contained at least 
one loss-of-function variant. We also removed the top 1% 
Research in context
Evidence before this study
Knowledge of factors causing predisposition to hereditary diffuse 
gastric cancer in families with no pathogenic variants in CDH1 is 
limited by the rarity of the disease, which makes doing large-scale 
association studies difficult. In 2015, Hansford and colleagues 
described variants in DNA repair-related genes in 144 families 
with hereditary diffuse gastric cancer without CDH1 pathogenic 
variants. These genes included PALB2, BRCA2, and ATM, which 
are associated with breast cancer risk. Further investigation of 
these genes, other known cancer-predisposing genes, and genes 
associated with DNA repair will aid in the disease management of 
families with hereditary diffuse gastric cancer without CDH1 
pathogenic variants, whose risk of disease development is 
currently unknown.
Added value of this study
This study is one of the largest germline, whole-exome 
sequencing analysis of families with hereditary diffuse gastric 
cancer without CDH1 mutation to date. Both affected and 
unaffected individuals were recruited from families with 
hereditary diffuse gastric cancer, providing the opportunity to 
look for protein-affecting variants that segregate with 
phenotype. We used a unique approach to pathway analysis that 
involved clustering of physically interacting genes that were 
enriched for variants in these families and annotating them with 
a Gene Ontology term. Additionally, combining findings from 
this study with data from previously published studies allowed a 
more complete analysis of the role of the cancer predisposition 
genes PALB2 and BRCA2.
Implications of all the available evidence
We identified a cluster of interacting genes involved in DNA 
repair that could be associated with predisposition to hereditary 
diffuse gastric cancer, in particular, PALB2. These findings should 
help guide future studies seeking to elucidate the clinical 
implications of genes that have not been previously associated 
with hereditary diffuse gastric cancer. Identification of these 
genes could provide families with hereditary diffuse gastric 
cancer without CDH1 pathogenic variants with improved 
information about the risks associated with their disease and 
allow them to make informed decisions about risk reduction 
and disease management.
For more on Sorting Intolerant 
From Tolerant see 
http://sift.bii.a-star.edu.sg
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most variable genes, which were identified by the 
number of rare, protein-affecting variants per gene. These 
genes typically possess many rare variants within the 
healthy population and, therefore, are unlikely to have a 
role in predisposition to hereditary diffuse gastric cancer 
or other diseases. Variant-filtering and gene-filtering steps 
are summarised in the appendix.
To analyse copy number variants, we applied the 
XHMM algorithm to the gene set, using principle 
component analysis to normalise read depth across 
exomes and a hidden Markov model to identify regions 
with variation in read depth.11 Around a 50% decrease or 
increase in read depth was required for the variant to be 
considered for further analysis. Copy number variants 
were further explored in selected individuals with a 
CytoScan 750K genotyping array (Affymetrix, Santa Clara, 
CA, USA), according to the clinical protocol.
The results published here are in whole or part based 
on data generated by The Cancer Genome Atlas (TCGA), 
managed by the National Cancer Institute and the 
National Human Genome Research Institute. Controlled 
access data was requested and downloaded for the 
TCGA-STAD dataset, of which a subset of data from 
88 cases of diffuse gastric cancer were analysed to further 
validate the role of the identified candidate genes in 
predisposition to diffuse gastric cancer.
Gene-interaction network analysis
Gene-interaction network analysis was used to identify 
variant-enriched candidate genes with interacting 
protein products; non-antagonistic, physically interacting 
proteins might have a similar effect on cell function and, 
therefore, might produce a shared phenotype when 
mutated. The filtered genes were put through the 
GeneMANIA Cytoscape plugin version 3.4.1, which 
places physically interacting genes into clusters.12 
A cluster was defined as a set of five or more physically 
interacting genes.
We used the PANTHER over-representation test 
(version 13.0) in the Gene Ontology Consortium 
enrichment analysis web-tool to assign Gene Ontology 
(GO) terms to clusters, applying the default Bonferroni 
correction for multiple testing.13 Of the significant terms 
highlighted in the analysis, the most significant term 
that encompassed between ten and 200 genes was 
selected, consistent with previous studies.14
Allelic counts of all filtered, loss-of-function variants 
within the selected GO terms (regardless of GeneMANIA 
Cytoscape clustering) were aggregated and contingency 
tables were drawn. Variants were also aggregated for 
each GO term over a comparably filtered set of genes 
from 503 European individuals in phase 3 of the 
1000 Genomes study (appendix).15 We did a one-tailed 
Fisher’s exact test using the R Stats package version 3.3.3 
to test for enrichment of loss-of-function variants within 
each selected GO term in the families with hereditary 
diffuse gastric cancer compared with the 1000 Genomes 
European dataset. For this test, only one occurrence of a 
variant was counted per affected family. A link to the 
custom R scripts used for this analysis can be found in 
the appendix.
Validation by Sanger sequencing
Candidate variants were validated by Sanger sequencing. 
Germline DNA from blood and extracted tumour DNA 
were quantified with the Qubit dsDNA HS Kit 
(Invitrogen, Carlsbad, CA, USA), and custom flanking 
primers were designed for each variant (primer 
sequences are shown in the appendix). DNA fragments 
were amplified by PCR and the products were sequenced 
on an ABI Genetic Analyser (Applied Biosystems Foster 
City, CA, USA) with BigDye Terminator version 3.1 
(Invitrogen, Carlsbad, CA, USA), according to the 
manufacturer’s instructions.
Tumour immunohistochemistry and microsatellite 
instability analysis
We used the Ventana MMR IHC Panel (Roche, 
Indianapolis, IN, USA) to do immunohistochemistry 
analysis of known mismatch repair genes in available 
tumours from individuals in which variants in mismatch 
repair genes were identified. The panel includes 
antibodies against MLH1, PMS2, MSH2, and MSH6.
To analyse microsatellite instability, 5-µm formalin-
fixed, paraffin-embedded tumour sections were mounted 
on glass slides for dewaxing and manual microdissection. 
DNA was extracted with the QIAamp DNA FFPE Tissue 
Kit (Qiagen, Hilden, Germany). We assessed the DNA 
for five standard microsatellite markers (BAT25, BAT26, 
NR21, NR24, and MONO27) using the Promega MSI 
Analysis System, version 1.2 (Promega, Madison, WI, 
USA). Poorly and moderately differentiated gastric tissue 
was compared with adjacent tumour-free tissue.
Analysis of PALB2 and BRCA2 variants in published studies
We searched PubMed without language restrictions 
between Jan 1, 2015, and Dec 31, 2017, using the term 
“hereditary diffuse gastric cancer” to identify sequencing 
studies reporting loss-of-function variants in PALB2 and 
BRCA2 in hereditary diffuse gastric cancer probands with 
no detected pathogenic CDH1 variants. We included only 
publications released after the initial report4 in 2015 of 
PALB2 and BRCA2 mutations associated with hereditary 
diffuse gastric cancer. For each of the four identified 
publications4,10,16,17 and this study, we aggregated the allele 
counts of loss-of-function PALB2 variants. The same 
counts were done across the 503 European samples from 
the 1000 Genomes Project and the 27 173 non-Finnish 
European individuals not in the TCGA from the Exome 
Aggregation Consortium (ExAC) control datasets.18 We 
removed the well characterised, non-pathogenic BRCA2 
polymorphic stop codon in c.9976A→T from all datasets. 
We did a one-tailed Fisher’s exact test using the R Stats 
package version 3.3.3 to test for enrichment of 
For more on The Cancer 
Genome Atlas see 
http://cancergenome.nih.gov
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loss-of-function PALB2 or BRCA2 variants in the families 
with hereditary diffuse gastric cancer compared with 
either control dataset.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the 
Article. EF, JR, and MT had access to the raw data. 
The corresponding author had full access to all of the 
data and the final responsibility for the decision to 
submit for publication.
Results 
A whole-exome sequencing dataset of 39 individuals 
from 22 families with hereditary diffuse gastric 
cancer without pathogenic CDH1 variants (table 1) was 
filtered to select 3973 uncommon, protein-affecting 
variants that were aggregated into 2847 genes. Exclusion 
of the top 1% of highly variable genes, and retention of 
genes with at least one loss-of-function variant in 
affected individuals, resulted in a set of 732 genes 
(1228 variants). Eight highly variable genes were 
excluded, including ANKRD36, CDC27, HLA-DRB1, 
HLA-DRB5, MUC3A, MUC4, MUC6, and OR4C5. 
Additionally, the presence of affected and unaffected 
family members within our dataset allowed for selection 
Number of samples 
sequenced*
Age of proband at 
diagnosis (years)




1 2 0 41 Diffuse gastric cancer (44)‡, gastric cancer (57) None
2 2 4 27 Peritoneal cancer, ovarian cancer (22), diffuse gastric cancer (24)‡, diffuse gastric cancer (28) None
3 1 0 40 Gastric cancer (28), diffuse gastric cancer (48) None
4 1 2 55 Breast cancer, lung cancer, laryngeal cancer, gastric cancer, and diffuse gastric cancer (44, 52) PALB2
5 1 0 36§ Diffuse gastric cancer (37), lung cancer (54), colorectal cancer (57), breast cancer (50), diffuse 
gastric cancer (61), diffuse gastric cancer (79), lung cancer (83)
None
6 1 0 37 Breast cancer, gastric cancer (63), gastric cancer (64) RECQL5
7 2 0 36 Colorectal cancer, breast cancer (43), diffuse gastric cancer (55)‡ None
8 1 0 47¶ Diffuse gastric cancer (44) MSH2||
9 1 0 44 Diffuse gastric cancer (28) None
10 1 2 28 Breast cancer, gastric cancer (44), gastric cancer (47) None
11 4 1 28 Signet-ring cells‡, Signet-ring cells‡, breast cancer (40s), diffuse gastric cancer (45)‡, 
prostate cancer (60s), colorectal cancer (75)
ATR, NBN
12 1 0 68 Lung cancer, gastric cancer (49), gastric cancer (50), gastric cancer (76) MSH2||
13 1 0 47 Gastric cancer, gastric cancer (50s), gastric cancer (60s) None
14 1 0 23 Diffuse gastric cancer (40s), diffuse gastric cancer (46), thyroid cancer (30) None
15 1 0 53 Gastric cancer (49), gastric cancer (67), gastric cancer (71) None
16 1 0 37 Gastric cancer, breast cancer (54), breast cancer (65), colorectal cancer (66) None
17 1 0 45 Diffuse gastric cancer (42) None 
18 1 0 48 Gastric cancer (44), gastric cancer (54) None
19 1 1 35 Lung cancer, uterine cancer (65) None
20 1 0 55 Gastric cancer (51), colorectal cancer (76) None 
21 1 1 28 Gastric cancer (53), breast cancer (76), gastric cancer (80) RECQL5
22 1 0 30 Gastric cancer, diffuse gastric cancer (67) None 
In total, 39 individuals were sequenced, including 11 unaffected relatives. Numbers in parentheses indicate age in years at diagnosis. *All probands were sequenced in this study. 
†Includes both first-degree and second-degree relatives; age in years at diagnosis is in parentheses when known. ‡Sequenced in this study. §This proband was also diganosed 
with colorectal cancer at age 47 years. ¶This proband was also diagnosed with lobular breast cancer at age 36 years. ||No microsatellite instability was detected in tumour. 
Table 1: Characteristics of 28 affected individuals in 22 families with hereditary diffuse gastric cancer without CDH1 pathogenic variants
Figure 1: Gene clusters identified via gene interaction analysis
Lines indicate a physical interaction, as assigned by the GeneMANIA plugin for Cytoscape.12 (A) Gene cluster to 
which the double-strand break repair GO term (GO:0006302) was assigned. (B) Gene cluster to which the negative 
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of variants that segregated with phenotype on a 
per-family basis.
Gene-interaction network analysis of the 732 filtered 
genes identified two physical interaction clusters, to 
which GO terms were applied (figure 1). A cluster of 
eight genes was associated with the GO term 
double-strand break repair (GO:0006302; p<0·0001; 
figure 1A). A second cluster of ten genes was associated 
with the GO term negative regulation of extrinsic 
apoptotic signalling pathway via death domain receptors 
(GO:1902042; p=0·00517; figure 1B).
Loss-of-function variants within the filtered set of 
1228 variants were aggregated under these two GO terms, 
including genes related to the GO terms that were not 
initially clustered by GeneMANIA. The double-strand 
break repair term was significantly enriched in families 
with hereditary diffuse gastric cancer compared with the 
1000 Genomes European set (p=0·00051). By contrast, the 
apoptotic signalling pathway term was not enriched in 
families with hereditary diffuse gastric cancer (p=0·186), 
suggesting that the differences between the datasets in 
allele counts of DNA double-strand break repair genes 
cannot entirely be explained by technical differences that 
arise when using an externally produced control dataset.
Genes in the double-strand break repair GO term 
included PALB2, MSH2, RECQL5, ATR, and NBN, all of 
which were shown to be physically interacting in 
GeneMANIA (figure 1A). BRCA2 was also a part of this 
set, but was disregarded from further study because it 
contained the well characterised, benign polymorphic 
stop codon c.9976A→T.19
Table 2 summarises the candidate variants. A 
heterozygous 2 bp frameshift deletion was identified in 
PALB2 (c.757-758TAG→T [rs180177092, NM_024675.3]) 
in a patient from family 4 who was diagnosed with 
diffuse gastric cancer at age 55 years (figure 2). This 
loss-of-function variant at aminoacid position 253 is 
predicted to result in an early stop codon seven aminoacids 
downstream of the variant. Family 4 has a history of 
breast, lung, laryngeal, and diffuse gastric cancer 
(table 1, figure 2). Exome sequencing was also done on 
two unaffected siblings, one of whom also had the PALB2 
(c.757-758TAG→T [rs180177092, NM_024675.3]) variant. 
The affected proband had previously received treatment 
for Helicobactor pylori infection, but had tested negative at 
subsequent endoscopies.
Two heterozygous loss-of-function variants were 
identified in the mismatch repair gene MSH2: a start 
site loss (c.1A→C [rs267607911, NM_000251.2]) in a 
patient from family 12 and a frameshift insertion of 
4 bp (c.967-968T→TCTCA [NM_000251.2]) in a patient 
from family 8 (table 2; appendix). Both families had a 
strong history of gastric cancer; however, only DNA 
from the probands was available for sequencing, so 
segregation analysis could not be done. Heterozygosity 
of both variants was maintained in tumour DNA 
from the patients, as confirmed by Sanger sequencing. 
Tumours from both probands showed normal 
expression of MSH2 and other mismatch repair 
proteins by immunohistochemistry compared with 
adjacent tumour-free tissue (appendix), and neither 
tumour showed evidence of microsatellite instability 
(appendix). Both probands with MSH2 variants had 
previously tested negative for H pylori.
Heterozygous variants in the DNA repair genes ATR 
and NBN—a splice-donor variant (c.1124+1G→C 
[NM_002485.4]) in NBN and a predicted stop site-gain 
variant (c.6075A→T [NM_001184.3]) in ATR—were 
identified in the proband from family 11, who was 
diagnosed with diffuse gastric cancer at age 28 years 
(figure 3, table 2). Two siblings underwent risk-reducing 
gastrectomies, and subsequent pathological analysis of 
gastric tissue revealed the presence of signet-ring cells 
in both individuals. As such, these individuals were 
considered to be affected family members in this 
analysis. The father of the proband was diagnosed with 
diffuse gastric cancer at age 60 years and the mother had 










4 3 PALB2 c.757-758TAG→T Frameshift deletion Leu253fs 0 0 NA NA
6 1 RECQL5 c.2806-2T→C Splice-acceptor variant NA 0 0 NA NA
8 1 MSH2 c.967-968T→TCTCA Frameshift insertion Ser323fs 0 0 NA NA
11 5 ATR c.6075A→T Stop site gain Tyr2025X 0 0 NA NA
11 5 NBN c.1124+1G→C Splice-donor variant NA 0 0 NA NA
12 1 MSH2 c.1A→C Start site loss Met1?* 0 0 Deleterious Benign
21 2 RECQL5 c.2828C→T Missense variant Arg943His 0·002 0·014332 Deleterious Probably damaging
SIFT=Sorting Intolerant From Tolerant. ExAC=Exome Aggregation Consortium. TCGA=The Cancer Genome Atlas. fs=frameshift. NA=not applicable. *Human Genome Variation Society nomenclature to indicate loss of 
a start site without experimental evidence of a new start site.20
Table 2: Candidate variants in six families with hereditary diffuse gastric cancer without CDH1 pathogenic variants
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which suggests that she had primary gastric cancer. 
All individuals in this family whose DNA was sequenced 
tested negative for H pylori. The proband and both 
siblings were heterozygous for loss-of-function variants 
in both ATR and NBN. The splice-donor variant in NBN 
was not seen in the father, and so was presumed to have 
been inherited maternally (DNA was only available for 
the father). The ATR variant was identified in the father, 
in whom no clinically relevant copy number variants 
were found. An unaffected, second-degree relative in 
family 11 did not have either variant.
Two variants were identified in the helicase gene 
RECQL5 in different families. One was a missense 
variant (c.2828C→T [rs200535477, NM_004259.6]) in 
the proband from family 21, who was diagnosed with 
diffuse gastric cancer at age 28 years, and the other was 
a loss-of–function, splice-acceptor variant (c.2806-2T→C 
[rs201841487, NM_004259.6]) in the proband from 
family 6, who was diagnosed with diffuse gastric cancer 
at age 37 years (table 2; appendix). Both of these families 
included individuals across three generations who 
were diagnosed with gastric cancer and breast cancer. 
The proband of family 6 tested negative for H pylori, and 
the H pylori status of the proband from family 21 was 
unknown. DNA from the father of the proband in 
family 21 was sequenced, and the missense variant in 
RECQL5 was not found.
We did not explore variants in other genes within the 
double-strand break repair cluster because the variants 
did not segregate with the disease in families containing 
affected and unaffected members.
We analysed data from previous studies4,10,16,17 to 
estimate enrichment of loss-of-function variants in 
PALB2 and BRCA2 in families with hereditary diffuse 
gastric cancer. A loss-of-function variant (c.1438A→T 
[rs1057520653, NM_024675.3]) was identified and 
reported to us by collaborators (Teixeira MR, 
unpublished), however this variant was not included in 
the analysis because it did not fit our search criteria. 
Five (2%) of the 329 probands tested in these studies 
(including the present study) had loss-of-function 
PALB2 variants (table 3). By contrast, PALB2 variants 
were identified in 26 (<1%) of 27 173 individuals in the 
non-TCGA, non-Finnish European ExAC database 
(p<0·0001) and in one (<1%) of 503 individuals in the 
1000 Genomes Project European database (p=0·039). 
Loss-of-function BRCA2 variants were not enriched in 
families with hereditary diffuse gastric cancer compared 
with ExAC (p=0·47) or 1000 Genomes Project (p=1·00) 
individuals. No loss-of-function PALB2 variants were 
identified in a set of 88 cases with sporadic diffuse 
gastric cancer from the TCGA.
Discussion
We found predicted pathogenic (protein-affecting) 
germline variants in known cancer-predisposing DNA 
repair genes (including PALB2, MSH2, ATR, NBN, and 
RECQL5) in six (27%) of 22 families with hereditary 
diffuse gastric cancer. This finding reflects the increasing 
number of cancer phenotypes found to be associated 
with existing cancer-predisposing genes as genomic 
analyses extend to rarer cancer subtypes. For example, 
mismatch repair genes were initially associated with 
increased risk of colorectal cancer, but were subsequently 
associated with risk of developing gastric and pancreatic 
cancers, among others.21,22
Simply identifying predicted pathogenic variants in 
known cancer-predisposing genes does not imply 
causality. For example, pathogenic germline variants in 
MSH2 were not accompanied by altered expression of 
DNA mismatch repair proteins in tumour tissue in our 
































T T T TG G G GGA A AAA C
T T T TG G GGA A A AAA C
T T T T TG C GG GA A A AA
A B
Figure 2: Pedigree and cancer history for family 4 
(A) Whole-exome sequencing was done on the three circled individuals; age at diagnosis of cancer is shown in parentheses when known. (B) Chromatograms 
showing the PALB2 frameshift variant (c.757-758TAG→T) in DNA from individuals 1 and 2 compared with control DNA. 
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matched controls are required, which is not typically 
feasible for rare diseases. The generation of large control 
datasets, such as ExAC and 1000 Genomes, can be used 
to strengthen possible associations, as we have shown in 
the case of PALB2. When combining our data with 
those from previously published relevant studies,4,10,16,17 
including those in which no PALB2 variants were found, 
we saw a significant over-representation of PALB2 
(but not BRCA2) pathogenic variants in families with 
hereditary diffuse gastric cancer compared with ExAC 
and 1000 Genomes controls; however, this finding 
was much less significant when comparing with the 
503 Europeans in the 1000 Genomes Project set than 
when comparing with the 27 173 individuals from the 
non-Finnish, non-TCGA ExAC dataset.15
In several of the cases described by Sahasrabudhe and 
colleagues,10 tumour molecular profiling was done and 
showed that carriers of PALB2 mutations had mutational 
signatures indicative of defects in homologous recomb-
ination. PALB2 has an important role in homologous 
recombination during double-stranded DNA break repair 
through recruitment of BRCA2 and RAD51 to DNA 
breaks. Mutations in this gene are associated with an 
increased risk of breast and pancreatic cancers.23–25 Even 
within families carrying PALB2 mutations, cases of diffuse 
gastric cancer are likely to be rare and could be masked by 
a larger number of sporadic gastric adenocarcinomas, 
which means that associations with certain cancer 
subtypes might be missed in epidemiological studies of 
these families unless the pathology of all reported cancers 
is known. For example, a recent study26 revealed that a rare 
serous subtype of endometrial cancer is over-represented 
in carriers of BRCA1 variants, identifying a novel cancer 
association with a gene that has been intensively studied 
for more than 20 years.
ATR and NBN are also involved in initiating the 
response to double-strand DNA breaks. The NBN gene 
product (NBS1) associates with MRE11 and RAD50 to 
form a complex involved in the activation of the ataxia 
proteins ATM and ATR, which have roles in the 
recruitment of damage repair proteins, cell cycle 
regulation, and apoptosis. We identified single 
loss-of-function variants in NBN or ATR in the parents of 
the proband in family 11, both of whom had, or were 
suspected to have, diffuse gastric cancer. These variants 
were co-inherited in all three siblings in the family. 
Expression of either one of these variants might 
predispose family members to diffuse gastric cancer, 
although no other incidences of gastric cancer, and only 
one instance of late-onset prostate cancer, were noted in 
an extensive maternal and paternal family history. Slavin 
and colleagues17 also identified a stop site-gain variant in 
ATR in an individual with intestinal-type adenocarcinoma 
and a strong family history of gastric cancer.
The unusual cancer pattern seen in family 11 (with all 
immediate family members [siblings and parents], but 
no extended family members, of the proband affected) 
might be attributed to multi-locus, inherited neoplasia 
alleles syndrome, in which inheritance of pathogenic 
mutations in multiple cancer-predisposing genes leads 
to an atypical or severe phenotype.27 The close functional 
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Figure 3: Pedigree and cancer history of family 11
(A) Whole-exome sequencing was done on the three circled individuals; the 
proband was patient 4. The presence of the variants in NBN (c.1124+1G→C) and 
ATR (c.6075A→T) among the four affected family members are shown. Age at 
diagnosis of cancer is shown in parentheses when known. *DNA was not 
available for the mother, and so the mother’s genotype was assumed on the 
basis of the genotypes of the father and children. †These individuals underwent 
risk-reducing gastrectomies. (B) Chromatograms showing the NBN variants in 
DNA from individual 2 compared with control DNA. (C) Chromatograms 
showing the ATR variants in DNA from individual 2 compared with control DNA. 
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DNA break repair could indicate a potential combinatorial 
effect of variants in these genes, as potentially suggested 
by the young age of diagnoses or the presence of 
signet-ring cells in the siblings carrying these variants. 
By contrast, double heterozygosity of mutations in the 
DNA repair genes BRCA1 and BRCA2 in patients with 
breast cancer was found to be no more deleterious 
than a single heterozygous mutation.28 Nevertheless, 
such double heterozygosity might have implications for 
genetic counselling that should be considered.
Genetic variants in genes involved in the mismatch 
DNA repair pathway are also associated with Lynch 
syndrome. A variant similar to the start-site loss variant 
that we identified in MSH2 (c.1A→G) has previously 
been shown to have only a mild effect on protein 
function;29 thus, this variant should not be treated as a 
typical loss-of-function variant. This attenuated effect on 
protein function could be due to the presence of an 
alternative start codon and a second non-mutated MSH2 
allele. Increased microsatellite instability, a measure of 
decreased MSH2 function, has been shown in patients 
and tumours with the c.1A→G start site-loss variant.29 
However, in tumours from both cases analysed here, 
MSH2 expression (detected by immunohistochemistry 
staining) was normal and no microsatellite instability 
was found. Although it is most likely that tumorigenesis 
was not caused by mismatch repair deficiency, we 
cannot rule out the possibility of a novel, non-mismatch 
repairmediated mechanism of carcinogenesis driven by 
variants in MSH2.
The helicase RECQL5 is important for prevention of 
aberrant homologous recombination and accumulation 
of double-strand DNA breaks, and thus for preservation of 
genome stability.30 A missense RECQL5 variant was 
identified in the proband from family 21, and was not 
found in the proband’s unaffected father. A splice-acceptor 
variant in RECQL5 was identified in an individual in 
family 6 who was diagnosed with diffuse gastric cancer at 
age 37 years. Both family 6 and family 21 had a history of 
breast and gastric cancer.
Previous studies have explored the role of known 
cancer predisposition genes in individuals with 
hereditary diffuse gastric cancer who do not have 
known CDH1 mutations. Sahasrabudhe and colleagues10 
identified germline variants in PALB2, BRCA1, and 
RAD51C in families with diffuse gastric cancer. Hansford 
and colleagues4 described variants in ATM, BRCA2, 
MSR1, and STK11, as well as a frameshift deletion in 
PALB2. This group has also uncovered a role for the 
CDH1-related adhesion gene CTNNA1. Although we did 
not find any variants of interest in ATM, BRCA1, BRCA2, 
CTNNA1, MSR1, RAD51C, or STK11, an exploration of 
PALB2 variants in all families with hereditary diffuse 
gastric cancer sequenced in recent studies showed 
enrichment of loss-of-function variants in these families 
compared with control datasets. This finding makes a 
case for inclusion of PALB2 in genetic testing for 
families with hereditary gastric cancer without CDH1 
mutations, and it is possible that individuals who carry 
PALB2 mutations might benefit from platinum-based 
chemo therapy and treatment with PARP inhibitors.31 
However, the evidence is not yet sufficient to recommend 
surveillance of diffuse gastric cancer in carriers of 
PALB2 mutations because the absolute risk is likely to 
be low in the absence of a family history.
Sporadic stomach cancers have been analysed as part of 
the TCGA study,32 and an association was identified 
between truncating PALB2 mutations and sporadic 
stomach adenocarcinoma. Of the individuals with sporadic 
stomach adenocarcinoma and PALB2 mutations from the 
TCGA database, we selected 88 individuals with diffuse 
gastric cancer, as described by Bass and colleagues,33 
among which we did not identify any truncating PALB2 
variants. However, the average age at diagnosis for this 
cohort was 66 years, so this finding is perhaps not 
unexpected given the younger age of onset usually 
observed in hereditary cancers.
The rarity of patients with hereditary diffuse gastric 
cancer without pathogenic CDH1 variants makes the 
collection of large datasets challenging. We used 
Race Patient ID Diagnosis of proband (age at 
diagnosis in years)
Variant Consequence Protein change
Hansford et al (2015)4 European P124 Diffuse gastric cancer (45) c.1193AC→A fs deletion Val398fs
Sahasrabudhe et al (2017)10 European CG-12 Intestinal gastric cancer (69) c.1240C→T Stop-site gain Arg414Ter
Sahasrabudhe et al (2017)10 European CG-008 Diffuse gastric cancer (48) c.1240C→T Stop-site gain Arg414Ter
Sahasrabudhe et al (2017)10 European GM037589 Gastric cancer (46) c.1240C→T Stop-site gain Arg414Ter
Sahasrabudhe et al (2017)10 European CG-05 Diffuse gastric cancer (50) c.3201+1G→T Splice-site variant NA
Sahasrabudhe et al (2017)10 European CG-039 Diffuse gastric cancer (47) c.1882_1890delAAGTCCTGC In-frame deletion Lys628_Cys630del
Sahasrabudhe et al (2017)10 Latin American CG-028 Intestinal gastric cancer (81) c.1882_1890delAAGTCCTGC In-frame deletion Lys628_Cys630del
Sahasrabudhe et al (2017)10 Latin American 3CG-103 Mixed (79) c.2753C→A Missense Pro918Gln
Fewings et al (this study) European GST_172_301 Diffuse gastric cancer (55) c.757_758TAG→T fs deletion Leu253fs
Teixeira (unpublished) European GM048157 Diffuse gastric cancer (56) c.1438A→T Stop-site gain Lys480Ter
None of the identified PALB2 variants appeared in the 1000 Genomes Project European samples or in the Exome Aggregation Consortium European datasets. fs=frameshift. NA=not applicable.
Table 3: PALB2 variants identified in hereditary diffuse gastric cancer sequencing studies
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gene-interaction network analysis to prioritise candidate 
gene variants that co-segregated with disease phenotype 
and were likely to be involved in predisposition to 
hereditary diffuse gastric cancer on the basis of 
knowledge of the biology of the disease. This approach 
did not overcome the problem of low statistical power 
due to a small sample size, which is often seen with rare 
cancer datasets, but it did allow for selection of the most 
plausible candidates from the available data.
We attempted an additional analysis of copy number 
variants within this dataset using the XHMM algorithm.11 
Although this analysis did not suggest any plausible 
candidates, at present, copy number variant analysis of 
germline whole-exome sequencing data is not validated 
and, therefore, some causal copy number variants could 
have been missed.
In summary, we found that rare, protein-affecting 
variants in DNA damage repair genes were enriched in 
families with hereditary diffuse gastric cancer without 
pathogenic CDH1 variants compared with control 
datasets. Further studies of these genes in similar 
families are required to increase knowledge of the 
genetic basis of hereditary diffuse gastric cancer so that 
better informed decisions about risk reduction and 
management in affected family members can be made. 
Lastly, for many families with hereditary diffuse gastric 
cancer without pathogenic CDH1 variants, the underlying 
cause remains unexplained even after whole-exome 
sequencing, and although whole-genome sequencing 
might identify some additional candidates in regulatory 
elements or structural variants, it seems unlikely that 
high-impact genes other than CDH1 will be implicated in 
hereditary diffuse gastric cancer. Therefore, focusing on 
moderate-impact or low-impact cancer genes, such as 
PALB2, might be the way forward for future studies 
of genes associated with predisposition to disease in 
these patients.
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PALB2 as a familial gastric cancer gene: is the wait over?
Gastric cancer is the third leading cause of cancer-related 
mortality, accounting for more than 730 000 deaths 
worldwide each year.1 The prognosis of patients with 
gastric cancer is dismal because most gastric tumours 
are diagnosed in late stages when 5-year survival 
is less than 20%.1 Whereas gastric tumours with 
intestinal histologies are linked to a history of 
Helicobacter pylori-associated gastritis, the natural 
history of diffuse gastric cancers is less well understood.1 
New tools for the prevention and early detection of early 
gastric cancer are needed to improve survival outcomes. 
Around one in ten patients with gastric cancer report a 
family history of malignancy, suggesting an underlying 
genetic predisposition.1 Thus, genetic information could 
be used for gastric cancer prevention. 
Until recently, CDH1 was the only known gene 
associated with familial gastric cancer.2 CDH1 mutations 
frequently cause hereditary diffuse gastric cancer 
syndrome, and detection of mutations in this gene 
is routinely used for risk assessment and disease 
management.1,2 However, more than 40% of families with 
hereditary diffuse gastric cancer syndrome do not carry 
CDH1 mutations, suggesting the existence of additional 
predisposing genes.3,4 In the past 3 years, our group and 
others have suggested that mutations in homologous 
recombination DNA repair genes, such as PALB2, 
probably explain a substantial proportion of inherited 
gastric cancers.3,5 The study by Eleanor Fewings and 
colleagues6 in The Lancet Gastroenterology & Hepatology 
further supports a role for PALB2 in predisposition to 
hereditary gastric cancer.
To identify new gastric cancer-associated genes, the 
investigators performed whole-exome sequencing 
in 22 families with hereditary diffuse gastric cancer 
syndrome that had previously tested negative for 
pathogenic variants in CDH1. Exome data from affected 
family members was used to prioritise candidate 
genes with predicted loss-of-function variants using 
interaction analyses. A cluster of DNA repair genes, 
which included known cancer-associated genes 
such as MSH2 and PALB2, was identified as being 
significantly enriched for loss-of-function variants. 
Subsequent analyses of this cluster provided evidence 
of co-segregation of loss-of-function variants with 
disease in six (27%) of the 22 families. A frameshift 
PALB2 variant was identified in one family, and 
loss-of-function variants in both ATR and NBN were 
identified in another family. RECQL5 mutations were 
identified in two families; two others had variants 
in MSH2, a gene known to be associated with Lynch 
syndrome.7 Tumour analyses in the individuals with 
MSH2 variants did not reveal microsatellite instability 
or loss of mismatch repair protein expression 
(both hallmarks of Lynch syndrome7), suggesting that 
these variants were either non-pathogenic or that a 
new mechanism leads to gastric cancer in these families. 
To exclude a possible environmental cause, the family 
members were assessed for history of H pylori infection, 
the strongest known risk factor for gastric cancer,1 and 
most mutation carriers had previously tested negative 
for the bacteria. The investigators also combined their 
data with those from two previous reports3,5 and found 
that PALB2 loss-of-function variants were substantially 
more common in families with hereditary gastric cancer 
than in the general population.
Genetic studies in gastric cancer have lagged behind 
those in other gastrointestinal cancers, such as 
colorectal cancer, for which several susceptibility genes 
have been reported.8 The study of gastric cancer genetics 
is difficult in part because the high mortality makes 
large family studies unfeasible. Furthermore, dissimilar 
to colorectal cancer, gastric cancer is more commonly 
diagnosed in low-income countries, where research and 
clinical practice of cancer genetics is limited by funding 
and the scarcity of medical professionals in the field, 
among other reasons.9
Therefore, the investigators should be commended 
for these findings. Nevertheless, given the small 
number of families with PALB2 variants (only ten have 
been reported thus far), translating these findings into 
prevention of gastric cancer will require additional 
research. For example, should cases of familial 
intestinal gastric cancer be tested for PALB2 variants? 
The study5 from our group identified seven individuals 
with PALB2 mutations, of whom three had intestinal 
tumours and one had a tumour of mixed histology. 
Given that hereditary diffuse gastric cancer syndrome 
includes only cases with diffuse histology, our findings 
suggest that PALB2 mutations define a unique 
syndrome with heterogeneous histological types. 
Lancet Gastroenterol Hepatol 
2018
Published Online 























2 www.thelancet.com/gastrohep   Published online April 26, 2018   http://dx.doi.org/10.1016/S2468-1253(18)30120-1
Further studies focusing on non-diffuse gastric cancer 
are therefore needed to understand whether PALB2 
mutations define a familial gastric cancer syndrome.
Germline mutations in PALB2 have already been 
associated with an increased risk of breast and 
pancreatic cancer, and hundreds of families are known 
to have mutations in this gene.10 It is now important 
to identify which factors increase the risk of gastric 
cancer in such families. Both the study by Fewings and 
colleagues6 and our study5 found insufficient evidence of 
a modifier role for H pylori infection in PALB2 mutation 
carriers, but it is possible that the risk of gastric cancer 
is affected by PALB2 mutation hotpots, modifier genes, 
and other unaccounted environmental factors. These 
questions highlight the need for further research. 
This emerging body of data provides a compelling case 
for offering PALB2 testing to families with hereditary 
gastric cancer that have previously tested negative for 
pathogenic CDH1 mutations. Given that the tumours of 
individuals with PALB2 mutations are likely to be deficient 
in homologous recombination DNA repair (as shown in 
our study5), these individuals could potentially benefit 
from PARP inhibitor therapies, which might be effective 
in homologous DNA repair-deficient tumours.11 20 years 
after the discovery of CDH1, the identification of PALB2 
as a new gene potentially associated with familial gastric 
cancer is of dual importance for both prevention and 
treatment of gastric cancer. 
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